



Pharmacovigilance Programme of India

PERFORMANCE REPORT 2021-2022

17th - 23rd September



INDIAN PHARMACOPOEIA COMMISSION

Ministry of Health and Family Welfare, Government of India




PHARMACOVIGILANCE PROGRAMME OF INDIA
Performance Report 2021-2022
(01st April 2021 to 31st March 2022)

National Coordination Centre
Pharmacovigilance Programme of India
Indian Pharmacopoeia Commission

Ministry of Health and Family Welfare, Government of India

Sector - 23, Raj Nagar, Ghaziabad-201002

The background of the page is a light blue gradient. It is decorated with faint, white-outlined chemical structures, including various hexagons and interconnected ring systems, which are typical of pharmaceutical or scientific publications.

No part of this publication may be reproduced, stored in retrieval system/transmitted in any form by any means such as electronic, mechanical including photocopying, recording or otherwise without the prior written permission of the Indian Pharmacopoeia Commission.

CONTENTS

1. Abbreviations.....	3
2. Foreword from Secretary-cum-Scientific Director.....	5
3. Highlights 2021-22.....	6
4. Indian Pharmacopoeia Commission and its services.....	7
5. Genesis.....	8
6. PvPI: An Overview.....	9
7. Email-Ids and functions of PvPI Divisions.....	12
8. Performance of PvPI as WHO-Collaborating Centre.....	13
9. PvPI Communication Channels.....	14
10. Channels for Reporting AE/ADR.....	17
11. AMCs: The Backbone of PvPI.....	19
12. ICSRs database at PvPI.....	21
13. Scientific Meetings organized by NCC-PvPI.....	29
14. Quality Management System in PvPI.....	31
15. Signal Detection.....	35
16. Contribution by MAHs.....	41
17. Skill Development Programme.....	44
18. Scientific Publications.....	113
19. Glimpses of PvPI in Press Communique.....	117
20. Publications PvPI-SRP recommendations in WHO Pharmaceutical..... Newsletter	119
21. List of newly enrolled AMCs under PvPI.....	121
22. Materiovigilance Programme of India.....	136
23. List of NCC-PvPI and MvPI Staff at NCC and AMCs.....	159
24. Photo Gallery.....	171
25. Acknowledgements.....	193
26. Annexures.....	194

ABBREVIATIONS

ADR	: Adverse Drug Reaction
ADRMS	: Adverse Drug Reaction Management System
AE	: Adverse Event
AEFI	: Adverse Event Following Immunization
AFMC	: Armed Forces Medical College
AI	: Active Ingredient
AIDS	: Acquired Immune Deficiency Syndrome
AIIMS	: All India Institute of Medical Sciences
AMC	: Adverse Drug Reaction Monitoring Centre
ART	: Anti-Retroviral Therapy
CDAC	: Centre for Development of Advanced Computing
CDSCO	: Central Drugs Standard Control Organization
CME	: Continuing Medical Education
CTP	: Core Training Panel
COVID-19	: Coronavirus Disease
DCG(I)	: Drugs Controller General (India)
GoI	: Government of India
GvP	: Good Pharmacovigilance Practices
HCP	: Healthcare Professional
HIV	: Human Immunodeficiency Virus
ICSR	: Individual Case Safety Report
IMA	: Indian Medical Association
IPC	: Indian Pharmacopoeia Commission
ITSU	: Immunization Technical Support Unit
MAH	: Marketing Authorization Holder
MDAE	: Medical Device Adverse Event
MedDRA	: Medical Dictionary for Regulatory Activities
MoHFW	: Ministry of Health and Family Welfare

MoU	: Memorandum of Understanding
MvPI	: Materiovigilance Programme of India
NABH	: National Accreditation Board for Hospitals and Healthcare Providers
NACO	: National AIDS Control Organisation
NCC	: National Coordination Centre
NFI	: National Formulary of India
NPW	: National Pharmacovigilance Week
NRA	: National Regulatory Authority
NTEP	: National Tuberculosis Elimination Programme
NCVBDC	: National Centre for Vector-Borne Diseases Control
PGIMER	: Post-Graduate Institute of Medical Education and Research
PHP	: Public Health Programme
PIL	: Prescribing Information Leaflet
PV	: Pharmacovigilance
PvPI	: Pharmacovigilance Programme of India
NABH	: National Accreditation Board for Hospitals & Healthcare Providers
NTEP	: National Tuberculosis Elimination Program*
RTC	: Regional Training Centre
SEARN	: South East Asia Regulatory Network
SMP	: Skill Development Programme on Pharmacovigilance of Medical Products
SOP	: Standard Operating Procedure
SRP	: Signal Review Panel
ToT	: Training of Trainer
TRM	: Traditional medicine
UIP	: Universal Immunization Programme
UT	: Union Territory
USFDA	: United States Food and Drug Administration
WHO	: World Health Organisation
UMC	: Uppsala Monitoring Centre
SMS	: Short Message Service

Message from the Desk of Secretary-cum-Scientific Director



I am immensely pleased to present the Performance Report of Pharmacovigilance Programme of India (PvPI) for the Financial Year 2021-22. The mission of PvPI is to safeguard the health of Indian population

by ensuring that the benefits of use of medicine outweigh the risks associated with its use. PvPI has undergone vast expansion to reach the common masses in the country through a network of Adverse Drug Reaction Monitoring Centres (AMCs). The PvPI has enrolled 188 new AMCs and total number of AMCs became 534 from 346 across the country. The National Coordination Centre (NCC)-PvPI has recommended 4 Signals and 4 Prescribing Information Leaflet changes to Central Drugs Standard Control Organization (CDSCO) for appropriate regulatory actions. The PvPI has also issued 15 Drug Safety Alerts for the sensitization of the healthcare professionals and common masses in the country.

The development of skilled human resource on continuous basis is the need of hour in the area of Pharmacovigilance. Therefore, in order to develop the skilled human resource in the area of Pharmacovigilance, PvPI has organized 1043 training programmes and has trained a total of 69971 participants across the country. Some of the important training programmes include Skill Development Programme on Basic Concepts of Pharmacovigilance, Advanced Level Training Programmes, Induction-cum-Training Programmes, etc.

It is noteworthy to mention that PvPI has organized several Interactive meets with Marketing Authorization Holders (MAHs)/Pharmaceuticals Industries to discuss & resolve their issues about the reporting of Individual Case Safety Reports (ICSRs) to PvPI. This provided them the opportunity to introspect the quality of ICSRs

submitted to PvPI. PvPI has also provided the technical support to MAHs/Pharmaceuticals Industries for the strengthening of Pharmacovigilance system at their site as per the Good Pharmacovigilance Practices guidelines.

The PvPI has initiated the celebration of National Pharmacovigilance Week (NPW) from 17th-23rd September, 2021 and this event will be celebrated annually across the country. The PvPI-IPC being a WHO-Collaborative Centre has organized Regional Training of Trainers (ToT) in collaboration with WHO-SEARO for SEARN countries from 26th – 28th October, 2021.

The Indian Pharmacopoeia Commission (IPC) is also functioning as a NCC for Materiovigilance Programme of India (MvPI) under the purview of PvPI, which deals in collection, monitoring, recording and analyzing the Adverse Events or risk associated with the use of medical devices. The MvPI has enrolled 100 new Medical Device Adverse Event Monitoring Centres (MDMCs) and total number of MDMCs became 150 from 50 across the country. To ensure effective Adverse Event reporting culture among Clinicians, Biomedical Engineers and other HCPs, MvPI has organized hands-on training programmes/ awareness sessions/e-CMEs/workshops, etc.

As a team, we will continue to work towards building patient safety culture in India.

I congratulate the PvPI team, AMCs, subject matter experts, MAHs/Pharmaceutical Industries, healthcare professionals and other stakeholders for their ceaseless efforts, cooperation and contribution in strengthening pharmacovigilance system in India.

(Dr Rajeev Singh Raghuvanshi)

Secretary-cum-Scientific Director

Indian Pharmacopoeia Commission

(Ministry of Health & Family Welfare, Govt. of India)

Ghaziabad-201002

HIGHLIGHTS

1

Enrolled 188 new AMCs under PvPI and expanded to 534 from 346 AMCs pan-India.

2

Total 88360 ICSRs were submitted to VigiBase.

3

PvPI is the 9th largest reporter of ICSRs in VigiBase at global level.

4

PvPI IPC was re-designated as WHO-Collaborating Centre.

5

PvPI has recommended 4 Signals & 4 PIL changes to CDSCO.

6

Issued 15 drug safety alerts.

7

Conducted 1043 trainings/workshops/CMEs/ALT programmes and trained 69,971 participants.

8

Celebrated 1st National Pharmacovigilance Week from 17th-23rd September 2021 pan-India.

9

Organized "Regional ToT on PV of TRM Medicines" in collaboration with WHO-SEARO for SEARN countries from 26th-28th October, 2021.

10

PvPI issued 4 newsletters on quarterly basis for the awareness of stakeholders about the Pharmacovigilance activities.

11

Participated in 6th #Medsafetyweek organized by WHO-UMC, Sweden

Indian Pharmacopoeia Commission and its Services

Indian Pharmacopoeia Commission is an autonomous institution of the Ministry of Health & Family Welfare, Government of India, engaged in evaluation and quality control of drugs and to deal with matters relating to the timely publication of the Indian Pharmacopoeia, the official document of standards for drugs.

Functions

The mandate of the commission is to perform *inter alia* functions such as revision and publication of Indian Pharmacopoeia and National Formulary of India (NFI) on a regular basis. IPC also provides IP Reference Substances and training to the stakeholders on Pharmacopoeial issues and also functions as National Coordination Centre for Pharmacovigilance Programme of India & Materiovigilance Programme of India.



Figure-1. Products & Services of Indian Pharmacopoeia Commission

Pharmacovigilance Programme of India

GENESIS

Pharmacovigilance Programme of India is Government of India's flagship drug safety monitoring programme, which collects, collates and analyses drug-related adverse events and send recommendations to CDSCO for taking appropriate regulatory actions.

Adverse Drug Reaction (ADR) is one of the leading causes of morbidity and mortality worldwide. The consequences of ADRs burden the healthcare system with increased cost of therapy and prolongation of hospitalization. In developing countries, the cost of management of adverse reactions in the general population is very high and under-recognized. It is, therefore, imperative to evaluate the safety of medicines through Pharmacovigilance system.

The Ministry of Health and Family Welfare, Government of India recasted PvPI on 15th April, 2011 and shifted the National Coordination Centre from All India Institute of Medical Sciences (AIIMS), New Delhi to IPC, Ghaziabad and is continuing.

PvPI: An Overview

Pharmacovigilance Programme of India is Government of India's flagship drug safety monitoring programme which collates and analyses drug-related adverse events. As adverse drug reaction is one of the leading causes of morbidity and mortality worldwide therefore, it is imperative to monitor the ADRs. Pharmacovigilance Programme of India was launched in July 2010 by Ministry of Health & Family Welfare (MoHFW), Government of India and All India Institute of Medical Sciences, New Delhi was National Coordination Centre for Pharmacovigilance Programme of India. However, Ministry of Health and Family Welfare, Government of India, Nirman Bhavan, New Delhi recasted this programme vide an Order No. X.11035/7/2011-DFQC dated 15 April, 2011 resulting in shifting of PvPI from AIIMS, New Delhi to Indian Pharmacopoeia Commission, Ghaziabad. Since then, IPC has been entrusted with the responsibility as the National Coordination Centre for Pharmacovigilance Programme of India. The Materiovigilance Programme of India and Hemovigilance Programme of India are also under the ambit of PvPI.

Mission

To safeguard the health of Indian population by ensuring that the benefits of use of medicines outweigh the risks associated with its use.

Vision

To improve patient safety and welfare of Indian population by monitoring safety of medicines, thereby reducing the risk associated with their use.

Aims and Objectives

- Create a Nation-wide system for patient-safety by ensuring drug-safety.
- Identify and analyse new signals from the reported cases.
- Analyse the benefit-risk ratio of marketed medications.
- Generate evidence-based information on safety of medicines.
- Support regulatory agencies in the decision-making process on use of medications.
- Communicate safety information on use of medicines to various stakeholders for preventing/minimizing the risk.
- Collaborate with other National Centres for exchange of information and data management.
- Provide training and technical support to other National Pharmacovigilance Centres across the globe.
- To organise and sensitize the stakeholders for celebration of National Pharmacovigilance Week from 17th - 23rd September every year.
- Promote rational use of medicines.
- Emerge as a National Centre of Excellence for Pharmacovigilance Activities.

Core committees at NCC-PvPI

Following committees are constituted at NCC-PvPI to ensure smooth and effective functioning of the programme:

Steering Committee

It is the chief administrative and monitoring body of NCC-PvPI, which guides and supervises the programme.

Working Group

All technical issues related to the establishment and implementation of the programme, including providing technical inputs, are handled by the Working Group, which reports to the CDSCO for regulatory interventions.

Quality Review Panel

Quality Review Panel is responsible for quality, causality assessment and completeness of ICSRs. The panel also makes recommendations to the PvPI Working Group after data analysis and devises formats and guidance documents for follow-up action.

Signal Review Panel

The Signal Review Panel (SRP) of PvPI comprises scientists and clinical experts affiliated to government and non-government academic institutions and hospitals. As and when required experts from the pharmaceutical industry are also invited for expert inputs, to analyse information from ICSRs. This panel assesses the results of identified computerized Signals from ICSRs to validate and confirm. It looks into biostatistical methods for analysis and creates standardized post-analytical reports that help in understanding the information derived from ADRs. It also decides upon actionable indicators.

Core Training Panel

The Core Training Panel (CTP) of PvPI guides in the identification of training needs, organizing National and International training programmes, designing training modules and helps to conduct the training for healthcare professionals and other stakeholders throughout the year. It also identifies trainers for zone-wise training Centres. The CTP interacts with National and International agencies for participation and implementation of training programmes in Pharmacovigilance. The Core Training Panel is assisted by the internal training team of PvPI.




Figure-2. Organogram of National Coordination Centre- Pharmacovigilance Programme of India

E-mail IDs and functions of PvPI Divisions

S. No.	PvPI Division	Functions	E-mail ID
1.	Technical Secretariat	Coordination with AMCs/Non-AMCs/CDSCO/other stakeholders	pvpi.ipc@gov.in
2.	Quality Assurance Division	Quality Management System of PvPI	qa.nccpvpi-ipc@gov.in
3.	Training & Education Division	Training and Skill Development	training.nccpvpi-ipc@gov.in
4.	Promotion, Communication & Publication Division	Publication of PvPI resource materials and communication with stakeholders	communication.nccpvpi-ipc@gov.in
5.	Signal Division	Drug Safety Alerts and other regulatory recommendations	signal.pvpi-ipc@gov.in
6.	National Health Programme Division	Integration with Public Health Programmes	nhp.nccpvpi-ipc@gov.in
7.	Information Technology Division	VigiFlow and other IT tools	it.nccpvpi-ipc@gov.in
8.	Human Resource Division	Human Resources Development	hr.nccpvpi-ipc@gov.in
9.	Individual Case Safety Report Processing Division	Submission of ADRs by non-AMCs	pvpi.ipc@gov.in
		Submission of ADRs by consumers/patients	pvpi.ipc@gov.in
		Processing of adverse events reported through PvPI Helpline	pvpihelpline@gmail.com
10.	PV Regulatory Affairs Division	Processing of ICSRs received from MAHs and review of PSUR	mah.nccpvpi-ipc@gov.in psur.nccpvpi@gmail.com

Performance of PvPI as WHO-Collaborating Centre

The NCC-PvPI, IPC being a World Health Organization (WHO)-Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services in SEARN countries, PvPI has done the following activities:

Activity	Outcomes
Development of e-tools for integration of ADR-reporting	<ul style="list-style-type: none"> Developing Indigenous Adverse Drug Reaction Management System (ADRMS) Software integrated with WHO-Drug Dictionary and MedDRA dictionaries. The ADRMS software will offer seamless processing & evaluation of ICSR reported with the use of medicines, vaccines and medical devices. Continuously updated the features of android Mobile App 'ADR PvPI' for the reporting of AEs/ADRs by consumers/patients/ HCPs etc.
PV data sharing with South-East Asia Regional Network (SEARN) countries	<ul style="list-style-type: none"> The NCC-PvPI has shared drug safety alerts with SEARN countries on monthly basis through e-mail. The NCC-PvPI has shared electronic version copy of newsletter with SEARN countries on quarterly basis through e-mail. The NCC-PvPI has also shared the identified Signals and Prescribing Information Leaflet changes with SEARN countries through e-mail. PvPI as a National Pharmacovigilance Centre of WHO Programme for International Drug Monitoring published drug safety information in WHO-Pharmaceuticals newsletter for global outreach.
Capacity Building and support for Public Health Programmes (PHPs) and Regulatory services	<ul style="list-style-type: none"> The NCC-PvPI, IPC has organized "Regional ToT on Pharmacovigilance of Traditional Medicines" in collaboration with WHO-SEAR Office for SEARN countries from 26th – 28th October, 2021. Coordination done with Adverse Event Following Immunization (AEFI) Secretariat of the MoHFW, Govt. of India by sharing of data related to vaccines. A multidisciplinary team having representatives from PvPI-IPC, National Centre for Vector Borne Disease Control (NCVBDC), PCI, CARE, WHO along with Ophthalmologist as an expert have visited to monitor the Visceral Leishmaniasis & PKDL status in Jharkhand on 07th – 11th March, 2022. This field visit was one of the action points decided in the meeting held on 22nd December, 2021 under the Chairmanship of the Director General of Health Services (DGHS), Nirman Bhawan, New Delhi. The main agenda of this visit was to monitor the VL & PKDL status in the state as well as to see the patients, who had experienced eye related complications with the use of Miltefosine. On the behalf of NCC-PvPI, IPC, Dr. Vijit Agrawal, Sr. Pv Associate had participated in this field visit. A detailed report on 11 eye complication cases was prepared and shared with the NCVBDC.

PvPI Communication Channels

Coherent and flawless communication channels are key to the successful functioning of any programme. The dissemination of knowledge and expertise at NCC-PvPI percolates to the target audience and across the board to the AMCs affiliated to it with the use of state-of-the-art information technology. The various modes of communication by which PvPI channelizes data flow are represented in the figure below:




Figure-3. Flow of data in PvPI

Reporting ADRs

Who can attend ?



Consumers/
Patients



Physicians



Pharmacists



Nurses



Healthcare
Professionals



Pharmaceutical
Industries/MAHs



ADR Monitoring
Centres

Whom to Report ?



AMCs



PvPI Helpline
(1800-180-3024)



PvPI Mobile App
ADR PvPI



icsr.nccpvpi@gmail.com
pvpi.compat@gmail.com

ADR reporting forms are available on the official website of IPC (www.ipc.gov.in) and the website of CDSCO (www.cdsc.gov.in)

Why to Report ?

- To ensure the safety of patients taking medicines
- To reduce the risks associated with the use of medicines (economic burden, quality of life)
- To help regulatory authority make vital policy decision regarding safe use of medicines

What to Report ?

All types of suspected ADRs:

- Known or unknown
- Serious or non-serious
- Frequent or rare

ADRs by:

- Medicines
- Medical Devices
- Biologicals including Vaccines
- Herbal Drugs/Nutraceuticals, etc

Medication Errors:

- Product dispensing/monitoring/prescribing/selection/storage error/issues
- Accidental exposure to product
- Inappropriate use of medical products
- Product transcribing errors and communication issues

Off-label Use:

Use of medicines for an unapproved indication, age group, dosage or route of administration.

Misuse/Overdose/Abuse:

- Use of a medication (for a medical purpose) other than as directed or as indicated; taking medicine more/more often or for a longer period.
- Ingestion/application of medicine in quantities much greater than recommended.
- Nonmedical use of a substance for psychic effect, dependence, or a suicide attempt or gesture, recreational use of substances for any reason.

Lack of Efficacy and other product quality-related issues

- No/Lack of drug effect
- Drug ineffective for approved/unapproved indication
- Delayed or incomplete drug effect
- Ineffective drug dosing regimen
- Drug effect faster/less than expected

Channels for Reporting AE/ADR

Suspected ADR Reporting Form for Healthcare Professionals (HCPs)

The Suspected ADR reporting Form is specifically designed for healthcare professionals to capture detailed information about an AE/ADR. This form is available on IPC (www.ipc.gov.in) or CDSCO (www.cdsc.gov.in) website and in National Formulary of India 2021 (**Annexure-I**).

Medicines Side-Effect Reporting Form (For Consumers)

Consumers/patients may also make use of Medicines Side-effect Reporting Form for reporting any suspected AE/ADR to PvPI. This form is available in 10 Indian languages: Hindi, Bengali, Gujarati, Kannada, Malayalam, Marathi, Assamese, Oriya, Tamil and Telugu (**Annexure-II**).

Suspected ADR Reporting Form (For drugs used in Prophylaxis/Treatment of COVID-19)

The Suspected ADR Reporting Form is designed for healthcare professionals during pandemic to capture detailed information about an AE/ADR related to the drugs used in Prophylaxis/ Treatment of COVID-19. This form is available on IPC (www.ipc.gov.in) (**Annexure-III**).

Personal Protective Equipment (PPE) Adverse Event Reporting Form

In view of COVID-19 Pandemic, NCC-MvPI has specially designed a PPE Adverse Event Reporting Form, which primarily aims to collect the adverse events associated with the use of PPEs used for medical purposes (**Annexure-IV**).

Miscellaneous ADR Reporting Forms

Healthcare Professionals and other stakeholders can also report AEs/ADRs using specific forms designed purposely for reporting AE/ADR associated with Medicines used in Kala-azar treatment – Adverse Drug Reaction Form for Kala-Azar treatment (**Annexure-V**), serious cases related to vaccine use - Serious AEFI Case Notification Form (**Annexure-VI**) and Cases related to Medical Device use- Medical Device Adverse Event Reporting Form (**Annexure-VII**).

PvPI Helpline

Patients/Consumers/Healthcare Professionals may report any suspected ADR associated with the use of medicinal/herbal products/vaccines or medical devices to NCC-PvPI via Toll-Free Helpline No. 1800-180-3024.



e-Reporting of ADRs

An indigenous android mobile app "ADR PvPI", which was dedicated to the nation on 29th September 2017, has been instrumental in equipping all stakeholders, including the consumers, for reporting ADRs.



E-mails

Hospitals/ Medical Colleges and other Healthcare Institutions which are not enrolled as AMCs under PvPI, may report adverse events by using email (pvpi.ipc@gov.in).



Similarly, consumers/ patients also have the option of reporting adverse events through a dedicated email (pvpi.ipc@gov.in).

1


Reporting ADRs by Non-AMCs
pvpi.ipc@gov.in

2

Reporting ADRs by Consumers
pvpi.ipc@gov.in

Suspected ADR Reporting Form in National Formulary of India

NFI serves as a guidance document to medical practitioners, pharmacists working in hospitals and sales establishments, nurses, medical and pharmacy students and other healthcare professionals. The principal objective of NFI is to promote the rational use and economic prescribing of medicines in the country. The healthcare professional may utilize the ADR Reporting Form which has been annexed at the end of the NFI 2021 to report suspected ADRs.



AMCs: The Backbone of PvPI

Medical institutions and hospitals play a major role both in teaching and providing specialized services to patients in India. Patient safety is one of their major concerns. Adverse Drug Reaction Monitoring Centres (AMCs) functioning at these Institutions under PvPI, across the country are playing a crucial role in collection, processing and monitoring ADRs.

Who can Enroll?

- Government hospitals/Autonomous bodies/ medical/pharmacy colleges
- Private hospitals/medical/pharmacy colleges
- District hospitals
- Primary/ Community Health Centres in India

Enrollment Procedure for AMCs




Figure-4. Enrollment Procedure for AMCs

Criteria for Enrolment of AMCs

- Availability of logistic and infrastructural facilities for PV at the proposed Centre
- Significant track-record of the Centre in Pharmacovigilance – on quality, quantity and frequency of Adverse Drug Reaction reporting
- Dean/Head of Institution/HoD of the proposed Centre is responsible to establish/ implement PvPI activities at the Centre
- The proposed AMC coordinator/ deputy coordinator should possess relevant experience
- States/Union Territories where no/ few AMCs exists will be preferred
- Demography based selection of AMCs

Upon recognition, NCC-PvPI provides regular training, skill development and technical training support to the personnel engaged in PvPI activities.

Criteria for De-Enrolment/ De-Recognition of AMCs

- Non-performance/ Zero reporting
- Non-compliance of Quality Management System

ICSRs Database at PvPI

The Pharmacovigilance Programme of India is responsible for collection, assessment, detection and communication of risks associated with the use of medicines in Indian Population. The ICSRs collected by Adverse Drug Reaction Monitoring Centres and Marketing Authorization Holders are communicated to NCC-PvPI. The annual database accounts for 88360 ICSRs for the index period. The reporting patterns are on the rise and have shot up in comparison to last year.

Month-wise Distribution of ICSRs



Figure-5. Month-wise distribution of ICSRs

Distribution of ICSRs based on Gender

PvPI database revealed that 49.9% ICSRs were of male patients and 45.4% were of female patients. No information was provided in 4.6% of ICSRs.




Figure-6. Distribution of ICSRs based on Gender

Distribution of ICSRs based on age

The database revealed that the maximum 42.0 % ICSRs were received from the age group of 18-44 years, whereas the minimum 0.1% ICSRs were received from the age group of 0-27 days. No information about the age of the patients were given in 11.3% ICSRs.




Figure-7. Distribution of ICSRs based on Age

Distribution of ICSRs based on reporter qualification

The NCC-PvPI has received 36.0% ICSRs from physicians, 16.3% from pharmacists, 27.0% from other healthcare professionals, 26.3 % from consumers/non-healthcare professionals and 0.01% from lawyers.




Figure-8. Distribution of ICSRs based on reporter qualification

Distribution of ICSRs based on seriousness

The database revealed that 19.5% ICSRs were serious and 80.5% were non-serious reported with the use of medicinal products.




Figure-9. Distribution of ICSRs based on seriousness

Distribution of ICSRs based on Seriousness Criteria

The seriousness criteria of ICSRs received revealed that 4.5% ICSRs due to death, 1.2% ICSRs due to life threatening condition, 8.2% ICSRs were due to prolonged hospitalization, 0.2% ICSRs due to disabling/incapacitating, 0.001% ICSRs due to congenital anomaly/birth defect whereas 8.6% ICSRs were due to other medically important conditions.




Figure-10. Distribution of ICSRs based on Seriousness criteria

Distribution of reactions based on System Organ Class

The ICSRs reported in PvPI database revealed that the maximum number of reactions 41.8% were reported from the System Organ Class (SOC)-General disorders and administration site conditions among the top ten reported SOC.




Figure-11. Distribution of reactions based on SOC

Distribution of ICSRs based on Anatomical Therapeutic Chemical Classification

The ICSRs reported in PvPI database revealed that the maximum number of suspected drugs 52.9% were reported from the Anatomical Therapeutic Chemical Classification (ATC)-Anti-infectives for systemic use among the top ten reported ATCs.



Figure-12. Distribution of ICSRs based on ATC Classification

Top 10 reported Preferred Term

The data reported in PvPI database revealed that the maximum percentage of adverse drug reactions (Preferred Term) reported was pyrexia (20.8%) coded by MedDRA dictionary.




Figure-13. Top 10 reported Preferred Term

Top 10 active ingredients reported in ICSRs

Analysis of Active Ingredients (AIs) from ICSRs revealed that COVID-19 vaccine (32.5%) was the most reported AI.




Figure-14. Top 10 active ingredients reported in ICSRs

ICSRs received from Non-AMCs

Besides receiving ICSRs from AMCs, NCC-PvPI, also received ICSRs through several hospitals, medical colleges and other institutions which are not enrolled as AMC under PvPI (non-AMCs) across India. The Non-AMCs sent the filled in Suspected ADR reporting form to NCC-PvPI through a dedicated e-mail-pvpi.ipc@gov.in. These reports were then forwarded to the nearest AMC for causality assessment. During the index period, 1061 ADRs were reported via non-AMCs, month-wise distribution of these ADRs is depicted below:



Figure-15. Month-wise ICSRs received from Non-AMCs

ICSRs received via PvPI Helpline

Tollfree Helpline was initiated on October 11, 2013, since then it has been serving as one of the reliable tools for reporting suspected adverse events. Patients/Consumers/Healthcare Professionals report suspected adverse events associated with the use of medical products/ Medical Devices. Calls are primarily responded in English and Hindi on all working days between 9:00 AM and 5:30 PM. The month-wise reports received by PvPI during the index period are shown in the graph below:



Figure-16. Month-wise ICSRs received from PvPI Helpline (Tollfree)

Year-wise reporting status of ICSRs




Figure-17. Year-wise reporting status of ICSRs upto March 2022

* 2022 indicates upto March 2022

India secured 9th position in Global reporting of ICSR




Figure-18. Global reporting of ICSR

Scientific Meetings organized by NCC-PvPI

S. No.	Date	Title
1.	June 28, 2021	11 th Working Group Meeting of PvPI
2.	July 3, 2021	47 th Meeting of the scientific body of the Indian Pharmacopoeia Commission
3.	July 13, 2021	Meeting with UMC Officials to discuss about ADRMS software development
4.	July 15, 2021	7 th Core Training Panel-cum-6 th RTC Coordinators Meeting of PvPI
5.	July 16, 2021	Meeting of Pharmacovigilance Committee for COVID-19 drugs
6.	July 20, 2021	IPC-PCI Meeting
7.	July 23, 2021	Meeting of Pharmacovigilance Committee for COVID-19 drugs
8.	July 30, 2021	Meeting with NACO Officials
9.	August 24, 2021	7 th Quality Review Panel Meeting
10.	September 2, 2021	Meeting with UMC Officials to discuss about ADRMS software development
11.	September 22, 2021	IPC-IMA Meeting
12.	October 25, 2021	19 th Signal Review Panel Meeting
13.	October 29, 2021	Meeting with UMC Officials to discuss about ADRMS software development
14.	December 8, 2021	IPC-NABH Meeting
15.	December 8, 2021	PvPI-WHO-NCVBDC Meeting
16.	December 14, 2021	FDA-INO meeting
17.	December 20, 2021	National AEFI Committee meeting
18.	January 5, 2022	12 th Working Group Meeting of PvPI

S. No.	Date	Title
19.	January 10, 2022	Meeting with NCVBDC officials
20.	January 14, 2022	Meeting of PvPI-NACO Officials
21.	January 17, 2022	National AEFI Committee meeting
22.	January 18, 2022	National AEFI Committee meeting
23.	January 19, 2022	AMC Coordinators Meeting
24.	February 4, 2022	7 th RTC Coordinators-cum-8 th Core Training Panel meeting of PvPI
25.	February 11, 2022	Meeting with PV Associates
26.	February 24, 2022	Meeting with HDFC Bank Marketing Team for Dissemination of PvPI Information to Public from their Banks
27.	February 25, 2022	Meeting with officials of National Medical Commission
28.	March 2, 2022	National AEFI Committee meeting
29.	March 7, 2022	Meeting with CDAC officials
30.	March 11, 2022	20 th Signal Review Panel Meeting
31.	March 14, 2022	Meeting with CDAC officials
32.	March 24, 2022	Meeting with CDAC officials

Quality Management System in PvPI

To ensure patient safety through a transparent approach and high-quality services, PvPI has been found to conform with ISO 9001:2008 Quality Management System (QMS) and also adopts Good Pharmacovigilance Practices (GvPs) as per one of the WHO Pharmacovigilance Indicators with a focused approach on scientific innovation and rationality. PvPI performance with reference to defined objectives was evaluated by officials of Quality Council of India & Quality Accreditation Institute and based on the evaluation report which was further submitted to MoHFW for extension of programme for the next five years (FY: 2021-2026).

List of SOPs in different divisions of PvPI is given below:

Technical Secretariat	
1	SOP for functioning of Technical Secretariat
Quality Assurance	
2	SOP for making SOP
3	Procedure for specimen signatures
4	Change control procedure
5	SOP for handling of deviation
6	SOP for handling of non-conformance
7	SOP for corrective and preventive action
8	SOP for Audit of NCC-PvPI
9	SOP for management review meeting
10	SOP for collection of ADR/AE Reports
11	SOP for preparation and submission of progress reports
12	SOP fill suspected ADR reporting form
13	SOP to perform causality assessment
14	SOP to enter ADR data to VigiFlow software
15	SOP for processing and quality review of ICSRs

16	SOP for documentation at AMCs
17	SOP for ensuring the functioning of AMCs
18	SOP for functioning of Quality Review Panel
19	SOP for archiving of documents
20	SOP for handling of medication error, lack of therapeutic efficacy ICSRs ¹
21	SOP for enrolment of new AMCs under PvPI
22	SOP for functioning of Working Group
23	SOP for functioning of Steering Committee
Signal Detection	
24	SOP for operational functioning of SRP
25	SOP for functioning of SRP
26	SOP for data mining of SUSARs and non-serious ADRs/AE from vigiflow
PV Regulatory Affairs	
27	Processing of ICSRs reported by MAHs
National Health Programme	
28	SOP for coordination between PvPI and NHPs
29	Processing & communication of AEFI-ICSRs
Training and Education	
30	SOP to conduct training under NCC-PvPI
31	SOP for functioning of RTCs under PvPI
32	SOP for functioning of Core training panel
Promotion Communication and Publication	
33	SOP for drafting, publication, distribution and control of resource material of PvPI
34	SOP for publication and communication between PvPI and stakeholders

Information Technology

- | | |
|----|--|
| 35 | SOP for data integrity |
| 36 | VigiFlow login distribution and retrieval procedure |
| 37 | SOP for establishing link at the Ministry of Health and Family Welfare web portal for the PvPI |

Human Resources

- | | |
|----|--|
| 38 | SOP for the recruitment of contractual employee under NCC-PvPI IPC |
| 39 | SOP for the job responsibility of employee under NCC-PvPI IPC |
| 40 | SOP for conducting teleconference meeting with AMCs PvAs |
| 41 | SOP for functioning of International Cooperation Division |

Individual Case Safety Report

- | | |
|----|---|
| 42 | SOP for processing ADR received through PvPI Mobile App - "ADR-PvPI" |
| 43 | SOP for processing Adverse Events received from consumers via e-mail |
| 44 | SOP for processing Adverse Reaction/ Events report by Non-AMC to NCC-PvPI |
| 45 | SOP for receiving ADR from healthcare professionals and consumers through PvPI helpline |

Quality of ICSRs Reporting

The VigiGrade™ Completeness score is a WHO system to measure the quality of the information provided on ICSRs. The graph represents the average completeness score of ICSRs submitted from India (Blue line) as compared to submitted ICSRs by all the other countries (Green line). The average completeness score for the last quarter of the index period accounts for about 0.71 out of 1.




Figure-19. Graphical representation of VigiGrade™ Completeness score of quality of ICSRs submitted by PvPI to UMC database

Signal Detection

WHO defines a Signal as "Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously". Signal detection and clinical assessment of ICSRs form a vital domain of Pharmacovigilance. NCC-PvPI is engaged in identifying potential signals from India-specific ICSRs with technical assistance by experts in the Signal Review Panel.

Methods used by PvPI for Signal Detection

Various methods are used for signal detection. The four usually considered methods for identifying a new signal from ICSRs in India include:

- Information Component (IC)
- Proportional Relative Risk/Proportional Reporting Ratio (PRR)
- Chi-square (χ^2) statistics (with 1 degree of freedom)
- Total number of reports on the specific Drug-ADR combination available in the Indian database (Ncomb)

Threshold values used by PvPI for the aforementioned methods to identify a potential signal are:

- $IC_{025} > 0$
- $PRR \geq 2$ with the lower bound of its 95% Confidence Interval > 1
- χ^2 statistics (with 1 degree of freedom) ≥ 4
- $N_{comb} \geq 3$, to highlight potential signals

Fulfilment of at least three of these four parameters is required for considering a specific drug-ADR combination as a potential signal.

Utilization of ICSR data

The National Coordination Centre – Pharmacovigilance Programme of India evaluates ICSRs for potential new signals, drug safety alerts and package insert updates in the Signal Review Panel (SRP) meetings. The outcomes of SRP meetings were communicated to Central Drugs Standard Control Organization (CDSCO) for appropriate regulatory actions as tabulated below:

Signal Review Panel (SRP) Recommendations for regulatory actions

The Indian Pharmacopoeia Commission, National Coordination Centre – Pharmacovigilance Programme of India evaluated spontaneously submitted ICSRs and further discussed in SRP meeting during indexed period. The outcomes of SRP meetings were communicated to the Central Drugs Standard Control Organization for appropriate regulatory actions as tabulated below:

S. No	SRP Meeting	Suspected drugs	Adverse drug reactions	Outcome
1.	19 th SRP Meeting held on 25 th October, 2021	Mefenamic Acid	Fixed Drug Eruption	Signal
		Doxycycline	Fixed Drug Eruption	Signal
2.	20 th SRP Meeting held on 11 th March, 2022	Minoxidil	Folliculitis	Signal
		Tigecycline	Coagulopathy	PIL Change
		Olanzapine	Hyponatraemia	PIL Change
		Haloperidol	Cogwheel Rigidity	PIL Change
		Cephalosporin Class	Fixed Drug Eruption	Signal
		Remdesivir	Sinus Bradycardia	PIL Change

Monthly Drug Safety Alerts Issued by IPC, NCC-PvPI

The IPC, NCC-PvPI has issued monthly drugs safety alerts during index period which aims to sensitize the Healthcare Professionals & Consumers through bulk SMS facility available at PvPI, periodically issued PvPI Newsletters, web-portal of IPC and strengthening of reporting to PvPI as tabulated below:

S. No.	Issue Date	Suspected drugs	Indication	Adverse Reactions
1	05 th April, 2021	Zinc (Acetate/ Oxide/ Sulphate/ Gluconate)	In the treatment of acute diarrhoea in children as an adjunct to oral rehydration.	Diarrhoea
2	28 th June, 2021	Baclofen	For the symptomatic treatment of neuronal spasticity due to multiple sclerosis, spinal cord, pathology & injury	Encephalopathy
3		Rosuvastatin & Ticagrelor Interaction	<p>Rosuvastatin: Risk reduction of MI stroke and arterial revascularisation procedure in patients without clinically evident CHD but with multiple risk factors.</p> <p>Ticagrelor: For the prevention of thrombotic events (cardiovascular death, Myocardial Infarction and stroke) in patients with Acute Coronary Syndromes unstable angina, non-ST Elevation Myocardial Infarction (STEMI) including patients managed medically and those who are managed with Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting.</p>	Rhabdomyolysis

S. No.	Issue Date	Suspected drugs	Indication	Adverse Reactions
4	28 th June, 2021	Clobazam	Acute and chronic anxiety states and as an adjunctive therapy in patients with refractory epilepsy.	Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome)
5	28 th July, 2021	Etoricoxib	For the treatment of pain, swelling & inflammatory conditions due to arthritis.	Acute Generalized Exanthematous Pustulosis
6		Torsemide	For the treatment of oedema associated with congestive heart failure & hypertension.	DRESS Syndrome
7		Quetiapine & Valproic Acid Interaction	<p>Quetiapine:</p> <ul style="list-style-type: none"> For the management of the manifestation of psychotic disorders (schizophrenia). For the additional indication "acute manic episode associated with bipolar disorder". <p>Valproic Acid:</p> <ul style="list-style-type: none"> As monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizure. As monotherapy or adjunctive therapy in the treatment of patients with complex partial seizure and manic episodes associated with bipolar disorder. 	Neuropsychiatric Adverse Events (Depressed level of consciousness/ Coma & Disorientation)
8	31 st August, 2021	Sofosbuvir	In combination with other medicinal products for the treatment of chronic hepatitis C in adults.	Stevens-Johnson Syndrome

S. No.	Issue Date	Suspected drugs	Indication	Adverse Reactions
9	30 th September, 2021	Dimethyl Fumarate	For Relapsing remitting multiple sclerosis	Alopecia
10		Cefazolin	Cephalosporin antibiotic-indicated in the treatment of serious infections due to susceptible organisms – respiratory tract infections, urinary tract infections, skin & skin structure infection, biliary tract infections, septicaemia	Acute Generalised Exanthematous Pustulosis
11	30 th November, 2021	Diclofenac	For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, painful post-operative pain following dental surgery, migraine attack and postoperative inflammation in patients who have undergone cataract operation.	Skin hyperpigmentation
12	28 th December, 2021	Remdesivir	Broad spectrum antiviral medication. Restricted emergency use for treatment of patients with severe COVID-19. Operative inflammation in patients who have undergone cataract operation.	Sinus Bradycardia
13	18 th January, 2022	Ibuprofen	For the treatment of chronic arthritic disorders and painful musculoskeletal conditions.	Fixed Drug Eruption
14	28 th February, 2022	Losartan	For the treatment of hypertension	Muscle Spasm
15	17 th March, 2022	Cephalosporin Class	Cephalosporins are beta-lactam antimicrobials used to manage a wide range of infections from Gram-positive and Gram-negative bacteria	Fixed Drug Eruption

SRP recommendations published in WHO Pharmaceutical Newsletter

The outcome of SRP recommendations was published in WHO Pharmaceutical Newsletter:

S. No	Suspected drugs	Adverse drug reactions
1.	Tinidazole	Risk of fixed eruption
2.	Tramadol	Risk of Urinary Retention



Contribution by MAHs

Marketing Authorization Holders (MAHs) play a crucial role in reporting ADRs to PvPI. The recent amendment to the Drugs and Cosmetics Rules, 1945 and New Drugs & Clinical Trials Rules 2019, has made Pharmacovigilance a legal obligation for MAHs. This has paved the way for collecting product-specific safety data, aimed at optimizing drug-safety and ensuring healthcare for Indian populace. During the index period a total of 130 MAHs/Pharmaceutical Industries (as listed below) had submitted 64649 ICSRs to NCC-PvPI.



Figure-20. Month wise ICSRs received from MAHs

List of Pharmaceutical Companies

S.No.	Industry Name	S.No.	Industry Name
1	Abbott India Limited	28	Kusum Healthcare Private Limited
2	Accent Pharmaceuticals & Diagnostics	29	Levim Biotech LLP
3	Akums Drugs & Pharmaceuticals Limited	30	LG Chem Life Sciences India Pvt.Limited
4	Alcon Laboratories India Private Limited	31	Lupin Limited
5	Alkem Laboratories	32	Lundbeck Pharmaceutical company
6	Allergan India Pvt. Ltd.	33	Macleods Pharmaceuticals Limited
7	Apotex Research Private Limited	34	Madras Pharma
8	Arco Lab Private Limited	35	Medley Pharmaceuticals Limited
9	Arisglobal LLC	36	MERCK Limited
10	Aristo Pharmaceuticals Private Limited	37	MSD Pharmaceuticals Ltd.
11	Astellas Pharma India Private Limited	38	MSN Laboratories Private Limited
12	AstraZeneca Pharma India Limited	39	Mylan Laboratories Private Limited/Viatris
13	Aurobindo Pharma Limited	40	Mankind Pharma
14	Amgen India	41	Mytomorrows India
15	AXA Parenterals Limited	42	Nestle Skin Health India Pvt.Limited
16	Axellia Pharmaceutical company	43	Novartis India Limited
17	Baxalta Bioscience India Private Limited	44	Novo Nordisk India
18	Baxter (India) Private Limited	45	Optimus Pharma Pvt. Limited
19	Bayer Healthcare Limited	46	Nitin Life Sciences
20	Bharat biotech	47	Organon & Company
21	Biocon Biologics Limited	48	Otsuka Pharmaceutical India Pvt. Limited
22	Biogen Idec Biotech India Private Ltd.	49	Oviya MedSafe Pvt limited
23	Boehringer Ingelheim India Private Limited	50	Pavlov Pharmaceuticals
24	Bristol-Myers Squibb India	51	Pfizer Limited
25	Bharat Serums And Vaccines Limited	52	Piramal Healthcare Limited
26	Biological E Limited	53	Prime Vigilance & Medical information
27	B Braun	54	The Procter & Gamble Company

55	Bracco Imaging S.p.A.	93	Panacea Biotech Limited
56	Blue Cross Laboratories Pvt Ltd.	94	Roche Products (India) Private Limited
57	Cadila Pharmaceuticals	95	Reliance Life Sciences
58	Cibeles Pharmaceuticals Private Limited	96	Recipha AB
59	Cipla Limited	97	Reckitt Benckiser (India) Limited
60	Concord Biotech Limited	98	RPG Life Sciences
61	DISPO SURGICALS	99	Rusan Pharma Limited
62	Dr. Reddy's Laboratories	100	Sandor Medicaids Private Limited
63	EISAI Pharmaceuticals India Pvt. Ltd	101	Samrudh Pharmaceuticals Pvt. Ltd.
64	Elder Pharmaceuticals Ltd.	102	Sanoft India Limited
65	Eli Lilly & Company (India) Private Limited	103	Santen India Pvt. Limited
66	Emcure Pharmaceuticals Limited	104	Serdia Pharmaceuticals (India) Limited
67	Eris Lifesciences Limited	105	Shilpa Medicare Limited
68	Exeltis India Private Limited	106	Shire Biotech India Pvt Limited
69	Farmaceutici Damor SpA.	107	Strides Shasun Limited
70	FDC Limited	108	Sovereign Pharma Pvt. Limited
71	Fresenius Kabi India Private Limited	109	Sun Pharmaceuticals Industries Limited
72	Glaxo Smithkline Pharmaceuticals Limited	110	Septodont Healthcare India Pvt. Ltd
73	Glenmark Pharmaceuticals	111	Serum Institute of India Limited
74	Galderma India Pvt.Limited	112	Synokem Pharmaceuticals Limited
75	Grifols India Healthcare Private Limited	113	Takeda Pharmaceutical Company
76	Guerbet	114	Tirupati Medicare Limited
77	Gilead Sciences	115	Torrent Pharmaceuticals Limited
78	Gulfic Biosciences	116	Themis Medicare Limited
79	Hetero Labs Limited	117	Troika Pharmaceuticals Limited
80	HLL Biotech Limited (HBL)	118	UrsaPharm India Pvt. Limited
81	Human Biologicals Institute II limited	119	UCB India Pvt. Limited
82	Indoco Remedies Limited	120	Universal Medicare Limited
83	Imaging Products India Pvt. Limited	121	USV Private Limited
84	Intas Pharmaceuticals Limited	122	Venus remedies Limited
85	Inventia Healthcare Ltd	123	Vifor Pharma Pvt. Limited
86	Italfarmaco SpA.	124	Viverra Pharmaceuticals
87	IPCA Laboratories Limited	125	Win Medicare Pvt Limited
88	J.B. Chemicals and Pharmaceuticals Ltd	126	Wipro GE Healthcare Pvt. Limited
89	Johnsons & Johnsons Private Limited	127	Wockhardt Pharmaceutical Limited
90	Kedrion Bio Pharma Limited	128	Wyeth Pharmaceuticals Limited
91	Kerala Medical Services Corporation Limited	129	Zydus Lifesciences Limited (Cadila Healthcare Limited)
92	Koye Pharmaceuticals Pvt. Limited	130	Zuventus Healthcare Limited

Skill Development Programme

NCC-PvPI holds the responsibility to generate the driving force for assuring safe use of medicines in India. In order to enhance Pharmacovigilance skills of the Healthcare professionals, PvPI conducted various trainings on Pharmacovigilance for Healthcare Professionals, Industry Personnel, Consumers and Other stakeholders. PvPI has developed practical tools which serve as scientific models to disseminate information and solutions to probable drug-related problems. Thus, PvPI has acquired a prominent platform for sustainable PV practices among all healthcare stakeholders.



Figure-21. Training: Objective and Perspectives

NCC-PvPI has recognized twelve Regional Training centre (RTC) to impart training in pharmacovigilance and to cater the needs of PV trainees and adapting good pharmacovigilance practices. The list is given below:

S. No.	Regional Training centre	State/UT under purview	Year of recognition
1.	All India Institute of Medical Sciences, Bhopal	Madhya Pradesh and Chhattisgarh	2015
2.	All India Institute of Medical Sciences, Rishikesh	Uttarakhand and Uttar Pradesh	2016
3.	BJ Medical College, Ahmedabad	Gujarat, Rajasthan, Daman & Diu	2014
4.	Institute of Postgraduate Medical Education & Research, Kolkata	Andaman Nicobar, West Bengal, Jharkhand, Bihar & Odisha	2011
5.	JSS Medical College Hospital, Mysuru	Karnataka, Kerala, Tamil Nadu, Puducherry and Lakshadweep	2011
6.	Nizam's Institute of Medical Sciences, Hyderabad	Andhra Pradesh and Telangana	2015
7.	Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh	Jammu & Kashmir, Himachal Pradesh, Punjab, Haryana, Chandigarh and Delhi	2011
8.	Seth GS Medical College & KEM Hospital, Mumbai	Maharashtra, Goa, Dadra & Nagar Haveli	2011
9.	Government Medical College, Guwahati	Assam, Arunachal Pradesh, Nagaland, Manipur, Meghalaya, Mizoram, Tripura, Sikkim	2020
10.	Maulana Azad Medical/Dental College, New Delhi	Delhi & Adjoining areas (Ghaziabad, Noida, Faridabad, Gurugram)	2021
11.	Madras Medical College, Chennai	Tamil Nadu	2021
12.	Amrita Institute of Medical Sciences, Kochi	Kerala	2021

Details of training programmes conducted by NCC-PvPI, IPC and AMCs:

A. Training/Sensitization of stakeholders by AMCs:

ADR Monitoring Centres function as the backbone of PvPI. The Pharmacovigilance team at each AMC under PvPI usually includes:

- One Coordinator
- One Deputy Coordinator
- One Pharmacovigilance Associate
- Causality Assessment Committee (Experts from different clinical fields)

Besides collecting and submitting ICSRs to PvPI, this team of dedicated medical and pharmaceutical professionals also conducts regular training/sensitization programmes, workshops for all healthcare professionals, non-healthcare professionals and other stakeholders at an AMC. The team also visits the peripheral hospitals, community and primary health centres in the adjoining areas to disseminate information on drug-related problems and reporting of any possible adverse events to PvPI.

Training Programmes conducted by AMCs

The training programmes at AMCs include:

- Regional & National Workshops
- Advanced Level Trainings (ALT)
- Continuing Medical/Pharmacy Education (CME/CPE) Programmes
- Sensitization and Awareness drives

During the index period, PvPI organised a total of 1,044 training/awareness-cum-sensitization programmes including CME/CPE in which 69,971 Healthcare Professionals and other stakeholders were trained on PV.

B. Sensitization/Awareness Programmes Conducted by AMCs (Including PvPI, IPC Sponsored Seminars/CMEs)

Details of Sensitization training programmes conducted at AMCs are summarized below:

S. No.	Date	Training Programmes	AMC	No. of Participants
1	3 rd April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	RIMS, Imphal	40
2	6 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	KMC, Kurnool	179
3	6 th to 19 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Patiala	225
4	9 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	TMMC-RC, Moradabad	100
5	10 th April 2021	CME-cum- sensitization programme on Pharmacovigilance and ADR Reporting	AIIMS, Mangalagiri	29
6	12 th April 2021	Adverse Drug Reaction Reporting related to COVID-19 Positive patients and COVID-19 Vaccination	KCGMC, Karnal	81
7	15 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	ESICMC, Faridabad	57
8	15 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	SRMCH, Chennai	220
9	15 th April 2021	Sensitization programme on Basics Need of Pharmacovigilance and its importance	RCSSHL, Sullur	15
10	15 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	SJCP, Thrissur	70
11	16 th April 2021	Pharmacovigilance: A Challenge in COVID - 19 Pandemic	SCBMC, Cuttack	85
12	16 th April 2021	Pharmacovigilance Programme of India and Modes of ADR Reporting	MMC, Chennai	42
13	19 th April 2021	Highlight of ADRs due to COVID-19 Vaccination	NDMCMC, New Delhi	25
14	22 nd April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMCRI, Mysuru	21
15	22 nd April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	SMCGH, Kurnool	25
16	23 rd April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	TMMC-RC, Moradabad	110

17	27 th April 2021	Highlight of ADRs due to COVID 19 vaccination and safety measure	NDMCMC, New Delhi	30
18	28 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	CMMCH, Durg	11
19	28 th April 2021	Sensitization programme on Pharmacovigilance and AEFI Reporting	VPCI, New Delhi	16
20	30 th April 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Thiruvananthapuram	250
21	5 th May 2021	Sensitization programme on Pharmacovigilance and Drug Alert	TMMC-RC, Moradabad	106
22	10 th May 2021	Sensitization programme on Pharmacovigilance and ADRs/AEFI Reporting	VPCI, New Delhi	29
23	10 th May 2021	Introduction on Causality assessment and different methods used for causality assessments	SJCP, Thrissur	27
24	13 th May 2021	Sensitization programme on Pharmacovigilance Presence and Future Perspectives	GMC, Miraj	80
25	13 th May 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MKCG, Berhampur	73
26	15 th May 2021	General Awareness and Sensitization programme on COVID-19 vaccination and its Reporting	TMMC-RC, Moradabad	30
27	15 th May 2021	Sensitization programme on Pharmacovigilance and Patient Safety	RCSSHL, Sullur	17
28	15 th May 2021	Sensitization on Pharmacovigilance, ADR Reporting and Causality Assessment	SRMC, Chennai	10
29	19 th May 2021	Sensitization programme on ADR reporting during COVID-19 Pandemic	TMMC-RC, Moradabad	100
30	19 th May 2021	Sensitization on Pharmacovigilance, ADR Reporting, How to Stables AMC and Vigiflow Introduction	SRMC, Chennai	85
31	20 th May 2021	Sensitization on Role of Pharmacovigilance during COVID 19 Pandemic and ADR Reporting	NDMCMC, New Delhi	30
32	21 st May 2021	Sensitization programme on Pharmacovigilance and Patient Safety	IMSRC, Jaipur	3
33	21 st May 2021	Sensitization on Adverse Event Following Immunization COVID-19 Vaccination and AEFI Data Entry in Vigiflow	SRMC, Chennai	85

34	21 st May 2021	Pharmacovigilance and drug safety: Recent development & future perspectives	SRMSIMS, Bareilly	1
35	21 st May 2021	Sensitization programme on Pharmacovigilance	GMC, Palakkad	100
36	22 nd May 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Palakkad	100
37	24 th May 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMCRI, Mysuru	11
38	29 th May 2021	Sensitization training on ADR Reporting-A core need in COVID- 19 Pandemic for Safe Therapy	VMCHRI, Madurai	26
39	29 th May 2021	Sensitization training on ADR Reporting-A core need in COVID- 19 Pandemic for Safe Therapy	VMCHRI, Madurai	24
40	31 st May 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	CMMCH, Durg	5
41	31 st May 2021	Sensitization programme on Import and Processing of ICSRs	SRMSIMS, Bareilly	1
42	2 nd June 2021	Sensitization programme on Pharmacovigilance and ADR Reporting	GMC, Amritsar	18
43	2 nd June 2021	Pharmacovigilance programme of Indian and modes of ADR reporting under PvPI	MMC, Chennai	240
44	5 th June 2021	Sensitization training on ADR Reporting-A core need in COVID- 19 Pandemic for Safe Therapy	ACP, Malappuram	30
45	5 th June 2021	Sensitization training on ADR Reporting-A core need in COVID- 19 Pandemic for Safe Therapy	ACP, Malappuram	20
46	8 th June 2021	Sensitization programme on Pharmacovigilance and ADR Reporting	GMC, Amritsar	53
47	9 th June 2021	Sensitization programme on Pharmacovigilance and ADR Reporting	GMC, Amritsar	54
48	10 th June 2021	Adverse drug reaction AEFI and their reporting	AFMC, Pune	40
49	14 th June 2021	Sensitization Session on Adverse Drug Reaction monitoring and reporting	BMPMC, Vijayapura	40
50	15 th June 2021	Sensitization programme on Pharmacovigilance and ADR Reporting	GMC, Amritsar	35
51	16 th June 2021	Sensitization programme on Adverse Drug Reaction monitoring and reporting	BMPMC, Vijayapur	63

52	16 th June 2021	Sensitization programme on Pharmacovigilance and ADR Reporting	GMC, Amritsar	52
53	17 th June 2021	Sensitization on Pharmacovigilance & ADR reporting	GMC, Secunderabad	4
54	18 th June 2021	Sensitization Session on Pharmacovigilance and ADR reporting	KAMSRC, Hyderabad	100
55	18 th June 2021	Sensitization on Pharmacovigilance: adverse drug reactions of antitubercular drugs	MMC, Chennai	240
56	20 th June 2021	Sensitization programme on Pharmacovigilance and Scope of AMC enrolment	MKCG, Berhampur	40
57	21 st June 2021	Sensitization programme on Adverse Drug Reaction monitoring and reporting	BMPMC, Vijayapur	56
58	23 rd June 2021	Sensitization programme on Adverse Drug Reaction monitoring and reporting	BMPMC, Vijayapur	30
59	23 rd June 2021	Indian regulation in Pharmacovigilance	MKCG, Berhampur	100
60	25 th June 2021	Sensitization on Pharmacovigilance & ADR reporting	GMC-Secunderabad	219
61	25 th June 2021	Sensitization on Pharmacovigilance	GMC, Thiruvananthapuram	100
62	26 th June 2021	Sensitization on Pharmacovigilance & AEFI reporting	MMC, Chennai	220
63	26 th June 2021	Importance of Pharmacovigilance	RCSSH, Sullur	30
64	26 th June 2021	ADR reporting: A core need in COVID-19 pandemic safe therapy	VMCHRI, Madurai	47
65	28 th June 2021	Sensitization programme on Adverse Drug Reaction monitoring and reporting	BMPMC, Vijayapur	38
66	30 th June 2021	Sensitization programme on post COVID-19 side effect Reporting	VPCI, New Delhi	14
67	1 st July 2021	Sensitization on Pharmacovigilance and Safety data Generation	ELMCH, Lucknow	12
68	2 nd July 2021	Sensitization on Pharmacovigilance and ADR reporting	RMC, Ahmednagar	10
69	5 th July 2021	Opportunity to Pharmacy Industries to work as an AMC	MKCG, Berhampur	118

70	5 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	KGMC, Kanyakumari	5
71	7 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	KGMC, Kanyakumari	5
72	8 th July 2021	Pharmacovigilance regulation in India	MKCG, Berhampur	303
73	8 th July 2021	Sensitization on ICH guidelines for Pharmacovigilance & ADR Form filling	ELMCH, Lucknow	12
74	09 th July 2021	Sensitization & awareness programme on Pharmacovigilance and drug safety alert	TMMC-RC, Moradabad	95
75	10 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	PDUMC, Rajkot	37
76	10 th July 2021	Global Pharmacovigilance conference	MKCG, Berhampur	741
77	10 th July 2021	Pharmacovigilance programme of India and ADR reporting	AIIMS, Nagpur	23
78	12 th July 2021	Role of ADR Monitoring centre	MKCG, Berhampur	180
79	12 th July 2021	Pharmacovigilance regulations in India	MKCG, Berhampur	200
80	13 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	KGMC, Kanyakumari	23
81	14 th July 2021	Sensitization on Pharmacovigilance and ADR reporting	SBKSMI/RC, Waghodia	53
82	15 th July 2021	Pharmacovigilance awareness to new committee members	VIMS, Bengaluru	10
83	17 th July 2021	Online symposium on medication errors	MMC, Chennai	41
84	17 th July 2021	Sensitization on Pharmacovigilance	KMC, Kurnool	30
85	17 th July 2021	Pharmacovigilance Programme of India and ADR reporting	AIIMS, Nagpur	37
86	20 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	KGMC, Kanyakumari	21
87	20 th July 2021	Sensitization on Pharmacovigilance and PvPI Drug alert	VPCI, New Delhi	16
88	23 rd July 2021	Awareness Regarding COVID-19 vaccination	ELMCH, Lucknow	13

89	26 th July 2021	Sensitization on Pharmacovigilance and ADR reporting in VigiFlow	GTDMC, Alappuzha	3
90	27 th July 2021	Sensitization on Pharmacovigilance and ADR reporting and monitoring	KGMC, Kanyakumari	26
91	28 th July 2021	Pharmacovigilance awareness and hands on training	NEIGRIHMS, Shillong	25
92	28 th July 2021	Sensitization & awareness programme on ADMRS	TMMC-RC, Moradabad	19
93	29 th July 2021	Pharmacovigilance awareness and hands on training	NEIGRIHMS, Shillong	23
94	30 th July 2021	Pharmacovigilance in Pharmacoepidemiologic studies	NEIGRIHMS, Shillong	10
95	30 th July 2021	Sensitization on Pharmacovigilance	GMC, Guwahati	11
96	30 th July 2021	How to report ADR?	BJMC, Ahmedabad	28
97	31 st July 2021	Sensitization on Pharmacovigilance and ADR reporting Protocol	AIMS, Kochi	15
98	3 rd August 2021	Sensitization on Pharmacovigilance	RDGMC-Ujjain	28
99	3 rd August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KGMC, Kanyakumari	25
100	4 th August 2021	Sensitization & awareness programme on Drug alerts	TMMC-RC, Moradabad	109
101	4 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	SHPL, Lucknow	35
102	5 th August 2021	How to fill ADR reporting form?	SMCH, Silchar	15
103	5 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	SHPL, Lucknow	36
104	5 th to 6 th August 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	JSS-Mysuru	15
105	7 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	IGMCRI, Puducherry	130
106	7 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	IGMCRI, Puducherry	124
107	8 th August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KAMSRC, Hyderabad	30

108	9 th August 2021	Pharmacovigilance An overview	AIMS, Kochi	35
109	9 th August 2021	How to fill ADR report?	GMC, Kozhikode	45
110	9 th August 2021	Sensitization on AEFI reporting	SJCP, Thrissur	30
111	10 th August 2021	Basic concept of Pharmacovigilance	VPCI, New Delhi	5
112	10 th August 2021	How to fill ADR report?	GMC, Kozhikode	42
113	10 th August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KGMC, Kanyakumari	26
114	10 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	11
115	10 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	SJCP, Thrissur	15
116	11 th August 2021	How to fill ADR report?	GMC, Kozhikode	79
117	16 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	23
118	17 th August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KGMC, Kanyakumari	17
119	17 th August 2021	Awareness and sensitization on Pharmacovigilance and ADR reporting	JSS, Mysuru	25
120	18 th August 2021	Seminar on Rational use of drugs	TMMC-RC, Moradabad	120
121	19 th August 2021	Seminar on Rational use of drugs	TMMC-RC, Moradabad	80
122	21 st August 2021	Sensitization on Pharmacovigilance and ADR reporting	AFMC-Pune	115
123	22 nd August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	20
124	23 rd August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	17
125	23 rd August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	25
126	23 rd August 2021	Webinar on Pharmacovigilance and ADR reporting	KAMSRC, Hyderabad	25
127	24 th August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KGMC, Kanyakumari	15

128	24 th August 2021	Hand on training an ADR reporting	SJCP, Thrissur	70
129	24 th August 2021	Sensitization on Pharmacovigilance and ADR reporting	SJCP, Thrissur	21
130	26 th August 2021	ADR Reporting and monitoring in India under PVPI	JLNMC, Ajmer	34
131	30 th August 2021	Risk and benefits taking COVID-19 vaccine	NDMCMC, New Delhi	20
132	31 st August 2021	Sensitization on Pharmacovigilance and ADR reporting/monitoring	KGMC, Kanyakumari	20
133	31 st August 2021	Workshop cum sensitization programme on Pharmacovigilance	BJMC, Ahmedabad	75
134	31 st August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Palakkad	100
135	31 st August 2021	Sensitization on Pharmacovigilance and ADR reporting	GMC, Amritsar	14
136	31 st August 2021	Sensitization on Pharmacovigilance Drug safety and ADR reporting	ACP, Malappuram	50
137	1 st September 2021	Training and Awareness Programme on Pharmacovigilance and reporting Suspected Adverse Drug Reaction	GMC, Amritsar	67
138	2 nd September 2021	Training and Awareness Programme on Pharmacovigilance and reporting Suspected Adverse Drug Reaction	GMC, Amritsar	66
139	3 rd September 2021	Training and Awareness Programme on Pharmacovigilance and reporting Suspected Adverse Drug Reaction	GMC, Amritsar	67
140	3 rd September 2021	Seminar on Pharmacovigilance Programme of India	PGIMER, Chandigarh	50
141	3 rd September 2021	Sensitisation & Awareness Programme on Pharmacovigilance and ADR reporting	SVIMS, Tirupati	160
142	4 th September 2021	Need of Pharmacovigilance reporting and monitoring	OMC, Hyderabad	600
143	5 th September 2021	Sensitization on COVID-19 vaccination and medication awareness campaign	ACP, Malappuram	50
144	9 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	KGMC, Kanyakumari	22

145	12 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance and how to fill ADR reporting	ARMCH/RC, Solapur	12
146	13 th September 2021	Hands on training on Vigiflow and ADR reporting form	AIMS, Thrissur	33
147	14 th September 2021	Online sensitization webinar PvPI-An Overview	SDSTRC, Bengaluru	27
148	14 th September 2021	An awareness cum sensitization programme on Pharmacovigilance: A step towards patients' safety	SLNMCH, Koraput	12
149	14 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	47
150	14 th September 2021	Hands on training on Vigiflow and ADR reporting form	AIMS, Thrissur	33
151	15 th September 2021	An awareness cum sensitization programme on Pharmacovigilance: A step towards patients' safety	SLNMCH, Koraput	6
152	15 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic for Rayat Bahra University and Fortis Hospital	PGIMER, Chandigarh	141
153	15 th September 2021	Hands on training on Vigiflow and ADR reporting form	AIMS, Thrissur	33
154	15 th September 2021	Sensitisation & Awareness Programme on Pharmacovigilance and ADR reporting	SHPL Lucknow	33
155	16 th September 2021	Awareness cum sensitization programme on Pharmacovigilance	GKMC, Chennai	850
156	16 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	30
157	16 th September 2021	ADR classification and identification	JNMC, Aligarh	26
158	16 th September 2021	Interactive Sensitization session on Medication safety and Pharmacovigilance	SJMC, Bengaluru	30
159	24 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Thrissur	75
160	24 th September 2021	Online Webinar on Pharmacovigilance programme of India - An Overview	SDSTRC, Bengaluru	202

161	24 th September 2021	Hands on training Programme on reporting Adverse Drug Reaction	ELMCH, Lucknow	35
162	25 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GMC, Thiruvananthapuram	15
163	25 th September 2021	Awareness programme on hands on training of ADR reporting	IMSBHU, Varanasi	83
164	25 th September 2021	Sensitisation of ADR reporting	VIMS, Bengaluru	100
165	25 th September 2021	Sensitization on future prospective of Pharmacovigilance	ACP, Malappuram	50
166	27 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting	ARMCH/RC, Solapur	27
167	28 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	KGMC, Kanyakumari	10
168	28 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GMERSMC, Ahmedabad	34
169	30 th September 2021	How to fill up suspected ADR form?	RGKMC, Kolkata	81
170	30 th September 2021	Sensitization on Pharmacovigilance and Clinical activities	ACP, Malappuram	100
171	31 st September 2021	How to fill up suspected ADR form?	RGKMC, Kolkata	84
172	01 st October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMIMSR, Mullanas	3
173	03 rd October 2021	International webinar on research and communication in Pharmacovigilance	MKCG, Berhampur	214
174	05 th October 2021	Seminar on Pharmacovigilance programme of India	KGMC, Kanyakumari	16
175	05 th October 2021	Pharmacovigilance and hands - on training in ADR form filling	ACP, Malappuram	30
176	05 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	TMMC&RC, Moradabad	121
177	06 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MIMER, Mizoram	100
178	07 th October 2021	National conference on Pharmacovigilance and ADRs Reporting	SVIMS, Tirupati	130

179	07 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	JIPMER, Puducherry	14
180	08 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	KAMSRC, Hyderabad	15
181	11 th October 2021	Sensitization programme on How to fill suspected ADR form	ACTRE, Navi Mumbai	11
182	12 th October 2021	Seminar on Pharmacovigilance programme of India	KGMC, Kanyakumari	48
183	12 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	KGMC, Kanyakumari	13
184	12 th October 2021	Sensitization programme on How to fill suspected ADR form	ACTRE, Navi Mumbai	5
185	13 th October 2021	Pharmacovigilance Awareness with biomedical waste programme	NDMCMC, New Delhi	9
186	13 th October 2021	Pharmacovigilance sensitization programme for pharmacist	NDMCMC, New Delhi	39
187	13 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	AFMC, Pune	120
188	13 th October 2021	Sensitization programme on How to fill suspected ADR form	ACTRE, Navi Mumbai	20
189	13 th October 2021	Sensitization programme on Pharmacovigilance: reporting of ADR	SHPL, Lucknow	28
190	14 th October 2021	Sensitization programme - Why Pharmacovigilance need & what to do	JNMC, Aligarh	20
191	14 th October 2021	Sensitization programme on Pharmacovigilance and ADR reporting	PGIMER, Chandigarh	22
192	18 th October 2021	Pharmacovigilance and hands - on training in ADR form filling	ACP, Malappuram	30
193	19 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMIMSR, Mullana	11
194	20 th October 2021	How to fill suspected ADR reporting form?	GTDMC, Alappuzha	150
195	21 st October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	KMC, Kurnool	28
196	21 st October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting; Where to report? Why to Report?	SGPGIMS, Lucknow	23
197	21 st October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	SGPGIMS, Lucknow	12

198	21 st October 2021	Sensitization programme on ADRs Reporting; Where to report? Why to Report?	SGPGIMS, Lucknow	16
199	22 nd October 2021	Seminar on Pharmacovigilance programme of India	MIMER, Mizoram	60
200	22 nd October 2021	Sensitization programme on How to fill suspected ADR form	ACTRE, Navi Mumbai	25
201	22 nd October 2021	Sensitization programme on Pharmacovigilance: Reporting of ADR	CIMS, Ahmedabad	33
202	25 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	SGPGIMS, Lucknow	12
203	26 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	VPCI, New Delhi	22
204	26 th October 2021	Awareness on ADR and Pharmacovigilance programme of India	TMMC&RC, Moradabad	34
205	27 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	KGMC, Kanyakumari	10
206	27 th October 2021	Sensitization programme on Pharmacovigilance and medication errors	JSS, Mysuru	60
207	27 th October 2021	Sensitization programme on ADR reporting and Pharmacovigilance programme of India	AIIMS, Bhopal	75
208	27 th October 2021	How to report ADR and methods find to ADR in Hospitals	SJCP, Thrissur	12
209	29 th October 2021	Basic aspects of ADR reporting	SJCP, Thrissur	10
210	29 th October 2021	How to report ADR and methods find to ADR in Hospitals	SJCP, Thrissur	12
211	29 th October 2021	How to Review ADR reporting ?	KIMS, Nalgonda	13
212	30 th October 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	VMCHRI, Madurai	71
213	30 th October 2021	Basic aspects of ADR reporting	SJCP, Thrissur	11
214	1 st November 2021	Sensitization programme on Environmental Pharmacovigilance	JNMC, Aligarh	251
215	1 st November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GCMCH, Chengalpattu	20
216	2 nd November 2021	Sensitization programme on Pharmacovigilance	JNMC, Aligarh	26
217	2 nd November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Baramulla	33

218	3 rd November 2021	Sensitization programme on Environmental Pharmacovigilance	JNMC, Aligarh	183
219	3 rd November 2021	Introduction to VigiFlow and key aspect of reporting through VigiFlow	SJCP, Thrissur	12
220	3 rd November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Baramulla	33
221	5 th November 2021	Sensitization programme on Pharmacovigilance and Analysis the pattern of ADR in TB	GMC, Trivandrum	16
222	5 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Baramulla	33
223	7 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	VPCI, New Delhi	17
224	8 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	MMIMS, Mullana	72
225	8 th November 2021	Sensitization programme on Pharmacovigilance	AIMS, Kochi	58
226	9 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	MMIMS, Mullana	75
227	11 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	KMC, Kurnool	85
228	11 th November 2021	Pharmacovigilance awareness programme regarding the adverse event	NDMCMC, New Delhi	25
229	12 th November 2021	Sensitization programme on Pharmacovigilance and Rational use of medicine	TMMC-RC, Moradabad	116
230	12 th November 2021	Pharmacovigilance awareness programme regarding the adverse event	NDMCMC, New Delhi	15
231	13 th November 2021	Awareness of vaccination related ADR in cancer patients	ACTRE, Navi Mumbai	20
232	15 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	MMIMS, Mullana	68
233	15 th November 2021	Importance of PvPI, collection and filling ADR form	HMCH, Bhubaneswar	18
234	16 th November 2021	Sensitization programme on Pharmacovigilance and Causality assessment Scale	MMIMS, Mullana	71
235	16 th November 2021	International webinar on Pharmacovigilance	MKCG, Berhampur	238

236	16th November 2021	Pharmacovigilance awareness and how to report ADR	GMC, Kozhikode	16
237	17th November 2021	Sensitization programme on Pharmacovigilance and hands on training of ADR reporting	PJNMC, Raipur	16
238	17th November 2021	Discussion on ADR report: Diclofenac injection included hypersensitivity	GMC, Miraj	15
239	17th November 2021	How to fill ADR form and ADR reporting and how can easily find out reporting form in hospital setting	SJCP, Thrissur	20
240	17th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SHPL, Lucknow	26
241	18th November 2021	Sensitization and awareness programme for safe medication practices	JSS, Mysuru	110
242	18th November 2021	Sensitization programme on Pharmacovigilance and Monitoring/ reporting of ADR	SVMC, Tirupati	60
243	18th November 2021	Awareness activity on "How to report ADR in India and ADR Toll free Number"	CMMCH, Durg	18
244	19th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	KFMSR, Coimbatore	25
245	20th November 2021	Pharmacovigilance -Importance of ADR reporting and modes of ADR reporting	MMC, Chennai	7
246	20th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	KAMSRC, Hyderabad	20
247	22nd November 2021	Importance of PvPI, collection and filling ADR form	HMCH, Bhubaneswar	23
248	22nd November 2021	Sensitization programme- A method of reporting in cancer clinical trials	ACTRE, Navi Mumbai	25
249	23rd November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	ELMCH, Lucknow	29
250	23rd November 2021	Webinar on antibiotic stewardship programme	JSS, Mysuru	244
251	23rd November 2021	Sensitization programme on Pharmacovigilance and reporting of adverse drug reaction	SVIMS, Tirupati	24
252	23rd November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GCMCH, Chengalpattu	86
253	24th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	IGIMS, Patna	15

254	24 th November 2021	Sensitization programme on Pharmacovigilance and Drug alert	TMMC-RC, Moradabad	18
255	24 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GCMCH, Chengalpattu	90
256	25 th November 2021	Sensitization and awareness on Pharmacovigilance	GMC, Nagpur	10
257	26 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Miraj	100
258	26 th November 2021	MvPI modes of ADR reporting under MvPI	MMC, Chennai,	17
259	27 th November 2021	Sensitization programme on Pharmacovigilance	IGMCRI, Puducherry	63
260	27 th November 2021	Sensitization programme on Pharmacovigilance and ADR reporting	AIMS, Kochi	15
261	29 th November 2021	Sensitization programme on Pharmacovigilance and reporting of adverse drug reaction	SVIMS, Tirupati	6
262	29 th November 2021	How to report ADR in India and ADR Toll free Number?	CMMCH, Durg	11
263	1 st December 2021	Reporting of Adverse Drug reaction and its need	ACP, Malappuram	150
264	1 st December 2021	Pharmacovigilance Programme of India and How to file ADR Report	AIIMS, Bhopal	58
265	2 nd December 2021	Sensitization Programme on ADR awareness and ADR reporting	JNIMS, Imphal	56
266	2 nd December 2021	Sensitization and Awareness Programme on Pharmacovigilance	MIMER, Mizoram	200
267	2 nd December 2021	Pharmacovigilance Programme of India and How to file ADR Report	AIIMS, Bhopal	61
268	3 rd December 2021	Sensitization Programme on Pharmacovigilance	KIMS, Nalgonda	25
269	4 th December 2021	Sensitization Programme on Pharmacovigilance	KFMSR, Coimbatore	150
270	4 th December 2021	Sensitization on Pharmacovigilance to improve ADR reporting	SRMC, Chennai	28
271	4 th December 2021	Pharmacovigilance and ADR reporting to PvPI and Hands on filling of HCPs ADR form	OMC, Hyderabad	35
272	6 th December 2021	Pharmacovigilance Programme of India and how to file ADR Report	AIMS, Kochi	15
273	6 th December 2021	Hands on training of Suspected ADR reporting form Version 1.4	KAMSRC, Hyderabad	20

274	6 th December 2021	Reporting of ADR through Vigiflow software	SJCP, Thrissur	15
275	8 th December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	ELMCH, Lucknow	13
276	8 th December 2021	Pharmacovigilance Programme of India and How to fill ADR Report	KIMS, Nalgonda	54
277	8 th December 2021	Strategies to improve ADR reporting and resource materials for ADR reporting	SHPL, Lucknow	29
278	9 th December 2021	Sensitization Programme on Pharmacovigilance: What is ADR and ADE, how to report and what is causality assessments	JNIMS, Imphal	40
279	9 th December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	38
280	9 th December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	28
281	10 th December 2021	Reporting of Adverse Drug reaction Hands on Training	AFMC, Pune	10
282	10 th December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	ELMCH, Lucknow	9
283	10 th December 2021	Sensitization Programme on Pharmacovigilance	GMC, Virudhunagar	26
284	13 th December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	GKMC, Chennai	130
285	13 th December 2021	Types of ADR reporting and its importance	HMCH, Bhubaneswar	32
286	13 th December 2021	Importance of Pharmacovigilance and ADR reporting	JNIMS, Imphal	14
287	13 th December 2021	ADRs and AEFIs Monitoring and Reporting System in India under PvPI	JLNMC, Ajmer	11
288	14 th December 2021	Awareness Programme on Pharmacovigilance, Hemovigilance, AEFI	GMC, Guntur	6
289	14 th December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	28
290	14 th December 2021	Hands on Training of VigiFlow entry	IPGMER, Kolkata	6
291	14 th December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	38
292	14 th December 2021	How to enhance ADR reporting?	RDGMC, Ujjain	37
293	15 th December 2021	Sensitization and awareness on Pharmacovigilance	GMC, Kozhikode	39
294	15 th December 2021	How to fill up ADR form?	RGKMC, Kolkata	6

295	15 th December 2021	Hands on training to fill ADR reporting form	JNMC, Aligarh	38
296	16 th December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	20
297	16 th December 2021	Sensitization Programme on Pharmacovigilance	MAIMSR, Chengalpattu	19
298	17 th December 2021	Introduction of Pharmacovigilance and Methods of ADR Reporting	ARMCH/RC, Solapur	28
299	17 th December 2021	How to fill up ADR form?	RGKMC, Kolkata	15
300	17 th December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	DRGMCH, Hamirpur	120
301	17 th December 2021	Introduction of Pharmacovigilance and methods of ADR reporting	ARMCH/RC, Solapur	28
302	18 th December 2021	Essential of Pharmacovigilance: Basic to Advanced	AIMS, Kochi	105
303	18 th December 2021	Webinar on "Essentials of Pharmacovigilance: Basics to Advanced"	JSS, Mysuru	110
304	20 th December 2021	Importance of Pharmacovigilance and ADR reporting	JNIMS, Imphal	52
305	20 th December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	GMERS, Gandhinagar	25
306	20 th December 2021	Reporting of vaccination related ADR through Vigiflow software	SJCPS, Thrissur	17
307	21 st December 2021	Awareness Programme on Pharmacovigilance and Hands on training	SMVMCH, Puducherry	26
308	21 st December 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	11
309	22 nd December 2021	Sensitization Programme on Pharmacovigilance: What is ADR and ADE, how to report and what is causality assessments	JNIMS, Imphal	30
310	22 nd December 2021	Hands on training to fill ADR reporting form	JNMC, Aligarh	39
311	22 nd December 2021	Sensitization Programme on Pharmacovigilance	GMC, Baramulla	10
312	22 nd December 2021	Workshop on Pharmacovigilance and reporting of adverse drug reaction	SVIMS, Tirupati	246
313	22 nd December 2021	ADR Sensitization along with query resolution	GMERS, Gandhinagar	27
314	23 rd December 2021	Importance of ADR reporting on Society	HMCH, Bhubaneswar	40
315	23 rd December 2021	Sensitization on Pharmacovigilance to improve ADR reporting	SRMC, Chennai	63

316	23 rd December 2021	Sensitization and awareness on Pharmacovigilance	SRMC, Chennai	38
317	23 rd December 2021	How to Fill and report of ADR form and Scope of Pharmacovigilance in India	SMCGH, Kurnool	90
318	23 rd December 2021	Sensitization Programme on Pharmacovigilance	GMC, Baramulla	10
319	24 th December 2021	Online Pharmacovigilance Awareness programme on Anti-Retroviral Drugs	IGMCRI, Puducherry	35
320	24 th December 2021	One day in persons conference Theme: Pharmacovigilance from students' perspective	IMT, Puri	86
321	24 th December 2021	Sensitization programme on Good Pharmacovigilance Practices	GMERS, Gandhinagar	20
322	27 th December 2021	Sensitization and awareness on Pharmacovigilance	MMIMS, Mullana	48
323	27 th December 2021	Pharmacovigilance Programme of India and How to file ADR Report	SMCH, Silchar	40
324	28 th December 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	35
325	29 th December 2021	Basic concepts of Pharmacovigilance and ADR reporting	IGIMS, Patna	42
326	29 th December 2021	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	15
327	29 th December 2021	Sensitization Programme on Pharmacovigilance	GMC, Virudhunagar	10
328	29 th December 2021	Sensitization Programme on Pharmacovigilance	GMC, Virudhunagar	15
329	30 th December 2021	Sensitization and awareness on Pharmacovigilance	MMIMS, Mullana	16
330	30 th December 2021	Awareness of vaccination related ADR in patients and Health care staff	ACTRE, Navi Mumbai	10
331	30 th December 2021	Basic concepts of Pharmacology and ADR reporting	IGIMS, Patna	75
332	31 st December 2021	Importance of Pharmacovigilance and How to file ADR report	AIMS, Kochi	38
333	31 st December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting	MGMC, Jaipur	20
334	31 st December 2021	Sensitization Programme on Pharmacovigilance and ADR reporting for Pharmacist	ACTRE, Navi Mumbai	6
335	31 st December 2021	ADR reporting with Dental prescription and ADR filling form	OMC, Hyderabad	87

336	3 rd January 2022	NABH training: Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Baramulla	9
337	3 rd January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	IGMCRI, Puducherry	60
338	5 th January 2022	How to fill ADR Form?	AIMS, Thrissur	6
339	5 th January 2022	Discussion on ADR reporting	GMC, Miraj	15
340	5 th January 2022	Sensitization training programme on Pharmacovigilance for consumer	LTMMCGH, Mumbai	13
341	5 th January 2022	Awareness sensitization activity on "PvPI and ADR Toll free Number"	CMMCH, Durg	80
342	6 th January 2022	How to filling of ADR forms?	HMCH, Bhubaneswar	16
343	6 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JSS, Mysuru	19
344	6 th January 2022	Sensitization programme on Pharmacovigilance	MMC, Chennai	20
345	6 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGMCH, Jaipur	46
346	6 th January 2022	Awareness sensitization activity on "PvPI and ADR Toll free Number"	CMMCH, Durg	30
347	7 th January 2022	Workshop cum Sensitization Programme on Pharmacovigilance	GMC, Virudhunagar	9
348	8 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JNMC, Wardha	26
349	8 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	SMCH, Silchar	43
350	10 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	AFMC, Pune	10
351	10 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting for nursing student	KGMC, Kanyakumari	44
352	10 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMIMSR, Mullana	36
353	10 th January 2022	Awareness and sensitization for ADR reporting	RMC, Loni	11
354	11 th January 2022	How to fill ADR Form?	AIMS, Thrissur	4
355	11 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KAMSRC, Hyderabad	20
356	12 th January 2022	COVID-19 and its impact on ADRs	HMCH, Bhubaneswar	14

357	12 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VIMS, Bengaluru	32
358	12 th January 2022	Sensitization & Awareness Programme on Pharmacovigilance	NIMS, Hyderabad	140
359	13 th January 2022	Sensitization on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	13
360	14 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	ACP, Malappuram	75
361	14 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	ACP, Malappuram	65
362	14 th January 2022	Sensitization programme on Pharmacovigilance and adverse drug reaction reporting form and entering data in VigiFlow	KEM, Mumbai	1
363	14 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	SGPGIMS, Lucknow	10
364	15 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	ELMCH, Lucknow	68
365	15 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	15
366	16 th January 2022	Online Sensitization programme on Pharmacovigilance and AEFI filing	SDSRTC, Bangalore	15
367	17 th January 2022	Basics on Pharmacovigilance	KIMS, Nalgonda	25
368	17 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	RMC, Loni	10
369	18 th January 2022	Sensitization and awareness on Pharmacovigilance and NFI	VPCI, New Delhi	5
370	18 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Miraj	100
371	19 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	BJGMC, Pune	15
372	19 th January 2022	Pharmacovigilance Awareness and ADR reporting	GMC, Kozhikode	45
373	20 th January 2022	How to fill ADR Form?	JNMC, Aligarh	17
374	20 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	PSGIMS, Coimbatore	33
375	20 th January 2022	Sensitization programme on Pharmacovigilance and adverse drug reaction reporting form and entering data in VigiFlow	KEM, Mumbai	1
376	20 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KIMS, Nalgonda	12

377	20 th January 2022	Sensitization programme on ADR reporting form	KMC, Kumool	29
378	20 th January 2022	Causality Assessment Committee Meeting - Monthly Training on Causality assessment scale and ADR Reporting	TNMC, Mumbai	24
379	21 st January 2022	Workshop cum Sensitization Programme on Pharmacovigilance	GMC, Virudhunagar	16
380	21 st January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	PSGIMSR, Coimbatore	2
381	21 st January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KFMSR, Coimbatore	25
382	22 nd January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	AFMC, Pune	28
383	22 nd January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KAMSRC, Hyderabad	150
384	22 nd January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	DRGMCH, Hamirpur	26
385	22 nd January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	SGPGIMS, Lucknow	14
386	24 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	15
387	25 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Nilgiris	38
388	25 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	SMCW, Pune	45
389	25 th January 2022	Sensitization training programme for HCP	LTMCGH, Mumbai	6
390	25 th January 2022	Demonstration on ADR reporting and Causality Assessment	MMC, Chennai	202
391	26 th January 2022	How to fill ADR Form?	JNMC, Aligarh	11
392	27 th January 2022	What is ADR and AE and how to Report and What is Causality assessments?	JNMC, Wardha	41
393	27 th January 2022	Awareness Programme on Pharmacovigilance, Hemovigilance, AEFI	GMC, Guntur	15
394	27 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VMCHRI, Madurai	101
395	27 th January 2022	Hands on exercise on PV and ADR reporting	MMIMSR, Mullana	24
396	28 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Amritsar	37

397	28 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	PSGIMSR, Coimbatore	3
398	28 th January 2022	Medication Safety and ADR reporting	JMMCRI, Thrissur	39
399	28 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	DRGMCH, Hamirpur	30
400	28 th January 2022	How to fill ADR reporting form?	SMCH, Silchar	20
401	28 th January 2022	How to collect and report ADR?	FMMC, Mangaluru	30
402	29 th January 2022	Sensitization on preparatory measures on identification of ADR and target setting -an integrated approach	GMC, Nilgiris	12
403	29 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	IGMCRI, Puducherry	100
404	29 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	SIMSRC, Mangalore	7
405	30 th January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MLBMC, Jhansi	50
406	30 th January 2022	Online Interaction on Clinical Perspective	SDSTRC, Bengaluru	73
407	31 st January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MLBMC, Jhansi	50
408	31 st January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Amritsar	57
409	31 st January 2022	Sensitization on preparatory measures on identification of ADR and target setting -an integrated approach	GMC, Nilgiris	15
410	31 st January 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KFMSR, Coimbatore	23
411	31 st January 2022	Reporting tools of AEFI filling and ADR reporting	SVIMS, Tirupati	54
412	1 st February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MLBMC, Jhansi	50
413	1 st February 2022	Sensitization programme on ADR Monitoring and reporting system in India under PvPI	JNMC, Ajmer	13
414	2 nd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JIPMER, Puducherry	3
415	3 rd February 2022	Awareness programme on Pharmacovigilance and ADR reporting	AIIMS, Nagpur	26
416	3 rd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Wardha	15
417	4 th February 2022	Awareness programme on Medication Error and ADR reporting	YMCH	30

418	4 th February 2022	Introduction of Pharmacovigilance programme of India	PGIMS- Haryana	15
419	4 th February 2022	Sensitization programme on ADR Monitoring and reporting system in India under PvPI	PSGIMSR, Coimbatore	3
420	5 th February 2022	Awareness programme on Pharmacovigilance and ADR reporting	YMCH	49
421	5 th February 2022	Training about importance of Pharmacovigilance activity and filling of ADR form	KEM, Mumbai	8
422	5 th February 2022	Importance and reporting of ADR and AE following immunization	SVIMS, Tirupati	55
423	5 th February 2022	How to fill ADR reporting form?	AIMS, Thrissur	10
424	7 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	NIMS, Hyderabad	40
425	7 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	RMC, Ahmednagar	11
426	7 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GKMC, Chennai	95
427	8 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GCMCH, Chengalpattu	240
428	8 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMC, Chennai	39
429	8 th February 2022	How to ADR form filling and reporting?	AIMS, Thrissur	15
430	9 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	AFMC, Pune	12
431	9 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMERS, Gandhinagar	25
432	9 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KIMS, Nalgonda	25
433	9 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMCRI, Mysuru	26
434	10 th February 2022	Essential Pharmacovigilance to patient safety	MMC, Chennai	256
435	10 th February 2022	Importance of Pharmacovigilance programme and how to fill ADR reporting forms	MLBMC, Jhansi	10
436	10 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMIMSR, Mullana	25
437	10 th February 2022	Importance of ADR reporting and Pharmacovigilance programme of India	AIMS, Kochi	20

438	10 th February 2022	How to ADR form filling and reporting?	AIMS, Thrissur	10
439	11 th February 2022	How to fill ADR reporting form?	PGIMS- Haryana	15
440	11 th February 2022	What is Adverse drug reaction and how to fill ADR form?	GMC, Miraj	50
441	11 th February 2022	How to report ADR and upload in VigiFlow?	PSGIMSR, Coimbatore	3
442	12 th February 2022	Importance of reporting to improve patient safety	RCSSH, Coimbatore	12
443	12 th February 2022	Awareness programme of Pharmacovigilance and tools of ADR reporting	DRGMCH, Hamirpur	32
444	13 th February 2022	Awareness programme of Pharmacovigilance and tools of ADR reporting	DRGMCH, Hamirpur	29
445	14 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Kozhikode	10
446	14 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JSS, Mysuru	70
447	14 th February 2022	Adverse drug reaction and demo on ADR form filling	PDUMC-Rajkot	6
448	14 th February 2022	Sensitization programme on Pharmacovigilance and how to establish AMC?	ACP, Malappuram	40
449	15 th February 2022	Sensitization programme on Reporting of ADR to AMCs	GMC, Miraj	15
450	15 th February 2022	Sensitization training about importance of Pharmacovigilance and filling of ADR form	KEM, Mumbai	6
451	15 th February 2022	Sensitization programme on SADR form reporting	RGKMC, Kolkata	2
452	15 th February 2022	What is Adverse drug reaction and how to fill ADR form	AIMS, Thrissur	7
453	15 th February 2022	Sensitization on Pharmacovigilance - A step towards patients' safety	VPCI, New Delhi	16
454	16 th February 2022	Awareness of Pharmacovigilance for consumers	BJMC, Pune	16
455	16 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JNIMS, Imphal	3
456	16 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KFMSR, Coimbatore	5
457	16 th February 2022	Awareness programme on Pharmacovigilance	NSMC, Kolkata	7
458	16 th February 2022	Enhance ADR Reporting awareness programme	RDGMC, Ujjain	90

459	16 th February 2022	Sensitization training about importance of Pharmacovigilance and filling of ADR form	KEM, Mumbai	2
460	16 th February 2022	Awareness programme on Pharmacovigilance and ADR reporting	VMCHRI, Madurai	105
461	17 th February 2022	Basic concept of Pharmacovigilance	JNMC, Aligarh	22
462	17 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KFMSR, Coimbatore	19
463	17 th February 2022	Filling of ADR form and reporting and improve quality of ADR	SMCGH, Kurnool	20
464	17 th February 2022	Sensitization programme on Medication safety and ADR reporting	JMMCRI, Thrissur	50
465	17 th February 2022	VigiFlow demonstration	JIPMER, Puducherry	3
466	18 th February 2022	Signal Detection in Pharmacovigilance	JSS, Mysuru	60
467	18 th February 2022	Hands on training of ADR form filling?	MMIMSR, Mullana	24
468	18 th February 2022	Hands on training of ADR form filling?	PSGIMSR, Coimbatore	3
469	18 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VIMS, Bengaluru	40
470	18 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Sevagram	12
471	18 th February 2022	Pharmacovigilance and Medicine safety	AIIMS, Bathinda	103
472	18 th February 2022	Sensitization programme on Pharmacovigilance and Materiovigilance	KMC, Kurnool	56
473	19 th February 2022	Sensitization programme on Pharmacovigilance and Materiovigilance	KMC, Kurnool	28
474	21 st February 2022	How to fill an ADR and Report it?	GMC, Baramulla	10
475	21 st February 2022	ADR Monitoring and reporting system in India under PvPI	JLNMC, Ajmer	9
476	21 st February 2022	Online VigiFlow training for under reporting AMC under Ease Zone RTC	IPGMER, Kolkata	6
477	21 st February 2022	Introduction of Pharmacovigilance programme of India and How to recognize and report Adverse Drug reaction	RMLIMS, Lucknow	118
478	22 nd February 2022	Introduction of Pharmacovigilance programme of India and How to recognize and report Adverse Drug reaction	RMLIMS, Lucknow	36
479	22 nd February 2022	Sensitization and Awareness Programme on Patient Safety	JSS, Mysuru	260

480	22 nd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MMCHRI, Kanchipuram	87
481	22 nd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	NIMS, Hyderabad	50
482	22 nd February 2022	Medication safety and ADR reporting	JMMCRI, Thrissur	76
483	22 nd to 23 rd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KMC, Manipal	250
484	23 rd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	CMCH, Coimbatore	5
485	23 rd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JSS, Mysuru	240
486	23 rd February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	KFMSR, Coimbatore	18
487	23 rd February 2022	Sensitization and Awareness Programme on Patient Safety	VPCI, New Delhi	23
488	24 th February 2022	Sensitization and Awareness Programme on Patient Safety	JSS, Mysuru	365
489	24 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VIMS, Bengaluru	26
490	24 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	RMC, Ahmednagar	15
491	24 th February 2022	Importance of ADR reporting and Pharmacovigilance programme of India	AIMS, Kochi	80
492	24 th February 2022	Sensitization programme on ADR Monitoring and drug information service	KMC, Manipal	40
493	24 th February 2022	Sensitization programme on Iron injection and its safer administration	ACP, Malappuram	127
494	25 th February 2022	Importance of ADR reporting, role of PvPI and How to fill ADR reporting forms	MLBMC, Jhansi	5
495	25 th February 2022	Sensitization on Pharmacovigilance and Vigiflow software	GMC, Guntur	160
496	25 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JNMC, Aligarh	6
497	25 th February 2022	Awareness Programme on Patient Safety	JSS, Mysuru	370
498	25 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting and uploading	PSGIMS, Coimbatore	3
499	25 th February 2022	Sensitization programme on Pharmacovigilance and ADR and AEFI Reporting	GMCH, Nagpur	7

500	25 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GKMC, Chennai	90
501	25 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VMCHRI, Madurai	101
502	25 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	RGKMC, Kolkata	6
503	26 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting along with query resolution	GMERS, Gandhinagar	30
504	26 th February 2022	Sensitization programme on Pharmacovigilance in medicine ward	JNIMS, Imphal	8
505	26 th February 2022	Sensitization programme on Pharmacovigilance at Jan Ausadhi Store	JNIMS, Imphal	3
506	26 th February 2022	Awareness Programme on Patient Safety	JSS, Mysuru	330
507	26 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	RCSSH, Coimbatore	11
508	26 th February 2022	Public awareness programme "Taking Medicine, the right way!"	AIMS, Kochi	40
509	26 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GKMC, Chennai	80
510	27 th February 2022	Awareness Programme on Patient Safety	JSS, Mysuru	430
511	28 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GCMCH, Chengalpattu	30
512	28 th February 2022	Introduction of Pharmacovigilance programme of India and How to recognize and report Adverse Drug reaction	RMLIMS, Lucknow	10
513	28 th February 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Guntur	12
514	28 th February 2022	Awareness Programme on Patient Safety	JSS, Mysuru	360
515	28 th February 2022	Pharmacovigilance sensitization Programme and ADR reporting	AIMS, Kochi	30
516	28 th February 2022	Sensitization programme on Pharmacovigilance and Drug safety	GMC, Thiruvananthapuram	71
517	1 st March 2022	How to fill ADR reporting form?	PDUMC, Rajkot	9
518	2 nd March 2022	Importance of Pharmacovigilance and filling of ADR form	KEM, Mumbai	1
519	2 nd March 2022	Sensitization programme on Pharmacovigilance and ADR Reporting System	MMIMSR, Mullana	60
520	2 nd March 2022	Sensitization training about importance of Pharmacovigilance and filling of ADR	KEM, Mumbai	11

521	3 rd March 2022	Training about importance of Pharmacovigilance and filling of ADR form and entering data in VigiFlow	KEM, Mumbai	1
522	3 rd March 2022	Pharmacovigilance and Materiovigilance Reporting and sensitization. An awareness seminar targeting medical students	CMJNM, Nadia	11
523	3 rd March 2022	Sensitization programme on Monitoring and reporting of Adverse Drug Reactions and AEFI	SVIMS, Tirupati	15
524	3 rd March 2022	Sensitization programme on Monitoring and reporting of ADRS and AEFI	SVIMS, Tirupati	15
525	3 rd March 2022	Sensitization programme on Pharmacovigilance on Deworming Day	SVIMS, Tirupati	100
526	4 th March 2022	Sensitization Programme an ADR awareness and ADR reporting	KEM, Mumbai	29
527	4 th March 2022	Sensitization programme on Medication Error and ADR reporting	YMC, Mangalore	39
528	4 th March 2022	Sensitization Program on ADR Awareness & ADR Reporting	JNMC, Wardha	63
529	4 th March 2022	Sensitization programme on ADR reporting	PDUMC, Rajkot	181
530	4 th March 2022	Sensitization and awareness programme on Pharmacovigilance Programme of India	VIMS, Bengaluru	12
531	4 th March 2022	Online webinar -"Adverse Drug Reaction Monitoring and Reporting"	KFMSR, Coimbatore	120
532	5 th March 2022	Pharmacovigilance Programme of India and Reporting of Adverse Drug Reactions	RMC, Kakinada	10
533	5 th March 2022	Adverse drug reaction Reporting and drug information services	KMC, Manipal	25
534	7 th March 2022	Sensitization programme on safe administration of Albendazole on National Deworming day's	GMC, Guntur	280
535	7 th March 2022	Pharmacovigilance ADR reporting System for Paediatrics	GMC, Amritsar	25
536	8 th March 2022	Adverse Drug Reaction reporting & Pharmacovigilance Program of India	MMC, Chennai	50
537	8 th March 2022	Principles of Pharmacovigilance and ADR Reporting	KMC, Warangal	86
538	8 th March 2022	Pharmacovigilance ADR reporting System for Ophthalmology	GMC, Amritsar	25
539	8 th March 2022	Pharmacovigilance ADR reporting System for Blood Transfusion Division	GMC, Amritsar	5
540	8 th March 2022	Online webinar on "Preventing ADR in women population"	KFMSR, Coimbatore	280

541	8 th March 2022	How to fill ADR reporting and objective of PvPI	RGKMC, Kolkata	17
542	9 th March 2022	Sensitization programme on PvPI & ADR monitoring	MGIMS, Sevagram	10
543	9 th March 2022	How to Increase ADR reporting?	MMIMSR, Mullana	25
544	9 th March 2022	Sensitization Programme on Pharmacovigilance and Adverse Drug Reaction reporting	MLBMC, Jhansi	3
545	9 th March 2022	Pharmacovigilance sensitization Programme	SBKSMI/RC, Waghodia	100
546	10 th March 2022	Hospitals Internship training on Pharmacovigilance	NSMC, Kolkata	2
547	10 th March 2022	ADR sensitization along with query resolution regarding ADR form	GMERS, Gandhinagar	30
548	10 th March 2022	Pharmacovigilance sensitization Programme and ADR reporting	AIIMS, New Delhi	50
549	10 th March 2022	Awareness and Sensitization activity on Pharmacovigilance	GKMCH, Chennai	250
550	10 th March 2022	Sensitization Programme on Pharmacovigilance and Adverse Drug Reaction Reporting	SMC, Meerut	147
551	10 th March 2022	Sensitization programme on Pharmacovigilance and ADR reporting for Paramedical students	KMC, Kurnool	20
552	10 th March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	ESIMCH, Hyderabad	20
553	11 th March 2022	Pharmacovigilance sensitization Programme for PG students	KIMS, Nalgonda	13
554	11 th March 2022	Sensitization and awareness programme on Pharmacovigilance	NIMS, Hyderabad	25
555	11 th March 2022	Sensitization programme on Carrier in Pharmacovigilance	IPGMER, Kolkata	80
556	11 th March 2022	Sensitization and awareness programme on Pharmacovigilance	VIMS, Bengaluru	22
557	12 th March 2022	Sensitization and Awareness Programme on Pharmacovigilance	SCBMC, Cuttack	11
558	14 th March 2022	ADR sensitization along with query resolution/ Case discussion	GMERS, Gandhinagar	35
559	14 th March 2022	Overview: Pharmacovigilance, ADR reporting & AEFI	SNMC, Agra	37
560	15 th March 2022	Pharmacovigilance Monitoring and Reporting Practices	KMC, Warangal	85
561	15 th March 2022	Introduction of PvPI and How to recognize and report Adverse Drug reaction	RMLIMS, Lucknow	5

562	15 th March 2022	Sensitization training about importance of Pharmacovigilance and filling of ADR form	KEM, Mumbai	6
563	15 th March 2022	Materiovigilance Programme of India & Modes of reporting under PvPI	MMC, Chennai	32
564	15 th March 2022	Sensitization programme on Pharmacovigilance and ADRs/ AEFI Reporting	SNMC, Agra	25
565	15 th March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	VMCHRI, Madurai	103
566	15 th March 2022	Sensitizing Healthcare professionals at PHC meeting	KFMSR, Coimbatore	100
567	15 th March 2022	Sensitization and Awareness Programme on Pharmacovigilance and ADR Reporting	CMCH, Coimbatore	100
568	16 th March 2022	Sensitization on drug interaction	GMC, Thrissur	4
569	16 th March 2022	Role of clinical pharmacist in ADR reporting and Monitoring	RCSSH, Sullur	9
570	16 th March 2022	PvPI Insights and Reporting Tools	OMC, Hyderabad	25
571	16 th March 2022	Sensitization on Medication safety and ADR reporting	JMMCRI, Thrissur	28
572	16 th March 2022	Sensitization on Pharmacovigilance and hands on training on ADR reporting	SNMC, Agra	30
573	16 th March 2022	Pharmacovigilance an Overview	JNMC, Aligarh	38
574	17 th March 2022	Pharmacovigilance awareness programme significance and ADR reporting Strategies	NEIGRIHMS, Shillong	10
575	17 th March 2022	Sensitization on Pharmacovigilance and ADR monitoring	GMC, Baramulla	34
576	17 th March 2022	Pharmacovigilance awareness programme significance and ADR reporting	IGMCRI, Puducherry	46
577	18 th March 2022	Pharmacovigilance awareness programme significance and ADR reporting	IGMCRI, Puducherry	42
578	19 th March 2022	Sensitization and awareness programme on Pharmacovigilance	VIMS, Bengaluru	32
579	19 th March 2022	Sensitization programme on Pharmacovigilance and ADR reporting	KMC, Kurnool	30
580	19 th March 2022	Role of Clinical Pharmacist in Adverse Drug Reaction monitoring and reporting	KFMSR, Coimbatore	60
581	21 st March 2022	Introduction of PvPI and How to fill ADR reporting form	AFMC, Pune	23
582	21 st March 2022	Pharmacovigilance Monitoring and Reporting Practices	KMC, Warangal	160

583	21 st March 2022	Sensitization programme on ADR-PvPI Mobile Reporting to Clinicians	OMC, Hyderabad	15
584	21 st March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	YMC, Mangalore	119
585	22 nd March 2022	Sensitization training about importance of Pharmacovigilance and filling of ADR form and entering data in VigiFlow	KEM, Mumbai	2
586	22 nd March 2022	Sensitization and awareness programme on PV	VIMS, Bengaluru	19
587	23 rd March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	MGIMS, Sevagram	10
588	23 rd March 2022	Pharmacovigilance sensitization Programme	SBKSMI/RC, Waghodia	75
589	24 th March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	JNIMS, Imphal	9
590	24 th March 2022	Sensitization Programme on Pharmacovigilance and Adverse Drug Reaction reporting	MLBMC, Jhansi	60
591	24 th March 2022	Sensitization Programme on Pharmacovigilance and Adverse Drug Reaction reporting	MLBMC, Jhansi	60
592	24 th March 2022	Materiovigilance Programme of India Sensitization training for HCPs	GMC, Baramulla	66
593	25 th March 2022	Sensitization programme - Need of Pharmacovigilance	RCSSH, Suler	8
594	25 th March 2022	Orientation on Pharmacovigilance Programme of India	MMCH&RI, Kanchipuram	15
595	25 th March 2022	What is ADR and AE, how to report and what is Causality assessments?	KEM, Mumbai	34
596	25 th March 2022	Sensitization programme on Pharmacovigilance and ADRs Reporting	GMC, Palakkad	104
597	25 th March 2022	Awareness on reporting of ADRs among Rural Population	JSS, Mysuru	166
598	25 th March 2022	Awareness on ADRs reporting for General Public	VMCHRI, Madurai	98
599	25 th March 2022	Adverse Drug Reaction monitoring and reporting	KFMSR, Coimbatore	30
600	26 th March 2022	Sensitization programme on ADR reporting and prescription audit	JMMCRI, Thrissur	17
601	26 th March 2022	Awareness on reporting of ADRs among Rural Population	JSS, Mysuru	40
602	26 th March 2022	Guest lecture on Pharmacovigilance and ADR reporting in India	JPH, Bhopal	156

603	27 th March 2022	Awareness on reporting of ADRs among Rural Population	JSS, Mysuru	112
604	28 th March 2022	Sensitization programme on ADR reporting	GMC, Thrissur	3
605	28 th March 2022	Sensitization programme on Medication Error and ADR reporting	YMC, Mangalore	18
606	28 th March 2022	Sensitization and awareness programme on Pharmacovigilance	NIMS, Hyderabad	27
607	28 th March 2022	Sensitization programme on filling of ADR forms and Vigiflow data	AIMS, Thrissur	30
608	29 th March 2022	Sensitization programme on filling of ADR forms and Vigiflow data entry	AIMS, Thrissur	33
609	30 th March 2022	Sensitization programme on Pharmacovigilance and ADRs reporting	JNIMS, Imphal	7
610	30 th March 2022	Sensitization programme on Pharmacovigilance and ADRs reporting System	MGM, Aurangabad	23
611	30 th March 2022	Sensitization programme on Pharmacovigilance and ADRs reporting	KIMS, Nalgonda	90
612	30 th March 2022	Sensitization programme on Pharmacovigilance and ADRs monitoring and reporting practices	OMC, Hyderabad	100
613	30 th March 2022	Sensitization programme on Pharmacovigilance and ADRs reporting	PIMS, Tiruvalla	100
614	30 th March 2022	Awareness on ADRs reporting and AEFI reporting	JNMC, Aligarh	36
615	30 th March 2022	Sensitization programme on filling of ADR forms and Vigiflow data entry	AIMS, Thrissur	33
616	31 st March 2022	Sensitization programme on Pharmacovigilance and ADR reporting	VIMS, Bengaluru	73

C. Advanced Level training-cum-coordinator's meet organized by RTC of PvPI

Regional Training Centres of PvPI across the country organised a total of 08 Advanced level training programmes in Pharmacovigilance in which 1,313 healthcare professionals including Coordinators, Deputy Coordinators and Pharmacovigilance and Associates of various AMCs were trained.

S. No.	Date	Organised at Regional Training Centre (RTC)	No. of Participants
1.	5 th to 6 th August 2021	JSS, Mysuru	15
2.	3 rd September 2021	NIMS, Hyderabad	689
3.	9 th September 2021	AIIMS, Bhopal	52
4.	13 th October 2021	BGMC, Ahmedabad	189
5.	29 th October 2021	JSS, Mysuru	50
6.	9 th December 2021	JSS, Mysuru	80
7.	13 th December 2021	IPGMER, Kolkata	213
8.	19 th February 2022	KEM, Mumbai	25

D. Induction-cum-training Programme for Newly recruited PV-Associates and Newly Appointed AMC Coordinators

Every year PvPI is extending its outreach across several states of India, hence new task force in terms of recruited Pharmacovigilance Associates and appointed Coordinators/Deputy Coordinators of newly inducted AMCs are trained at NCC-PvPI, IPC through induction-cum-training programme as mentioned below:

S. No.	Date	Mode	No. of Participants
1.	27 th to 28 th April 2021	Virtual	88
2.	26 th to 27 th August 2021		100
3.	16 th to 18 th November 2021		106
4.	31 st January 2022 to 2 nd February 2022		133

E. Skill Development Programme on Pharmacovigilance of Medical Products

Since its inception in 2017, NCC-PvPI successfully conducted 20 Skill Development Programmes on Pharmacovigilance, focussed on understanding of the basic concepts of PV. The training programme provides an opportunity for the participants to work in Pharmacovigilance units of the organisations by following Good Pharmacovigilance Practices (GVP) to ensure better patient safety. This training programme also encourages them to become entrepreneurs in Pharmacovigilance. During the index period, NCC-PvPI organized a total of 4 Skill Development Programmes on Pharmacovigilance of Medical Products through virtual mode in which a total of 621 participants were trained.

S. No.	Date of Training Programmes	Title of Training Programmes	No. of Participants
1.	21 st to 25 th June 2021	17 th Skill Development Programme	152
2.	13 th to 17 th September 2021	18 th Skill Development Programme	199
3.	8 th to 12 th November 2021	19 th Skill Development Programme	189
4.	07 th to 11 th March 2022	20 th Skill Development Programme	81

F. Regional Workshops conducted for MAHs

Regional Workshop on "Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries– A Way Forward" is a featured training programme. It exclusively provides training to MAH professionals on:

- Establishing PV system in Pharmaceutical Industry
- Legislations regarding PV in India as per Drugs & Cosmetics Rules 1945, Schedule Y, Schedule M and New Drugs & Clinical Trials Rules 2019
- Process of reporting ADRs/AEs (E2B XML format) in PvPI

PvPI has organized 01 training programme during the index period with the support of pharmaceutical industries and CDSCO, the details are given below:

S. No	Date	Title	Mode	No. of Participants
1.	29 th March 2022	15 th Regional Workshop on Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries A Way Forward	Virtual	35

G. PV training for National Accreditation for Board of Hospitals & Healthcare Providers

With an objective of providing a platform for the NABH accredited hospitals and to broadly comprehend the system and procedures involved in ADR reporting, PvPI conducts a specialised Workshop-cum-training programme on Pharmacovigilance for officials of NABH Accredited Hospitals. These training sessions help in sensitizing the healthcare professionals to monitoring and reporting AE/ADRs. During the index period, 94 HCPs in the following workshops were trained:

S. No.	Date	Training Programmes	Place	No. of Participants
1.	21 st January 2022	Virtual Workshop-cum-Training Programme on Pharmacovigilance for NABH Accredited Hospitals in India	Virtual	94

H. Interactive Meeting with MAHs

NCC-PvPI, regularly conducts interactive sessions with MAHs to update them on the collation, analysis and quality scoring procedures for individual ICSRs, followed at PvPI, as the completeness score of ICSRs is one of the main criteria of quantitatively assessing the power of individual ICSR for contributing towards potential regulatory recommendations. Thus, the interactive meeting with MAHs serves the purpose of improving the overall quality of PvPI data submitted to VigiBase. Six interactive meetings were conducted in which 27 participants were trained.

S. No.	Date	MAHs	Mode	No. of Participants
1.	2 nd April 2021	Dr. Reddy's Laboratories Limited	Virtual	7
2.	24 th June 2021	Emcure Pharmaceuticals Limited		3
3.	17 th November 2021	Amgen India		3
4.	30 th March 2022	Intas Pharmaceuticals Limited		5
5.	19 th April 2022	J B Chemicals and Pharmaceuticals Ltd		3
6.	25 th April 2022	Macleod's Pharmaceuticals Limited		6

I. National Pharmacovigilance Week Celebration 2021

The National Pharmacovigilance week was celebrated by National Coordination Center-Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission (IPC) from 17th-23rd September 2021 on the theme "Pharmacovigilance: A Step towards Patient Safety" across the country via Physical and virtual mode. The celebration of National Pharmacovigilance Week was aligned with the World Patient Safety Day on 17th September and completion of 10 years of its operations at Indian Pharmacopoeia Commission. The approval for celebration of National Pharmacovigilance Week across the country was accorded by Governing Body of Indian Pharmacopoeia Commission. The National Pharmacovigilance Week will be celebrated every year on this day which will go a long way in reaching common masses about the importance of reporting Adverse Drug Reaction.

The major focus of National Pharmacovigilance week celebrations is to focus on PV activities aimed at creating awareness amongst the public, healthcare professionals, pharmaceutical Industries and healthcare authorities about the reporting of adverse drug reactions and encourage carrying out the activities related to Pharmacovigilance to the general public during the National Pharmacovigilance Week. The Pharmacovigilance Week Celebration is about recognizing the role of healthcare professionals like Physicians, Nurses, Pharmacists, students, Academicians in reporting adverse drug reactions. The Pharmacovigilance Week celebration can be ideal platform to honour our fellow healthcare professionals who are an integral part of the healthcare system and drug safety.

During the National Pharmacovigilance Week PvPI organised a total of 398 training/awareness-cum-sensitization programmes including CME/CPE in which 33,854 Healthcare Professionals and other stakeholders were trained on PV.

Details of Sensitization training programmes conducted at AMC's during the NPW 2021 are summarized below:

Sr. No.	Date	Training Programmes	AMC	No. of Participants
1	17 th September 2021	Sensitization and Awareness of ADRs Importance of Pharmacovigilance	CMJNM, Nadia	55
2	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	ESICMC, Chennai	65
3	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Shivpuri	82
4	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Shivpuri	67
5	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	KGH, Visakhapatnam	30
6	17 th September 2021	Awareness programme on safe use of drugs	AIIMS, Gorakhpur	200
7	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Datia	99
8	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Nalgonda	30
9	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Karur	25
10	17 th September 2021	Sensitization programme on Pharmacovigilance: A step towards patients' safety	BJMC, Ahmedabad	65
11	17 th September 2021	Workshop on ADRs filing form and reporting	GMC, Palakkad	100
12	17 th September 2021	Sensitization & Awareness training on Pharmacovigilance	AGMC, Agartala	63
13	17 th September 2021	Community awareness/sensitization in OPD/IPD through poster and interaction about ADR reporting	AIIMS, Jodhpur	50

14	17 th September 2021	Sensitization on General public & patients in Pharmacovigilance, safe use OPD complex of medicine with Patient Safety, ADR Reporting	AIIMS, Patna	55
15	17 th September 2021	Sensitization Programme on Pharmacovigilance with Patient Safety	AIIMS, Patna	10
16	17 th September 2021	Awareness cum sensitization on Pharmacovigilance programme of India and reporting of adverse drug reaction	DRGMCH, Hamirpur	120
17	17 th September 2021	Awareness cum sensitization programme on Pharmacovigilance	GMC, Amritsar	75
18	17 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GTDMC, Alappuzha	100
19	17 th September 2021	Sensitization and hands of training on Pharmacovigilance and ADR reporting	GTMC, Thoothukudi	67
20	17 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IGICH, Bengaluru	30
21	17 th September 2021	Seminar on current updates of PvPI	IMS BHU, Varanasi	15
22	17 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	JIPMER, Puducherry	154
23	17 th September 2021	Sensitization programme on Pharmacovigilance	JPH, Bhopal	80
24	17 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GMC, Musheerabad	10
25	17 th September 2021	Training and reporting of ADR and activity of filling form of ADR	GMC, Miraj	40
26	17 th September 2021	Workshop cum Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Virudhunagar	31
27	17 th September 2021	Sensitization programme: On what is Pharmacovigilance, importance of Pharmacovigilance, how to fill ADR Form, what to report, where to report, who can report and channels of reporting ADR etc.	IGIMS, Patna	48
28	17 th September 2021	Offline sensitization "Importance Pharmacovigilance and critically in ADR patient safety"	SDSTRC, Bengaluru	23
29	17 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	1196

30	17 th September 2021	Sensitization and interaction with healthcare professionals and patients in the Radiotherapy wards & casualty for awareness of Pharmacovigilance by distributing the pamphlet	RIMS, Imphal	80
31	17 th September 2021	Sensitization on Adverse Drug Reactions and safe use of medicines for Patients and HCPs	PJNGMC, Chamba	8
32	17 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	155
33	17 th September 2021	Sensitization programme on Pharmacovigilance	GMC, Dindigul	15
34	17 th September 2021	Sensitization training programme on Pharmacovigilance	ESICMC, Faridabad	94
35	17 th September 2021	Patient Education involving clinicians in "in-patient wards" for patients care givers via vernacular language posters	OMC, Hyderabad	150
36	17 th September 2021	Sensitization training programme on Pharmacovigilance	KEM, Mumbai	65
37	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	RCSSH, Sullur	60
38	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance of patients and Healthcare Professionals by distribution of Pamphlets by PHC	SMVMCH, Puducherry	175
39	17 th September 2021	Sensitization of patients and healthcare workers by distribution of pamphlets at SMVMCH Hospital campus	SMVMCH, Puducherry	350
40	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance and importance of reporting adverse drug reaction	KMCH, Coimbatore	25
41	17 th September 2021	Pharmacovigilance Awareness program & Suspected ADR Filling workshop	MMC, Madurai	100
42	17 th September 2021	Pharmacovigilance Awareness program & Suspected ADR Filling workshop	MMC, Madurai	110
43	17 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	DYPUSM, Navi Mumbai	20

44	17 th September 2021	Sensitization and Awareness programme on Pharmacovigilance	GDIMSH, Durgapur	160
45	17 th September 2021	Sensitization & Awareness Programme on 'Importance of Reporting of Adverse Drug Reaction'	JSS, Mysuru	840
46	17 th September 2021	Sensitization and awareness to primary health center, healthcare professional at srirangavaram medical on Pharmacovigilance, vaccine vigilance and Materiovigilance	MAMS, Hyderabad	75
47	17 th September 2021	Sensitization and awareness on reaction to vaccine at vaccine vigilance sub center srirangavaram, medical	MAMS, Hyderabad	25
48	17 th September 2021	Sensitization Programme of Pharmacovigilance	MAIMSR, Chengalpattu	240
49	17 th September 2021	Sensitization and Awareness on Drug induced adverse reactions of Skin	MAIMSR, Chengalpattu	240
50	17 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	4
51	17 th September 2021	Sensitization on importance ADR reporting under PvPI	MMC, Madurai	41
52	17 th September 2021	Sensitization on ADR reporting drug safety in pregnancy and lactation	PSGIMSR, Coimbatore	35
53	17 th September 2021	Patient orientation on self-reporting of ADR	PSGIMSR, Coimbatore	40
54	17 th September 2021	Awareness programme on ADR reporting	CHRI, Chengalpattu	88
55	17 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance Department of dermatology	CMCH, Ludhiana	10
56	17 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SRMMC, Kattankulathur	100
57	17 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	GDIMSH, Durgapur	160
58	17 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SMCH, Chennai	70

59	17 th September 2021	Sensitization & Awareness Programme on Medication error & ADR reporting	SVMCHRC, Puducherry	61
60	17 th September 2021	Organized interactive Sensitization session on Medication safety and Pharmacovigilance	SJMC, Bengaluru	50
61	17 th September 2021	Public awareness programme on Pharmacovigilance	SNMC, Agra	70
62	17 th September 2021	Role of Pharmacovigilance for vaccine safety	SJCP, Thrissur	30
63	17 th - 23 rd September 2021	Lectures in Sensitization and awareness on Pharmacovigilance	AIIMS, Bathinda	250
64	18 th September 2021	Hands on training Programme reporting Suspected Adverse Drug Reaction on Suspected Adverse Drug Reaction Form	CMJNM, Nadia	50
65	18 th September 2021	Community Awareness on Pharmacovigilance for National Pharmacovigilance Week 2021	GMC, Amritsar	15
66	18 th September 2021	Community Awareness on Pharmacovigilance for National Pharmacovigilance Week 2021	GMC, Amritsar	15
67	18 th September 2021	Sensitization and Awareness on Pharmacovigilance ADR reporting through Poster at Drug Stores	JNIMS, Imphal	10
68	18 th September 2021	Training on Pharmacovigilance- A step toward patient safety and ADR reporting	AIIMS, Gorakhpur	25
69	18 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	KGMC, Kanyakumari	82
70	18 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Karur	25
71	18 th September 2021	Sensitization programme on Pharmacovigilance: A step towards patients' safety	BJMC, Ahmedabad	55
72	18 th September 2021	Sensitization & awareness training on Pharmacovigilance and importance of ADR reporting	AGMC, Agartala	18
73	18 th September 2021	Common Academic Programme on Pharmacovigilance: A Step towards Patient Safety	AIIMS, Patna	50
74	18 th September 2021	Awareness and sensitization programme regarding Pharmacovigilance & ADR Reporting.	AIIMS, Patna	60

75	18 th September 2021	Hands-on- Training Programme of reporting Suspected Adverse Drug Reaction on the Suspected Adverse drug reaction reporting form	CMJNM, Nadia	50
76	18 th September 2021	Awareness cum sensitization on Pharmacovigilance programme of India and reporting of adverse drug reaction	DRGMCH, Hamirpur	35
77	18 th September 2021	Awareness cum sensitization programme on Pharmacovigilance	GGSMCH, Faridkot	150
78	18 th September 2021	Community awareness-Role plays in Skin & VD	GMC, Amritsar	15
79	18 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GTDMC, Alappuzha	40
80	18 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GTDMC, Alappuzha	5
81	18 th September 2021	Sensitization and hands of training on Pharmacovigilance and ADR reporting	GTMC, Thoothukudi	30
82	18 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting and toll-free no of PvPI	JPH, Bhopal	250
83	18 th September 2021	Sensitized on reporting of ADR to AMC for HCP at department of pharmacology Bharti hospital and medical college	GMC, Miraj	15
84	18 th September 2021	Awareness session on Pharmacovigilance for staff nurse	GMC, Srinagar	22
85	18 th September 2021	Workshop cum Sensitization programme	GMC, Virudhunagar	21
86	18 th September 2021	Online Webinar-PvPI an Overview	SDSTRC, Bengaluru	72
87	18 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	34
88	18 th September 2021	Workshop/awareness programme of Pharmacovigilance and hands on training for reporting of adverse Drug Reactions (ADRs)	RIMS, Imphal	68
89	18 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic for Regional Drug Testing Laboratory	PGIMER, Chandigarh	389

90	18 th September 2021	Pharmacovigilance: A step towards patients' safety	GRMC, Gwalior	22
91	18 th September 2021	Sensitization training programme on Pharmacovigilance	ESICMC, Faridabad	92
92	18 th September 2021	Causality assessment Tools in Pharmacovigilance	OMC, Hyderabad	200
93	18 th September 2021	Sensitization training programme on Pharmacovigilance	KEM, Mumbai	92
94	18 th September 2021	Sensitization training programme on Pharmacovigilance	KEM, Mumbai	14
95	18 th September 2021	Awareness of ADRs Importance of Pharmacovigilance	SMCGH, Kurnool	25
96	18 th September 2021	Awareness of ADRs Importance of Pharmacovigilance	SMCGH, Kurnool	100
97	18 th September 2021	CME and Awareness Programme on Pharmacovigilance	MMIMSR, Mullana	26
98	18 th September 2021	Awareness programme on Pharmacovigilance	MMIMSR, Mullana	9
99	18 th September 2021	Community Awareness on Pharmacovigilance in community pharmacy through pamphlet	RCSSH, Suler	14
100	18 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting form	SBKSMI/RC, Waghodia	25
101	18 th September 2021	Sensitization and Awareness on Pharmacovigilance and ADR reporting	SMCGH, Kurnool	25
102	18 th September 2021	Webinar on Pharmacovigilance: A step towards patients' safety	SMCGH, Kurnool	100
103	18 th September 2021	Pharmacovigilance Awareness camp to sensitize public for ADR reporting	TNMC, Mumbai	20
104	18 th September 2021	Role play on importance of Pharmacovigilance/ADR reporting	TNMC, Mumbai	20
105	18 th September 2021	Community level sensitization on Covid-19 and ADR reporting	ACP, Malappuram	50
106	18 th September 2021	Pharmacovigilance Awareness program & Suspected ADR Filling workshop	MMC, Madurai	350

107	18 th September 2021	Role of AMCs in reporting of Adverse Events/Adverse Drug Reactions– Sensitization Training	MMC, Madurai	109
108	18 th September 2021	Awareness programme on Pharmacovigilance activities & ADR reporting	AJIMS, Mangalore	50
109	18 th September 2021	Awareness programme camp on Pharmacovigilance and ADR reporting	AM, Kochi	52
110	18 th September 2021	Sensitization programme: Role of Pharmacists in preventing Adverse Drug Reaction	JMMCRI, Thrissur	22
111	18 th September 2021	National Webinar on Pharmacovigilance: A step towards patient safety	AIMS, Kochi	135
112	18 th September 2021	Awareness on Pharmacovigilance and ADR reporting	BMC, Hyderabad	50
113	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	KIMS, Bhubaneswar	29
114	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MAIMSR, Chengalpattu	150
115	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance: A step towards patient safety	MAIMSR, Chengalpattu	10
116	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	15
117	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	RPCP, Anand	136
118	18 th September 2021	Sensitization Training/Department of surgery	CMCH, Ludhiana	15
119	18 th September 2021	Sensitization Training on Pharmacovigilance	SMC, Meerut	80
120	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SRMMC, Kattankulathur	100
121	18 th September 2021	Sensitization Training on Patient Safety and ADR reporting	TMCH, Navi Mumbai	130
122	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	VIMS, Bengaluru	4
123	18 th September 2021	CME on Pharmacovigilance - Step Towards Efficient Patient Safety	YMC, Mangalore	106

124	18 th September 2021	Community level Sensitization & Awareness Programme on Pharmacovigilance	RDGMC, Ujjain	65
125	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	NCP, Calicut	260
126	18 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance and causality assessment methods	APOLLO, New Delhi	20
127	18 th September 2021	Sensitization on Pharmacovigilance: A Step towards patients safety	EPCMSRC, Bangalore	13
128	18 th September 2021	Community level sensitization programme on COVID-19 and ADR reporting	ACP, Malappuram	60
129	18 th to 23 rd September 2021	Sensitization programme for common public in COVID-19 vaccination	IGIMS, Patna	500
130	19 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	NDMCMC, New Delhi	45
131	19 th September 2021	Online Sensitization and Awareness Programme on Pharmacovigilance and ADR reporting	KGH, Visakhapatnam	78
132	19 th September 2021	Online sensitization Programme on Pharmacovigilance	BJMC, Ahmedabad	48
133	19 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	GMC, Siddipet	50
134	19 th September 2021	Sensitization & Awareness Programme on safety for antibiotics	JNMC, Aligarh	104
135	19 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	20
136	19 th September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	20
137	19 th September 2021	Workshop on Topic: Pharmacovigilance activities & training on AE Form filling	AJIMS, Mangalore	66
138	19 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	10

139	19 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	CMCH, Ludhiana	5
140	19 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	SNMC, Agra	14
141	20 th September 2021	Sensitization and Awareness Training on Pharmacovigilance	CMJNM, Nadia	12
142	20 th September 2021	Community Awareness Programme at Chakmandola Rural Health and Training Centre	RGMCH, Birbhum	29
143	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Datia	55
144	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	KGMC, Kanyakumari	18
145	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Nalgonda	150
146	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	GMC, Karur	150
147	20 th September 2021	Webinar on Pharmacovigilance: A step towards patients' safety	AIIMS, Bhopal	148
148	20 th September 2021	Sensitization programme on Pharmacovigilance: A step towards patients' safety	BJMC, Ahmedabad	130
149	20 th September 2021	Sensitization and Awareness programme on Pharmacovigilance	GMC, Palakkad	150
150	20 th September 2021	Sensitization and Awareness programme on Pharmacovigilance	GMCH, Udhagamandalam	75
151	20 th September 2021	Hands on training and sensitization programme on Pharmacovigilance	AGMC, Agartala	25
152	20 th September 2021	Sensitization and Awareness programme on Pharmacovigilance	CMJNM, Nadia	12
153	20 th September 2021	Awareness cum sensitization on Pharmacovigilance programme of India and reporting of adverse drug reaction	DRGMCH, Hamirpur	87
154	20 th September 2021	Awareness cum sensitization programme on Pharmacovigilance	GGSMCH, Faridkot	70

155	20 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GTDMC, Alappuzha	150
156	20 th September 2021	Sensitization and hands of training on Pharmacovigilance and ADR reporting	GTMC, Thoothukudi	26
157	20 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IMSBHU, Varanasi	7
158	20 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	JIPMER, Puducherry	60
159	20 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting and toll-free no of PvPI	JPH, Bhopal	70
160	20 th September 2021	Awareness programme on NPW among undergraduate nursing student and ADR form fill up.	RGKMC, Kolkata	36
161	20-21 st September 2021	National Online Workshop on Pharmacovigilance: on stration of Various Drug Safety Databases	NIPER, Guwahati	3122
162	20 th September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	NSMC, Kolkata	5
163	20 th September 2021	Seminar on Pharmacovigilance & Hands on Training on How to Fill ADR form	PJNMC, Raipur	80
164	20 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Thrissur	30
165	20 th September 2021	Workshop cum Sensitization programme on Pharmacovigilance	GMC, Virudhunagar	9
166	20 th September 2021	Hand on training on ADR Form Filling and reporting	IGIMS, Patna	110
167	20 th September 2021	Sensitization programme on Pharmacovigilance	JMC, Jorhat	15
168	20 th September 2021	Sensitization programme on Pharmacovigilance camp	JMC, Jorhat	30
169	20 th September 2021	Online Webinar on Pharmacovigilance programme of India - An Overview	SDSTRC, Bengaluru	43
170	20 th September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	30

171	20 th September 2021	Sensitization programme on Pharmacovigilance	GMC, Dindigul	30
172	20 th September 2021	How to fill up suspected ADR form	VPCI, New Delhi	14
173	20 th September 2021	Sensitization training programme on Pharmacovigilance	ESICMC, Faridabad	62
174	20 th September 2021	Role of Pharmacist in Pharmacovigilance Monitoring Challenges	OMC, Hyderabad	150
175	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	MMMSR, Mullana	10
176	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	RCSSH, Suler	20
177	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	SMVMCH, Puducherry	200
178	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	TNMC, Mumbai	100
179	20 th September 2021	CME on sensitization for the monitoring and reporting of ADR related to SGLT2 inhibitors	TMCH, Kollam	18
180	20 th September 2021	Pharmacovigilance awareness programme to sensitize public for ADR reporting	VMCHRI, Madurai	106
181	20 th September 2021	Hands on training Programme How to fill reporting Suspected Adverse Drug Reaction form	VMCHRI, Madurai	47
182	20 th September 2021	Sensitization and Awareness Programme on Pharmacovigilance	DYPUSM, Navi Mumbai	20
183	20 th September 2021	Sensitization programme: Role of Pharmacists in preventing Adverse Drug Reaction	JMMCRI, Thrissur	26
184	20 th September 2021	Sensitization and Awareness programme on Pharmacovigilance	GDIMSH, Durgapur	100
185	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	KIMS, Bhubaneswar	33
186	20 th September 2021	Sensitization and awareness on Pharmacovigilance & Materiovigilance	MAMS, Hyderabad	65
187	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	15

188	20 th September 2021	Sensitization to healthcare worker on Pharmacovigilance	MMCHRI, Kanchipuram	68
189	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	60
190	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance Department of medicine	CMCH, Ludhiana	16
191	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	VIMS, Bengaluru	35
192	20 th September 2021	Sensitization programme for prescription communication	VIMS, Bengaluru	350
193	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	GDIMSH, Durgapur	100
194	20 th September 2021	Organized interactive Sensitization session on Medication safety and Pharmacovigilance	SJMC, Bengaluru	14
195	20 th September 2021	Sensitization & Awareness Programme camp on Pharmacovigilance	RDGMC, Ujjain	90
196	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	SNMC, Agra	43
197	20 th September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MSRMC, Bengaluru	30
198	21 st September 2021	Sensitization and Awareness Training on Pharmacovigilance	CMJNM, Nadia	8
199	21 st September 2021	Sensitization and Awareness Training on Pharmacovigilance	CMJNM, Nadia	14
200	21 st September 2021	Community Awareness on Pharmacovigilance for National Pharmacovigilance Week 2021	GMC, Amritsar	25
201	21 st September 2021	Awareness on Pharmacovigilance at Vaccination Centre	JNIMS, Imphal	50
202	21 st September 2021	One day sensitization cum awareness programme on Pharmacovigilance: A step towards patient safety.	SMCH, Silchar	31

203	21 st September 2021	Awareness programme on Adverse events related to vaccines and Awareness programme on safe use of drugs and reporting of ADRs via 1800 180 3024 at their nearest AMC	AIIMS, Gorakhpur	250
204	21 st September 2021	Sensitization programme for Adverse drug reaction training (Interns Doctors)	GMERS, Gandhinagar	107
205	21 st September 2021	Sensitization programme of pharmacovigilance committee members regarding recent updates and underreporting of Suspected Adverse drug reactions	GMERS, Gandhinagar	11
206	21 st September 2021	Sensitization and Awareness programme on Pharmacovigilance	BJMC, Ahmedabad	150
207	21 st September 2021	Sensitization and Awareness programme on Pharmacovigilance	GMCH, Udhagamandalam	75
208	21 st September 2021	Sensitization training on Pharmacovigilance about Vigiflow	GMC, Surat	25
209	21 st September 2021	Sensitization & awareness training on Pharmacovigilance	GTMC, Thiruvavur	238
210	21 st September 2021	Awareness and sensitization programme regarding Pharmacovigilance	AIIMS, Patna	10
211	21 st September 2021	Awareness and sensitization programme regarding Pharmacovigilance	CMJNM, Nadia	8
212	21 st September 2021	Awareness and sensitization programme regarding Pharmacovigilance	CMJNM, Nadia	14
213	21 st September 2021	Awareness cum sensitization programme on Pharmacovigilance	GGSMCH, Faridkot	200
214	21 st September 2021	Awareness and sensitization programme regarding Pharmacovigilance	GMC, Amritsar	25
215	21 st September 2021	Awareness cum sensitization programme on Pharmacovigilance	GMC, Anantnag	22
216	21 st September 2021	Sensitization and hands of training on Pharmacovigilance and ADR reporting	GTMC, Thoothukudi	34
217	21 st September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IMSBHU, Varanasi	56

218	21 st September 2021	Sensitization programme on Pharmacovigilance	JPH, Bhopal	30
219	21 st September 2021	Sensitization programme on Pharmacovigilance programme of India	RGKMC, Kolkata	42
220	21 st September 2021	Seminar on Pharmacovigilance & Hands on training on How to Fill ADR form ADR Form	PJNMC, Raipur	150
221	21 st September 2021	Sensitized local pharmacy store about how to report ADR nearby AMC and directly to PvPI	GMC, Miraj	25
222	21 st September 2021	Workshop cum Sensitization programme on Pharmacovigilance	GMC, Virudhunagar	30
223	21 st September 2021	Sensitization programme on Pharmacovigilance	IGIMS, Patna	15
224	21 st September 2021	Workshop cum Sensitization programme on Pharmacovigilance	JMC, Jorhat	20
225	21 st September 2021	Interaction with common public and conducting awareness about safe use of Medicines, use of helpline number 1800 180 3024 to report ADRs.	JMC, Jorhat	30
226	21 st September 2021	Sensitization programme on Pharmacovigilance	PDUMC, Rajkot	27
227	21 st September 2021	Online Webinar-Tools for ADR Reporting	SDSTRC, Bengaluru	64
228	21 st September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	SGPGIMS, Lucknow	14
229	21 st September 2021	Workshop/awareness programme of Pharmacovigilance and hands on training for reporting of adverse Drug Reactions	RIMS, Imphal	52
230	21 st September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	62
231	21 st September 2021	Medication safety awareness programme	NIPER, Hajipur	150

232	21 st September 2021	Pharmacovigilance: A step towards patients' safety	GRMC, Gwalior	18
233	21 st September 2021	Sensitization programme on Pharmacovigilance	GMC, Dindigul	15
234	21 st September 2021	Pharmacovigilance: A step towards patient safety	VPCI, New Delhi	50
235	21 st September 2021	Sensitization training programme on Pharmacovigilance	ESICMC, Faridabad	172
236	21 st September 2021	Sensitization training programme on AEFI Monitoring and Reporting	OMC, Hyderabad	200
237	21 st September 2021	Sensitization training programme on Pharmacovigilance	KEM, Mumbai	43
238	21 st September 2021	Hands on training Programme reporting Suspected Adverse Drug Reaction on Suspected Adverse Drug Reaction	MMIMSR, Mullana	53
239	21 st September 2021	Sensitization and Awareness Programme on Pharmacovigilance	RBVRRWCP, Hyderabad	250
240	21 st September 2021	Sensitization and Awareness Programme on Pharmacovigilance	RCSSH, Suler	25
241	21 st September 2021	Pharmacovigilance awareness programme to sensitize public for ADR reporting	VMCHRI, Madurai	110
242	21 st September 2021	Hands on training Programme How to fill reporting Suspected Adverse Drug Reaction form	VMCHRI, Madurai	43
243	21 st September 2021	Sensitization Programme on Pharmacovigilance and Monitoring & reporting adverse drug reaction	KMCH, Coimbatore	100
244	21 st September 2021	Pharmacovigilance Awareness programme and workshop	MMC, Madurai	158
245	21 st September 2021	Pharmacovigilance Awareness programme and workshop	AJIMS, Mangalore	133
246	21 st September 2021	Pharmacovigilance sensitization Community Awareness programme	IMTPC, Gopalpur	500
247	21 st September 2021	A webinar on topic Pharmacovigilance tools for ADR reporting	ACP, Bengaluru	55

248	21 st September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting	DCDSIMER, Ramanagar	30
249	21 st September 2021	Sensitization training on PV, ADR Reporting and Patient safety	IMSSH, Bhubaneswar	17
250	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	KMC, Manipal	196
251	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MAIMSR, Chengalpattu	45
252	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	10
253	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MMCHRI, Kanchipuram	50
254	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PIMS, Tiruvalla	65
255	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	89
256	21 st September 2021	Webinar on Pharmacovigilance: A step towards patient safety	AAH, Perungalathur	42
257	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	BIPS, Warangal	150
258	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	DCDSIMER, Ramanagar	30
259	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance and Role play on ADR reporting	CHRI, Chengalpattu	6
260	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	CMCH, Ludhiana	10
261	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SGRRIMHS, Dehradun	32
262	21 st September 2021	Workshop cum sensitization training on Pharmacovigilance at Panna Dhai Maa Subharti Nursing College	SMC, Meerut	50
263	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance	VIMS, Bengaluru	15
264	21 st September 2021	Sensitization & Awareness Programme on Medication safety and Pharmacovigilance	SJMC, Bengaluru	50

265	21 st September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	APOLLO, New Delhi	18
266	21 st -24 th September 2021	Pharmacovigilance training for sensitization and reporting of adverse drug reaction.	SMIMER, Surat	221
267	22 nd September 2021	Sensitization and Awareness training on Pharmacovigilance	CMJNM, Nadia	5
268	22 nd September 2021	CME and Awareness Programme on Pharmacovigilance	ESICMC-Chennai	100
269	22 nd September 2021	Sensitization and Awareness Programme on Pharmacovigilance and ADR reporting	JNIMS, Imphal	100
270	22 nd September 2021	Sensitization Programme on regarding COVID-19 vaccination for peripheral Hospitals	NDMCMC, New Delhi	35
271	22 nd September 2021	General public awareness programme on Pharmacovigilance	SKIMS, Srinagar	300
272	22 nd September 2021	Sensitization of health care workers on Pharmacovigilance	SKIMS, Srinagar	98
273	22 nd September 2021	Drug safety: Awareness and monitoring" For Physicians: A series of hands-on, interactive lecture	RGMCH, Birbhum	52
274	22 nd September 2021	Interactive session for pharmacists on ADR reporting	GMERS, Gandhinagar	22
275	22 nd September 2021	Sensitization and Awareness programme on Pharmacovigilance	GMC, Srikakulam	100
276	22 nd September 2021	Sensitization & awareness about Pharmacovigilance & Medication Error to nursing students	GMC, Surat	54
277	22 nd September 2021	Sensitization & awareness training on Pharmacovigilance	GTMC, Thiruvapur	35
278	22 nd September 2021	National Webinar on Pharmacovigilance: A step towards patient safety	AIIMS, Patna	190
279	22 nd September 2021	National Webinar on Pharmacovigilance: A step towards patient safety	CMJNM, Nadia	5

280	22 nd September 2021	Awareness cum sensitization on Pharmacovigilance programme of India and reporting of adverse drug reaction	DRGMCH, Hamirpur	20
281	22 nd September 2021	Awareness cum sensitization programme on Pharmacovigilance	GKMC, Chennai	80
282	22 nd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GMC, Kozhikode	128
283	22 nd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IGICH, Bengaluru	65
284	22 nd September 2021	Awareness programme on hands on training of ADR reporting	IMSBHU, Varanasi	79
285	22 nd September 2021	Pharmacovigilance awareness programme for Urban Health Centre	JIPMER, Puducherry	30
286	22 nd September 2021	Pharmacovigilance awareness programme for Urban Health Centre	JIPMER, Puducherry	11
287	22 nd September 2021	Awareness programme through distribution of newly proposed medicine side effect form fasciculation language coordination taken a class for student about PvPI	RGKMC, Kolkata	34
288	22 nd September 2021	CME on Pharmacovigilance programme of India an orientation and update	GMCH, Nagpur	62
289	22 nd September 2021	Sensitized to hospital pharmacist and health worker about reporting of ADR	GMC, Miraj	20
290	22 nd September 2021	Awareness training on Pharmacovigilance	GMC, Srinagar	100
291	22 nd September 2021	Sensitization programme on Pharmacovigilance and ADR reporting	GMC, Thrissur	23
292	22 nd September 2021	Workshop cum Sensitization programme on Pharmacovigilance	GMC, Virudhunagar	26
293	22 nd September 2021	Workshop cum Sensitization programme on Pharmacovigilance	JMC, Jorhat	45
294	22 nd September 2021	Workshop cum Sensitization programme on Pharmacovigilance	JMC, Jorhat	25

295	22 nd September 2021	Spreading awareness about the need of Pharmacovigilance	JMC, Jorhat	20
296	22 nd September 2021	Introduction to Pharmacovigilance	SDSTRC, Bengaluru	38
297	22 nd September 2021	Online training on various tools used for ADR reporting	SDSTRC, Bengaluru	178
298	22 nd September 2021	Community awareness programme on Pharmacovigilance	LTMMCGH, Mumbai	15
299	22 nd September 2021	Awareness cum sensitization about Pharmacovigilance	RIMS, Imphal	25
300	22 nd September 2021	An awareness cum sensitization programme on Pharmacovigilance: A step towards patients' safety	SLNMCH, Koraput	40
301	22 nd September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	93
302	22 nd September 2021	Pharmacovigilance awareness programme	NIPER- Hajipur	50
303	22 nd September 2021	Sensitization cum training programme	KCGMC, Karnal	20
304	22 nd September 2021	Sensitization programme on Pharmacovigilance	KCGMC, Karnal	52
305	22 nd September 2021	Pharmacovigilance: A step towards patients' safety	GRMC, Gwalior	11
306	22 nd September 2021	Sensitization programme on Pharmacovigilance	GMC, Dindigul	30
307	22 nd September 2021	Sensitization training programme on Pharmacovigilance	VPCI, New Delhi	7
308	22 nd September 2021	Sensitization training programme on Pharmacovigilance	OMC, Hyderabad	98
309	22 nd September 2021	Pharmacovigilance global trend of reporting	OMC, Hyderabad	100
310	22 nd September 2021	Sensitization on Pharmacovigilance training	RCSSH, Sullur	18
311	22 nd September 2021	Sensitization on Pharmacovigilance training	RCSSH, Sullur	18
312	22 nd September 2021	Hands-on workshop on Pharmacovigilance	SMVMCH, Puducherry	50

313	22 nd September 2021	Visiting General Practitioners to sensitize them about ADR reporting to our AMCs	TNMC, Mumbai	10
314	22 nd September 2021	Pharmacovigilance awareness Programme for hospital staff	TMCH, Kollam	15
315	22 nd September 2021	Hands on training Programme How to fill reporting Suspected Adverse Drug Reaction form	VMCHRI, Madurai	46
316	22 nd September 2021	Sensitization training on AE form filling	AJIMS, Mangalore	66
317	22 nd September 2021	Pharmacovigilance sensitization and Awareness program	IMTPC, Gopalpur	250
318	22 nd September 2021	Sensitization programme: Role of Pharmacists in preventing Adverse Drug Reaction	JMMCRI, Thrissur	50
319	22 nd September 2021	Webinar on Pharmacovigilance: A step towards patients' safety	ACPTE, Sangrur	226
320	22 nd September 2021	Sensitization training on PV, ADR Reporting and Patient safety	IMSSH, Bhubaneswar	18
321	22 nd September 2021	Sensitization & Awareness Programme on 'Importance of Reporting of Adverse Drug Reaction'	JSS, Mysuru	51
322	22 nd September 2021	Sensitization and awareness to primary health center, healthcare professional at Bollaram medical on Pharmacovigilance and Materio-vigilance	MAMS, Hyderabad	50
323	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	5
324	22 nd September 2021	Online CME on Pharmacovigilance: A step towards patient safety	MMCHRI, Kanchipuram	168
325	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	162
326	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	70
327	22 nd September 2021	Street play public programme on ADR Identification and reporting	DCDSIMER, Ramanagar	50

328	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	CMCH, Ludhiana	16
329	22 nd September 2021	Sensitization of Nursing towards their key role in Pharmacovigilance	SAIMS, Indore	62
330	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SGRRIMHS, Dehradun	60
331	22 nd September 2021	Awareness programme at Rural community Health and Training Centre, Khajuri	SMC, Meerut	26
332	22 nd September 2021	CME on Pharmacovigilance- A step towards patient safety	SRMMC, Kattankulathur	414
333	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SMCH, Chennai	74
334	22 nd September 2021	Sensitization & Awareness Programme on Medication safety and Pharmacovigilance	SJMC, Bengaluru	162
335	22 nd September 2021	Sensitization & Awareness Programme on Medication safety and Pharmacovigilance	SJMC, Bengaluru	7
336	22 nd September 2021	Sensitization & Awareness Programme camp on Pharmacovigilance	RDGMC, Ujjain	50
337	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	SNMC, Agra	38
338	22 nd September 2021	Sensitization & Awareness Programme on Pharmacovigilance and medication error	APOLLO, New Delhi	21
339	23 rd September 2021	Sensitization and Awareness Training on Pharmacovigilance	CMJNM, Nadia	10
340	23 rd September 2021	CME and Awareness Programme on Pharmacovigilance Suspected ADR reporting	GMC, Amritsar	81
341	23 rd September 2021	Drug safety: Awareness and Monitoring	RGMCH, Birbhum	45
342	23 rd September 2021	Interactive session on Pharmacovigilance- A step toward patient safety and ADR reporting	AIIMS, Gorakhpur	80

343	23 rd September 2021	National Webinar –VIGICON-2021 in connection with National Pharmacovigilance Week 2021	GMC, Kottayam	425
344	23 rd September 2021	Sensitization & Awareness Programme on reporting of suspected ADRs form	GMERS, Gandhinagar	52
345	23 rd September 2021	Sensitization and Awareness Programme on unexpected ADRs to all department heads of Gandhinagar civil Hospital and medical college.	GMERS, Gandhinagar	27
346	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR reporting	GMC, Karur	40
347	23 rd September 2021	Webinar on an introduction to PvPI	AIIMS, Bhopal	223
348	23 rd September 2021	Sensitization programme on Pharmacovigilance: A step towards patients' safety	BJMC, Ahmedabad	123
349	23 rd September 2021	Awareness-cum-Sensitization programme on Pharmacovigilance	GMC, Kathua	30
350	23 rd September 2021	Sensitization & awareness training on Pharmacovigilance	GTMC, Thiruvapur	40
351	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance	GMC, Amritsar	81
352	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance	GMC, Anantnag	85
353	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance	GMC, Thiruvananthapuram	20
354	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	GTDMC, Alappuzha	35
355	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IGICH, Bengaluru	36
356	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	IGICH, Bengaluru	4
357	23 rd September 2021	Awareness cum sensitization programme on Pharmacovigilance and ADR reporting	JIPMER, Puducherry	85

358	23 rd September 2021	CME on Pharmacovigilance and AEFI Reporting	JPH, Bhopal	60
359	23 rd September 2021	Community awareness programme in urban healthcare center	IPGMER, Kolkata	70
360	23 rd September 2021	Sensitization on Pharmacovigilance.	GMC, Musheerabad	250
361	23 rd September 2021	Awareness and sensitization programme of Pharmacovigilance and Adverse drug reaction	GMCH, Nagpur	7
362	23 rd September 2021	CME cum Sensitization programme: ADR and its clinical implications	GMC, Virudhunagar	90
363	23 rd September 2021	Interaction with general public in Tarajan area, Jorhat for spreading awareness about Pharmacovigilance	JMC, Jorhat	24
364	23 rd September 2021	Seminar on patients' safety and Pharmacovigilance during COVID-19 pandemic	PGIMER, Chandigarh	25
365	23 rd September 2021	Sensitization programme on Pharmacovigilance	KCGMC, Karnal	75
366	23 rd September 2021	Sensitization programme on Pharmacovigilance	KEM, Mumbai	100
367	23 rd September 2021	Sensitization on Pharmacovigilance training in Clinical Pharmacy	RCSSH, Sullur	12
368	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance	RCSSH, Sullur	40
369	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting form	RMC, Ahmednagar	50
370	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting form	RMC, Ahmednagar	200
371	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance and How to fill ADR reporting form	SBKSMI/RC, Waghodia	26
372	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance	SGMC/RF, Trivandrum	40
373	23 rd September 2021	Conduct of causality assessment meeting for department training activity in Pharmacovigilance	TNMC, Mumbai	20

374	23 rd September 2021	Sensitization and Awareness Programme on Pharmacovigilance	TNMC, Mumbai	100
375	23 rd September 2021	Sensitization programme - ADR reporting: Role in patients' safety and welfare	VMCHRI, Madurai	136
376	23 rd September 2021	Sensitization training on Causality Assessment	KMCH, Coimbatore	50
377	23 rd September 2021	Awareness-cum-Sensitization programme on Pharmacovigilance through Virtual mode	ELMCH, Lucknow	62
378	23 rd September 2021	Awareness on Pharmacovigilance for nursing staff	BMC, Hyderabad	75
379	23 rd September 2021	Sensitization training on PV, ADR Reporting and Patient safety	IMSSH, Bhubaneswar	100
380	23 rd September 2021	Sensitization & Awareness Programme on 'Importance of Reporting of Adverse Drug Reaction'	JSS, Mysuru	104
381	23 rd September 2021	Creating PV Awareness amongst patient at DOTS centre	KMC, Manipal	3
382	23 rd September 2021	Sensitization and awareness on adverse drug reaction-case	MAMS, Hyderabad	100
383	23 rd September 2021	Awareness programme in RHTC and Distribution of pamphlets	MAIMSR, Chengalpattu	45
384	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	MGIMS, Wardha	20
385	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PIMS, Tiruvalla	50
386	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	17
387	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	PMCSKH, Anand	27
388	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	AAH, Perungalathur	37
389	23 rd September 2021	Sensitization and awareness programme on Pharmacovigilance	BIPS, Warangal	250
390	23 rd September 2021	Awareness programme on Pharmacovigilance	SMC, Meerut	45

391	23 rd September 2021	Community outreach program on Pharmacovigilance Kothandam Nagar	SRMMC, Kattankulathur	125
392	23 rd September 2021	Sensitization about importance of ADR reporting of medicine	TMCH, Navi Mumbai	60
393	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance and ADR & Medication	YMC, Mangalore	45
394	23 rd September 2021	Community level Sensitization & Awareness Programme on Pharmacovigilance	DSP, Hyderabad	350
395	23 rd September 2021	Pharmacovigilance a sensitization programme- a step towards patient safety 2021	SMCH, Chennai	50
396	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SMCH, Chennai	30
397	23 rd September 2021	Sensitization & Awareness Programme on Pharmacovigilance	SMCH, Chennai	20
398	23 rd September 2021	Organized interactive Sensitization session on Medication safety and Pharmacovigilance	SJMC, Bengaluru	260
Total Participants				33,854

The National Pharmacovigilance week was inaugurated on 17th September 2021 by Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, Indian Pharmacopoeia Commission by lighting the lamp and welcome address to the audience. Dr. Jai Prakash, Officer-in-Charge, Pharmacovigilance Programme of India delivered a presentation on the successful journey of PvPI in a decade of its existence at IPC.

Esteemed dignitaries from across the globe Prof. Y.K. Gupta (National Scientific Advisor, PvPI), Dr. VG Somani (Drugs Controller General (India)), Dr. Shanti Pal (Group Lead, Medicines Safety, Safety & Vigilance, World Health Organization, WHO), Dr. Mira Harrison Woolrych (President, International Society of Pharmacovigilance, ISoP), Dr. Kim Sunghchol, Dr. Bejon Misra (International Consumer Policy Expert) and Dr. Madhur Gupta (Technical Officer, WHO Country Office, India) highlighted the importance of Pharmacovigilance and emphasized the role of PvPI in patient safety in India on the inaugural day of National Pharmacovigilance week.

During the inaugural day of National Pharmacovigilance Week, a 10-year performance report of PvPI entitled "10 Year Highlights of Achievement, 2011-2021" was released by Dr Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC on 17th September 2021. The report highlights the successful journey of PvPI in the field of Pharmacovigilance in India during the last decade. Along with it, PvPI also released the updated version of Suspected Adverse Drug Reaction Reporting Form for Healthcare professionals.

NCC-PvPI hosted a virtual interactive session with all the Coordinators and Pharmacovigilance Associates of Adverse Drug Reaction Monitoring Centers (AMCs) on 20th September, 2021. Dr. Jai Prakash, Officer-in-Charge, PvPI inaugurated the session by welcoming all the members and explained the 'Role of AMCs in Reporting of Adverse Events/Adverse Drug Reactions'. The esteemed speaker Prof. Nilima Kshirsagar, National Chair, Indian Council of Medical Research (ICMR) gave insights on the development of ADR reporting culture in India. Prof. Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh shared his experience as an AMC- Coordinator. The AMC Coordinators Meet was ended with an interactive session on "Issues & Challenges of Adverse Drug Reaction reporting to PvPI". All the queries by AMCs representative were taken very well and resolved by the PvPI representatives.

NCC-PvPI hosted a virtual meet with Market Authorization Holders (MAH) on 21st September, 2021. Dr. Jai Prakash, Officer-in-Charge, PvPI inaugurated the session by welcoming all the members and explained the 'Role of MAHs in Reporting of Adverse Events/Adverse Drug Reactions'. The Panel comprising of Dr. Jai Prakash, Dr. Rubina Bose (Deputy Drugs Controller, Central Drugs Standard Control Organization, CDSCO) and Dr. Vivek Ahuja (Vice President - Medical Affairs & Head Global Pharmacovigilance at Sun Pharma) discussed on the issues and challenges during Adverse Drug Reaction reporting.

During the National Pharmacovigilance week celebration, IPC-PvPI intends to create awareness and educate the public and other healthcare professionals about the importance of Pharmacovigilance. Various supporting materials such as Posters, Banners, Hoardings, Pamphlets, Brochures and Social Networking Media (WhatsApp/ Facebook/Twitter/ Instagram etc.) were disseminated to PvPI stakeholders. They all are encouraged to celebrate the National Pharmacovigilance Week via Quiz, Essay, Poster, Audio-Visual Animation Competitions and community level sensitization. In this reference, NCC-PvPI had organized Quiz, Essay, Poster, Audio-Visual Animation Competitions as a part of National Pharmacovigilance Week celebrations 2021 on 22nd September 2021, for participants across the country. The last date for the participants to send their entries for these events was 18th September, 2021.

Details of activities organized by NCC-PvPI during National Pharmacovigilance Week

Activity	Topic/ Theme
Essay Competition	<ul style="list-style-type: none"> Social Media: A tool for spreading awareness on Pharmacovigilance Pharmacovigilance in Patient Safety: Challenges and Perspective
e-Posters	<ul style="list-style-type: none"> Importance of Pharmacovigilance in Indian Population Medication Errors: Detection and Prevention
Audio – visual Animations	<ul style="list-style-type: none"> Public Engagement in Pharmacovigilance. Medication Errors: Detection and Prevention
Pharmacovigilance Quiz	<ul style="list-style-type: none"> Basics of Pharmacovigilance

On 22nd September 2021 during the celebration of National Pharmacovigilance Week 2021, staff at NCC-PvPI, IPC has organised a Pharmacovigilance quiz. A total of 18 participants from NCC-PvPI, IPC were divided in 6 teams and participated in the quiz programme. The results of these events were announced on 23rd September, 2021 during the valedictory ceremony of the National Pharmacovigilance Week. NCC-PvPI congratulated the winners for their achievements and also acknowledged the efforts made by all the participants.

During the Valedictory ceremony, on the last day, i.e., 23rd September, 2021 of National Pharmacovigilance Week, PvPI-IPC organized a Valedictory Ceremony. Dr. Jai Prakash, Officer-in-Charge, PvPI delivered a welcome note to start the discussion which was moderated by Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director. The distinguished panelists comprising of learned experts like Prof. Y.K. Gupta, Prof. Urmila Thatte, Prof. Bikash Medhi, Dr. Bejon Misra, Prof. P. Usha Rani and Mr. Sachin Gandhi congratulated Dr. Rajeev Singh Raghuvanshi, Dr. Jai Prakash and the whole PvPI team for successful completion of this national level event. They also discussed the impact of National Pharmacovigilance Week on ground and shared their views on the roadmap ahead for PvPI in ensuring patient safety in India. During the Valedictory Session of National Pharmacovigilance Week Celebration 2021, Dr. Rajeev Singh Raghuvanshi released the PvPI newsletter Volume 11 Issue 35 on 23rd September 2021.

National Pharmacovigilance Week 2021 received an overwhelming response across the country from Coordinators, Deputy Coordinators, Pharmacovigilance Associates and Healthcare Professionals from AMCs. The ADR monitoring centres across the country have organized various sensitization programmes and other community level sensitization

programmes activities to spread awareness on reporting of ADRs. PvPI-IPC released a video 'Recap of Activities Performed during National Pharmacovigilance Week' from 17th to 23rd September, 2021 in order to thank and congratulate all the stakeholders who were effortlessly involved in promotion of PvPI. NCC-PvPI conducted the Pharmacovigilance Quiz competition on 22nd September, 2021 at IPC. The results of this event were announced on 23rd September, 2021 during the Valedictory Ceremony of National Pharmacovigilance Week. The winners were felicitated by Secretary-cum-Scientific Director, IPC and congratulated them for their active participation in the National event.

J. Miscellaneous Training/Workshops

Apart from the regular training Programs, IPC-PvPI also organized various trainings at IPC, Ghaziabad. The list of which are as follows:

S. No.	Date	Title	Mode	No. of Participants
1.	29 th April 2021	How to develop a positive culture of Adverse Event Reporting by Pharmaceutical Industries/ Marketing Authorization Holders	Virtual	54
2.	3 rd June 2021	Processing and Quality review of ICSRs-Report Completeness		153
3.	28 th July 2021	Training on ADRMs Software		30
4.	29 th December 2021	Webinar on "Basics of Good Pharmacovigilance Practices with reference to Module VI" for Pharmacovigilance Associates posted at AMCs and NCC-PvPI		103
5.	15 th February 2022	Quality Management System for Patient Safety		186

Summary of Training Programmes organized by PvPI

S.No.	Training Programmes	Organized at	No. of Trainings	No. of Participants
1.	Trainings/Sensitization/Awareness Programmes conducted by AMCs	AMCs	616	33,074
2.	Trainings/Sensitization/Awareness Programmes conducted by AMCs during National Pharmacovigilance Week 2021	AMCs	398	33,854
3.	Advanced Level Training	RTCs	8	1313
4.	Induction-cum-Training Programme	NCC-PvPI	4	427
5.	Skill Development Programme on Pharmacovigilance of Medical Products	NCC-PvPI	4	621
6.	Regional Workshops conducted for MAH	NCC-PvPI	1	35
7.	PV Training programme for NABH Accredited Hospitals	NCC-PvPI	1	94
8.	Interactive Meetings for MAHs	NCC-PvPI	6	27
9.	Other important Training Programmes	NCC-PvPI	5	526
Grand Total			1,043	69,971

Scientific Publications

NCC-PvPI and AMCs published the following scientific communications in following journals:

1. Ambwani S, Dutta S, Mishra G, Lal H, Singh S, Charan J. Adverse Drug Reactions Associated with Drugs Prescribed in Psychiatry: A Retrospective Descriptive Analysis in a Tertiary Care Hospital. *Cureus*. 2021;13(11):12-13.
2. Gulati K, Sharma N, Kumar R, Prakash J, Ray A. Role of Pharmacovigilance in Drug Safety: An Overview of Activities at an Adverse Drug Reaction Monitoring Centre (AMC) of Delhi. *E C Pharmacology and Toxicology*. 2022; 10(2):28-41.
3. Boopathi D, Akshatha JS, Buggi U, Siva H, Arun KP, Mani D. Analysis of adverse drug reactions associated with anti-tubercular drugs-A retrospective study. *Research Journal of Pharmacy and Technology*. 2022;15(4):1483-6.
4. Chandrasekhar D, Karattuthodi MS, Panakkal LM, William AM, Anjana A, Benny A, Karuppam A, Sam BS, Cholanugath S, Parambil JC, Joy AP. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) for COVID-19 Vaccine in a Tertiary Care Hospital-Kerala. *Indian Journal of Pharmaceutical Education and Research*. 2022;56(2s): s1-s8.
5. Chaudhary D, Jhaj R. A case report on azathioprine-induced euprolactinemic galactorrhea. *Indian Journal of Pharmacology*. 2021;53(3):234.
6. Datta S, Zosangpuii C, Ningthoujam G, Paonam S D, Leisangthem T D, Nameirakpam M D, Nameirakpam S S. ADRs of Anticancer Drugs: A Retrospective Study. *Journal of Clinical and Diagnostic Research*. 2021;15(11): Fc01-Fc05
7. Faruqui AR, Xavier D, Kamat SK, Chandy SJ, Medhi B, Tripathi RK, Shetty YC, Raj JM, Kaushal S, Balakrishnan S, Atal S. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. *The Indian Journal of Medical Research*. 2021;153(1-2):219.
8. Ghosh A, Ghosh S, Saha A, Begum S A, Chattaraj R, Bera T. Knowledge, attitude and practice (KAP) of pharmacovigilance among the different categories of frontline Covid-19 healthcare workers in a tertiary care hospital in West Bengal, India. *International Journal of Health and Clinical Research*. 2022 ;5(1): 296–301.
9. Gohil JB, Desai CK, Panchal JR, Patel RR, Rathod GH. An evaluation of trigger tool method for adverse drug reaction monitoring at a tertiary care teaching hospital. *Indian Journal of Pharmacology*. 2022; 54:19-23.
10. Jhaj R, Asati DP, Chaudhary D, Sadasivam B. Topical steroid containing combinations: Burden of adverse effects and why the recent regulatory action may not be enough. *Indian Journal of Pharmacology* 2021; 53:371-6.

11. Grover IS, Latha CD, Prasad RV, Satyagama S. Analysis of drug use in patients of analgesic nephropathy. *National Journal of Physiology, Pharmacy and Pharmacology*. 2022;12(1):1-4.
12. Joshi D, Sharma I, Gupta S, Singh TG, Dhiman S, Prashar A, Gulati M, Kumar B, Vishwas S, Chellappan DK, Gupta G. A global comparison of implementation and effectiveness of materiovigilance program: overview of regulations. *Environmental Science and Pollution Research*. 2021;28(42):59608-29.s
13. Kasukurthi S R, Chakradhar T, Rani A S, Bhuvaneshwari E, Marpaka S. Assessment of knowledge, attitude, and practice of haemovigilance among post-Graduates at a tertiary care teaching hospital in Hyderabad–A cross-sectional study. *Asian Journal of Pharmaceutical and Clinical Research*, 2022;15(3): 29-32.
14. Kaur H, Kaur M, Bhattacharyya A, Prajapat M, Thota P, Sarma P, Kumar S, Kaur G, Sharma S, Prakash A, Saifuddin Pk. Indian contribution toward biomedical research and development in Covid-19: A systematic review. *Indian journal of pharmacology*. 2022;53(1):63.
15. Kaur S, Sarma P, Kaur H, Prajapat M, Shekhar N, Bhattacharyya J, Kaur H, Kumar S, Medhi B, Ram J, Das D. Efficacy and safety of topical cysteamine in corneal cystinosis: A systematic review and meta-analysis. *American Journal of Ophthalmology*. 2021;223: 275-85.
16. Mukhyaprana SK, Devipriya S, Thirumalaiappan M. Study of adverse drug reactions associated with antiepileptic drugs: a pharmacovigilance study using spontaneous reporting system. *International Journal of Basic and Clinical Pharmacology*. 2021; 10:1125-9.
17. Malempati Y, Devisetty S, Vusurumarthi SB, Nallani VR, Yangalasetty S, Chandrakala K, Nadendla R. Identifying, Assessing and Reporting Adverse Drug Reactions in Government General Hospital: A Prospective Observational Study. *International Journal of Pharmacy and Pharmaceutical Research*. 2021;23 (1): 21-33.
18. Patel, S, Shah S, Desai C. An Analysis of Banned Fixed-Dose Combinations in India. *Asian Journal of Pharmaceutical and Clinical Research*, vol. 2021;14(2): 158-61.
19. Patil S B, Gade R, Raghuveer B, Rao V Y, Yamani V. An Annual Retrospective Analysis of ADRs Reported at Adverse Drug Reaction Centre, Nalgonda. *National Journal of Physiology, Pharmacy and Pharmacology*. 2022; 12(01):26-29.
20. Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India. *Indian Journal of Pharmacology*. 2021;53(2):143.
21. Pharmacovigilance Programme of India in Public Health: Creating A Better Tomorrow. *Pharma times*. 2022.

22. Rani AS, Chakradhar T, Kasukurthi SR, Bhuvaneshwari E, Marpaka S. A cross-sectional, questionnaire-based study on knowledge, attitude and practice of pharmacovigilance among post-graduates at a tertiary care teaching hospital, Telangana. *International Journal of Basic and Clinical Pharmacology*. 2022; 11:242-8.
23. Ramanathan R, Brahmanapalli VD. Pharmacovigilance Study in Geriatric Patients of a tertiary care hospital. *Journal of Pharmacovigilance and Drug Research*. 2021;2(2):33-38.
24. Sarangi SC, Medhi B, Prakash A, Prakash J, Gupta YK. Questionnaire-based Pan-India survey for impact assessment of National Formulary of India. *Indian Journal of Pharmacology*. 2021;53(2):115.
25. Shukla S, Rastogi S, Abdi SA, Dhamija P, Kumar V, Kalaiselvan V, Medhi B. Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase®. *Seizure*. 2021; 91:332-8.
26. Sujith T, Chakradhar T, Sravani Marpaka, Sowmini K. Aspects of Utilization and Limitations of Artificial Intelligence in Drug Safety. *Asian Journal of Pharmacy and Clinical Research*. 2021;14(8):34-39.
27. Kumar S, Sharma L, Sharma S, Jakhar P, Sharma K, Rani M. Assessment of the knowledge of Pharmacovigilance among medical students. *International Multispecialty Journal of Health*. 2019;5(6):112-116.
28. Kumar S, Sharma S, Sharma L. Evaluation of Adverse Drug Reactions using drop box at tertiary care centre: A step towards Pharmacovigilance. *International Journal of Scientific Research*. 2020;9(5):73-74.
29. Trivedi S, Solanki M, Dave D J. Cosmetovigilance: Current Status and Need in India. *National Journal of Integrated Research in Medicine*. 2022; 12(6):94-97.
30. Vusurumarthi BS, Malempati Y, Devisetty BS, Yangalasetty S, Nallani VR, Chandrakala K, Nadendla RR. A new discernment for advancing the adverse drug reaction monitoring and reporting in a tertiary care teaching hospital: A prospective observational study. *European Journal of Pharmaceutical and Medical Research*. 2021;8(12).
31. Zosangpuui C, Ningthoujam G, Gunindro N, Nameirakpam M D, Leisangthem T D, Nameirakpam S. A Study on Adverse Drug Reaction Patterns of Injectable Antibiotics Reported in The Pharmacovigilance Centre of a Tertiary Care Teaching Institute, Manipur. *International Journal of Advanced Research*. 2021; 9(12):843-850
32. Zosangpuui C, Datta S, Gunindro N, Nameirakpam M, Nameirakpam S. Adverse Drug Reaction Patterns of Anti-Retroviral Drugs: A Study in a Tertiary Care Teaching Institute of North East India. *Asian Journal of Pharmaceutical and Clinical Research*, 2022; 1863(1): 38
33. Kalaiselven V, Shukla S, Mishra N, Kumar P. Basics and Essentials of Medical Devices Safety Surveillance. *New Insights into the Future of Pharmacoepidemiology and Drug Safety*. 2021;173.

34. Kalaiselvan V, Santhanakrishnan R K, Mishra N, Kumar P, Raghuvanshi R S. Adverse Drug Reactions associated with Anti-Tuberculosis Therapy. *New Insights into the Future of Pharmacoepidemiology and Drug Safety*. 202.
35. Shukla S, Rastogi S, Abdi SA, Dhamija P, Kumar V, Kalaiselvan V, Medhi B. Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase®. *Seizure*. 2021; 91:332-8.
36. Srivastava GK, Kalaiselvan V, Andrés-Iglesias C, Shukla S, Saxena R, Pastor JC. Acute intraocular toxicity caused by perfluorocarbon liquids: safety control systems of medical devices. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 2022; 5:1-8.

Glimpses of PvPI in Press Communique

In order to spread awareness about ADR-reporting in PvPI, two advertisements were published in English (Pharmabiz) e-News portal on February 1, 2022 and February 9, 2022 respectively. The first advertisement was specifically targeted to spread awareness about reporting the ADRs related to Ibuprofen through dedicated form designed by NCC-PvPI while in the second one DCGI issued the direction to state DCs, based on recommendations of the subject expert committee, to ask manufacturers of 11 drugs to incorporate newly identified ADRs in their package insert.

PvPI in Press Media



IPC flags safety alert against nonsteroidal anti-inflammatory drug, ibuprofen

Laxmi Yadav, Mumbai

Tuesday, February 1, 2022, 08:00 Hrs [IST]

The Indian Pharmacopoeia Commission (IPC), which is the National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI), has flagged drug safety alert revealing that ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) which is used to treat pain and inflammatory diseases, is linked with adverse event known as fixed drug eruption.

This came to light after the preliminary analysis of adverse drug reactions (ADRs) from the PvPI database.

Ibuprofen, one of the most popular over the counter medicines, is used as an analgesic, anti-inflammatory and antipyretic. It is indicated for the treatment of chronic arthritic disorders and painful musculoskeletal conditions. Unlike most other NSAIDs, ibuprofen also acts as an inhibitor of Rho kinase and is useful in recovery from spinal-cord injury.

Ibuprofen works by inhibiting the cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandin H₂ (PGH₂). PGH₂, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever) and to thromboxane A₂ (which stimulates platelet aggregation, leading to the formation of blood clots).

As per drug safety alert issued by IPC on January 18, 2022, ibuprofen is associated with fixed drug eruption, a distinctive type of cutaneous drug reaction that characteristically recurs in the same locations upon re-exposure to the offending drug.

Healthcare professionals and patients have been advised to closely monitor the possibility of the above ADR associated with the use of ibuprofen. If such a reaction is encountered, it needs to be reported to the NCC-PvPI for suitable action.

IPC had earlier also flagged drug safety alerts revealing that Covid-19 drug remdesivir was linked to an adverse event known as sinus bradycardia.

Besides this, it had earlier also flagged drug safety alerts revealing that diclofenac, a NSAID, was linked to skin hyperpigmentation while dimethyl fumarate, used for relapsing-remitting multiple sclerosis, was associated with adverse drug reaction alopecia.

Cefazolin, a cephalosporin antibiotic, was linked to acute generalized exanthematous pustulosis (AGEP), according to the preliminary analysis of ADRs from the PvPI database.

The CDSCO had started PvPI in July 2010 across the country. Since then, IPC has been mandated to establish clinical evidence between the drug and the ADR event through a robust system of causality assessment.

Reference: <http://www.pharmabiz.com/NewsDetails.aspx?aid=145542&sid=1>

DCGI directs state DCs to ask manufacturers of 11 drugs to incorporate newly identified ADRs in their package insert

Laxmi Yadav, Mumbai

Wednesday, February 9, 2022, 08:00 Hrs [IST]

In a bid to promote patient safety, the Drugs Controller General of India (DCGI) has directed all state drug controllers in the country to take steps to ensure that manufacturers of eleven drug formulations— ranitidine IV, ceftriaxone, azithromycin, cloxacillin, itraconazole, ibuprofen, amoxicillin/clavulanate, ciprofloxacin, dipeptidyl peptidase-4 (DPP4) inhibitors, doxycycline and tinidazole – mention newly identified adverse reactions in the package insert of the drugs.

The DCGI issued the direction to state DCs on February 4, 2022 based on recommendations of the subject expert committee (SEC) of the respective therapeutic area.

The respective SEC had deliberated cardiac arrest as an adverse reaction to ranitidine IV, Stevens Johnson Syndrome (SJS) as an adverse event of Ceftriaxone, acute generalized exanthematous pustulosis (AGEP) as an adverse reaction related to azithromycin and cloxacillin, photosensitivity as an adverse reaction to itraconazole, Stevens Johnson Syndrome/toxic epidermal necrolysis (TEN) as adverse reaction related to ibuprofen, amoxicillin/clavulanate and ciprofloxacin, arthralgia as an adverse event involving dipeptidyl peptidase-4 (DPP4) inhibitors like sitagliptin, vildagliptin, saxagliptin etc. and fixed drug eruption as an adverse event related to doxycycline and tinidazole based on recommendations of Pharmacovigilance Programme of India (PvPI).

The respective SEC suggested that the newly identified adverse events should be incorporated in the package insert of ranitidine IV, ceftriaxone, azithromycin, cloxacillin, itraconazole, ibuprofen, amoxicillin/clavulanate, ciprofloxacin, dipeptidyl peptidase-4 (DPP4) inhibitors, doxycycline and tinidazole which are approved by CDSCO and marketed in the country in various dosage forms.

The National Co-Ordination Centre for PvPI, functioning at Indian Pharmacopoeia Commission (IPC) had forwarded their recommendation on adverse drug reaction reports on above medicinal products to CDSCO with an objective to detect signal/prescribing information leaflet change from Indian database and promote patient safety.

The PvPI had evaluated ADRs associated with the eleven drugs on the basis of individual case study reports (CSR) and recommended CDSCO to take necessary steps to incorporate cardiac arrest as an ADR into the prescribing information leaflet (PIL) of ranitidine IV marketed in the country and include Stevens Johnson Syndrome (SJS) as an ADR into PIL of ceftriaxone and AGEP as an ADR into PIL of azithromycin and cloxacillin.

It also suggested CDSCO to ensure that photosensitivity gets mentioned as an ADR into PIL of itraconazole. It further said the PIL of ibuprofen, amoxicillin/clavulanate and ciprofloxacin should incorporate SJS/ toxic epidermal necrolysis (TEN) as an ADR of the drug.

The PIL of dipeptidyl peptidase-4 (DPP4) inhibitors like sitagliptin, vildagliptin, saxagliptin etc. should mention arthralgia as an ADR of the drug and fixed drug eruption should be incorporated as an ADR in PIL of doxycycline and tinidazole formulations, said PvPI in its recommendation to CDSCO.

Reference: <http://pharmabiz.com/PrintArticle.aspx?aid=145700&sid=1>

PvPI recommendations published in WHO Pharmaceutical Newsletter



World Health
Organization

WHO Pharmaceuticals NEWSLETTER

2022

No. 1

Tinidazole

Risk of fixed eruption

India. The National Coordination Centre – Pharmacovigilance Programme of India (NCC-PvPI), Indian Pharmacopoeia Commission (IPC) has advised the Central Drugs Standard Control Organization (CDSCO) to revise the prescribing information leaflet (PIL) for tinidazole to include fixed eruption as an adverse drug reaction.

Tinidazole is indicated for the treatment of intestinal amoebiasis, giardiasis, trichomoniasis and anaerobic infections.

NCC-PvPI, IPC reviewed 71 case reports of tinidazole associated fixed eruption and a strong causal relationship between them was found.

Reference:

Based on the communication from IPC, India, November 2021 (ipc.gov.in)

Tramadol

Risk of urinary retention

India. The NCC-PvPI, IPC has advised the CDSCO to revise the PIL for tramadol to include urinary retention as an adverse drug reaction.


Tramadol is indicated for the treatment of moderate to severe pain, diagnostic procedures and surgical pain.

NCC-PvPI, IPC reviewed seven reports of tramadol-associated urinary retention and a causal relationship between them was found.

Reference:

Based on the communication from IPC, India, November 2021 (ipc.gov.in)

PvPI Newsletter



List of Newly Enrolled AMCs under PvPI

S. No.	State	Name of Institutions	Coordinator	Email- ID
1	Andhra Pradesh	Kamini Healthcare (P) Ltd D. No. 1-51, 100 Feet Road, New Auto Nagar, Poranki Rural, Penamaluru (Mandi), Krishna Dist, Andhra Pradesh-521137	Mr. Hanuman Naik	pharmacy.vja@kaminienihospitals.com gmoperations.vja@kaminienihospitals.com
2		Apollo Institute of Medical Sciences and Research, Murakambattu, Chittoor, Andhra Pradesh-517127	Dr Sivachandra Raju	ssraju97@gmail.com
3		Raghavendra Institute of Pharmaceutical Education & Research (RIPER) – Autonomous, Saigram, Near SK University, KR Palli Cross, Chiyvedu (PO), Anantapuramu, Ananthapur Dist., Andhra Pradesh-515721	Dr. G. Narayana	narayanagoruntia@gmail.com
4		Sri Venkateswara College of Pharmacy, RVS Nagar, Chittoor, Andhra Pradesh-517127	Dr. D. Jothieswari	drjothieswari@svcop.in
5		Hindu College of Pharmacy, Amaravathi Road, Guntur, Andhra Pradesh-522002	Dr. P. Seetharaman	psr040650@gmail.com
6		Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram. Chowdavaram, Guntur, Andhra Pradesh-522019	Dr. R. Hari Babu	haris760@gmail.com
7		KVSR Siddhartha College of Pharmaceutical Sciences, Polyclinic Road, Municipal employees colony road, Siddhartha Nagar, Vijayawada, Andhra Pradesh-520008	Dr.G.Vijaya Kumar	ghanta.vijay@gmail.com
8		Annamacharya College of Pharmacy, New Boyanapalli Post, Rajampet Mandal, Kadapa-516126	Dr. D. Giri Raja Sekhar	giriraj.pharma@gmail.com
9		Tirumala Multi Speciality Hospitals India pvt.ltd. Near R.T.C. Complex, Vizianagaram-535003	Dr. Chejarla Mahesh	medicaloperations@tirumalahospitals.com
10		Government Medical College, IIInd Floor, Balaga - Srikakulam, Andhra Pradesh-532001	Dr. D. Syamala	Pharmacogmcslm@gmail.com
11		Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur, Andhra Pradesh-522034	Dr. Venkata Rama Rao Nallani	chalapathipvpamc@gmail.com

12	Assam	School of Health Sciences, The Assam Kaziranga University Koraikhowa, NH-37, Jorhat, Assam-785006	Dr. Suryakanta Swain	suryakanta@kazirangaunivers ity.in
13		Fakhruddin Ali Ahmed Medical College & Hospital, Barpeta Assam	Dr. Pradumna Pathak	drpradumna@gmail.com
14	Bihar	Netaji Subhas Medical College & Hospital, Amhara, Bihta, Patna, Bihar-801106	Prof. Dr. Santanu K. Tripathi	tripathisantanu@gmail.com
15		National Institute of Pharmaceutical Education and Research (NIPER) Hajipur, Export Promotions Industrial Part (EPIP), Industrial Area Hajipur, Dist. Vaishali, Bihar-844102	Dr. Sameer Dhingra	sameerdhingra78@gmail.com
16	Chhattisgarh	Shri Shankaracharya College of Pharmaceutical Sciences, SSTC CampusJunwani, Bhillai-490020	Dr. Rajesh Choudhary	rajesh080987@gmail.com
17		Faculty of Pharmacy, Kalinga University,Village Kotni, Near Mantralaya, Naya Raipur, Chhattisgarh-492101	Ms. Rajni Yadav	rajni.yadav@kalingauniversity .ac.in
18	Gujarat	Maliba Pharmacy College, Uka Tarsadia University, Bardoli-Mahuva Road, Tarsadi, Dist. Surat, Gujarat-394350	Dr. Bhavin Vyas	bhavin.vyas@utu.ac.in
19		C.U. Shah Medical College, Dudhrej Road, Surendranagar, Gujarat-363001	Dr. Madhav D. Trivedi	dr.madhav.trivedi@gmail.com , madhav.trivedi@cusmc.org
20		GCS Medical College, Opp. DRM Office, Near Chamunda Bridge, Naroda Road, Ahmedabad-380025	Dr. Vipul Chaoudhari	drvip79@yahoo.co.in
21		HCG ONCOLOGY LLP, Sun-Pharma Atiadra Rd., Pramukh Swami Nagar, Tandalja, Vadodara, Gujarat-390012	Dr. Nisarg Hajariwala	clinicalpharmacy.hccbrd@ hcgel.com
22		HCG Cancer Centre, Sola-Science City Road, Near Sola Bridge, Ahmedabad-380060, Gujarat	Mr. Pankaj Leuva	pankaj.leuva@hcgel.com
23		L.M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat-380009	Dr. Gaurang B. Shah	gaurang.shah@lmcp.ac.in
24		Anand Pharmacy College, Opp. Town Hall, Anand, Gujarat-388001	Dr. Vaibhav Patel	Vaibhavbpatel@yahoo.com

25		BAPS Pramukh Swami Hospital Shri Pramukh Swami maharaj Marg, Adajan Char Rasta, Adajan, Surat-395009	Dr. Manish Vaghasiya	anandpharmacy011@gmail.com medadminsarat@bapshospital.org
26		Smt. R.B. Shah Mahavir Superspeciality Hospital Shree Mahavir Health Campus, Opp. Jivan Bharti School, Nanpura, Surat, Gujarat-395001	Mahesh Parmar	mahesh.parmar@mahavirhospital.com
27		Ramanbhai Patel College of Pharmacy, Charusat Campus, Changa, Dist. Anand, Gujarat-388421	Dr. Jalpa Suthar	jalpasuthar.ph@charusat.ac.in
28		HCG Hospitals (A unit of HCG SUN Hospitals), Ayodhya Chowk, HCG Hospital Road, Nr. Astha Avenue, Off 150 ft Ringh Road, Rajkot, Gujarat-360005	Ms. Bhavna Gohel	clinicalpharmacy.hhr@hcgel.com
29		Parul Institute of Pharmacy, Parul University, P.O. Limda, Tal Waghodia, Vadodara, Gujarat-391760	Dr. Mrudangsing M Rathod	mrudangsingh.rathod16126@paruluniversity.ac.in
30	Haryana	Al-Falah School of Medical & Research Centre, Dhauj, Faridabad 121004, Haryana	Dr. Sana Tafseer	sana2apr@gmail.com
31		Paras Hospital, (a unit of Paras Healthcare (P) Ltd.), Plot No. H-1, HSIIDC Tech Park, Near Nada Sahib Gurudwara, Panchkula, Haryana-134109	Mohd. Shahid	clinicalpharmacist.pkl@parashospitals.com
32		M.M. College of Pharmacy, MM (DU), Room No. 0412, 1st Floor, Near MM Health Care (Chemist Shop), MM Superspeciality Hospital, Mullana-Ambala, Haryana-133207	Dr. Inderjeet Verma	inderjeet.verma@mmumullan.a.org
33		SGT Medical College Hospital and Research Institute C/o Dr. Vijay Bhalla, Dept. of Pharmacy Practice, Third Floor, D-Block, SGT College of Pharmacy, SGT University, Chandu-Budhera Road, Gurugram, Haryana-122505	Dr. Vijay Bhalla	dean.fphs@sgtuniversity.org
34	Himachal Pradesh	All India Institute of Medical Sciences, Bilaspur, Himachal Pradesh-174001	Dr. Meenakshi Meenu	meenakshimeenu185@gmail.com

35	Jharkhand	Bhagwan Mahavir Medica Superspecialty Hospital, Near Bariatu Road, P.H.E.D. Colony, Booty More Road, Jai Prakash Nagar, Ranchi, Jharkhand-834009	Dr. Ashish Kumar Saha	asishkumar.saha@medicasynergie.in
36		All India Institute of Medical Sciences, Deoghar, Devipur Campus, Jharkhand-814152	Dr. Harminder Singh	harminder.pharmacology@aiimsdeoghar.edu.in
37		Sheikh Bhikhari Medical College & Hospital, Kolghatti, Hazaribag-825301	Dr. Asish Kumar Biswas	drasishbiswas@hotmail.com
38		Raj Hospital, Mahatma Gandhi main road, Behind Central, Ranchi – 834001	Dr. Govind Singh	rhs.clinicalpharmacy@gmail.com
39		Brahmananda Narayana Mutispeciality Hospital, Tamolia (Near Pardih Chowk) NH-33, Jamshedpur-831012 (Jharkhand)	Dr. Pankaj Kumar	drpkumar2010@gmail.com
40	Karnataka	Aster CMI Hospital (Unit of DM Health Cape Ltd.) Dept. of Clinical Pharmacy No. 43/2, NH.7, Intl. Airport Road, Sahakar Nagar, Hebbal, Bengaluru, Karnataka-560092	Dr. Renoy Philip	drrenoy.philip@asterhospital.com
41		Dr. Chandramma Dayananda Sagar Institute of Medical Education and Research, Devarakaggalahalli, Kanakapura Taluk, Ramanagar Dist., Karnataka 562112	Dr. Shiva Murthy N	amc.cdsimer.@dsu.edu.in
42		Kidwai Memorial Institute of Oncology, Dr. M.H. Marigowda Road, Bengaluru, Karnataka-560029	Dr. Linu Abraham Jacob	mannellinujacob@gmail.com
43		N.E.T. Pharmacy College, Navodaya Medical College Hospital & Research Centre, Navodaya Nagar, Mantralaya Road, Raichur, Karnataka-584103	Dr. Shiv Kumar	shivkumarmatur@gmail.com
44		Sankara Eye Hospital, Kundalahalli Signal, Varthur Main Road, Bangalore, Karnataka-560037	Ravindra Nath Dattu Murame	ravimurame1097@gmail.com
45		Bhagwan Mahaveer Jain Hospital, Millers Road, Vasanth Nagar, Bengaluru, Karnataka-560052	Dr. MD Marker	drmarker@gmail.com
46		Sri Siddhartha Institute of Medical Sciences and Research Center, T. Begur, Nelamangala Taluk, Bangalore Rural, Karnataka-562123	Dr. Lohit K.	ssimstbegur@gmail.com, lohitek4u@gmail.com

47	Acharya & BM Reddy College of Pharmacy, Acharya Dr. Sarvepalli Radhakrishnan Road, Soladevanahalli, Acharya Post Office, Bengaluru, Karnataka-560107	Dr. Geetha Jayaprakash	geethajayaprakash@acharya. ac.in
48	Visveswarapura Institute of Pharmaceutical Sciences, Room No. 57, 4th Floor, 22nd Main, 24th Cross, Opp. To BDA Complex, Banashankari IIInd Stage, Bengaluru, Karnataka-560070	Dr. Gopinatha.K	dr.gopigowda@gmail.com
49	Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education Madhav Nagar, Manipal, Udupi Dist., Karnataka-576104	Dr. Rajesh V	rajesh.v@manipal.edu
50	Rajiv Memorial Education Society's College of Pharmacy, Balaji Nagar, Old Jewargi Road, Gulbarga, Karnataka-585102	B. Shankar Reddy	bsreddi2005@gmail.com
51	BVVS, Hanagal Shri Kumareshwar College of Pharmacy, BVVS Old Campus, Bagalkot, Karnataka-587101	Dr. Chandrashekha r.VM	chandupharm@yahoo.com
52	KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka-580031	Dr. Sanatkumar B. Nyamgoud	dr.sanathnyamagoud@gmail.c om
53	Yenepoya Medical College, University Road, Derlakatte, Mangalore, Karnataka-575018	Dr. Roopa.P. Nayak	roopapnayak@yenepoya.edu.i n
54	Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University B.G. Nagar, Mandya, Karnataka-571448	Dr. Rajesh Venkataraman	rajeshvenky_research@hotma il.com
55	KLE College of Pharmacy, KLE Dr. Prabhakar Kore Hospital and Medicfal Research Centre, Belagavi, Karnataka-590010	Dr. M. S. Ganachari	msganachari@gmail.com
56	Gadag Institute of Medical Sciences, Malasamudra, Gadag-582103, Karnataka-582103	Dr. Rajani Patil	dr.rajani_patil@yahoo.co.in
57	Nargund College of Pharmacy, Banashankari 3rd stage, Bangalore-560085	Dr. D. S. Puranik	dayanandpuranik@rediffmail. com
58	Sakra World Hospital, 52/ 2 & 52/ 3, Deverabeesanahalli, Varthur Hobli, Bangalore-560 103	Dr. Vishnu Dev K	ClinicalPharmacology@sakraw orldhospital.com
59	Sri Siddhartha Medical college and Research center, Agalakote, BH Road, Tumakuru-572107	Dr. Naveen Kumar	cknaveena@gmail.com, ssmcpv123@gmail.com

60		Shridevi Institute of Medical Sciences and Research Hospital , Sira Road , Tumakara, Karnataka – India	Dr. Priyadarshni bai – G	priya.ravik17@gmail.com
61		P.D. Hinduja Sindhi Hospital, 12th A Cross, Sindhi Hospital Road, Sampangirama Nagar, Bengaluru, Karnataka-560027	Nagaraj H R	speakwithnagaraj@gmail.com
62	Kerala	Government Medical College, Paripally, Kollam, Kerala-691574	Dr. Reeja R	drreejapraveen@gmail.com
63		Jubilee Mission Medical College and Research Institute, Moospet Rd, Fathima Nagar, Mahatma Nagar, Nellikunnu, Thrissur 580005 Kerala	Dr. Maria Jose	marianinkujos@gmail.com
64		KMCT Medical College, Manassery P.O. Mukkam, Kozhikode, Kerala-673602	Dr. Shaikh Ubedulla Shaikh Iqbal Daud	drubaidulla@gmail.com
65		Apollo Adlux Hospital, Near Adlux Convention Center Cable Junction, Ernakulam Dist., National Highway 47, Karukutty, Angamaly-683576, Kerala-683576	Dr. Stelvin Sebastian	stelvinsebastian@gmail.com
66		Nirmala College of Pharmacy, Muvattupuzha, Ernakulam Dist., Kerala-686661	Dr. Shaji George	shajige@gmail.com
67		Malabar Medical College Hospital & Research Centre, Ulliyeri, Kerala - 673315	Dr. P.V. Narayanan	narayananpv55@gmail.com
68		Malankara Orthodox Syrian Church Medical College & Hospital, Kolenchery, Ernakulam, Kerala-682311	Dr. Susan Mani	adrpharmacmoscmc@gmail.com
69		KIMS Health, P.B. No. 1, Vinod Nagar Rd., Anayara, Thiruvananthapuram, Kerala – 695029	Dr. Susan Mani	minuboban3@gmail.com
70		National College of Pharmacy, Manassery (PO), Calicut, Kerala-673602	Dr. Rajeev P Thomas	rajeevpthomas@gmail.com
71		Karuna Medical College Hospital, Vilayodi, Chittur, Palakkad, Kerala-678103	Dr. Gurudeva	gurudeva2006@gmail.com
72		Sree UthradamThirunal Academy of Medical Science's, Vattappara, Thiruvananthapuram – 695028	Dr. Sangeetha Gopinath	sangeetha.twinkles@gmail.com
73	Madhya Pradesh	Amity Institute of Pharmacy, Amity University Madhya Pradesh, Maharajpura, Gwalior, Madhya Pradesh	Dr. A. N Nagappa	annagappa@gwa.amity.edu

74	Maharashtra	Rajarshee Chhatrapati Shahu Maharaj Government Medical College, Shenda Park, Kolhapur, Maharashtra-416013	Dr. Karande V.B.	drhnaikarande@gmail.com
75		Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital Ahmednagar, Opp. Govt. Milk Dairy, Vadgaon Gupta, MIDC, Ahmednagar, Maharashtra - 414111	Dr Balwant Kisanrao Choure	pharmac@vims.edu.in, drchourebk@gmail.com
76		Dr. G.D. Pol Foundations Y.M.T. Dental College & Hospital, Ground Floor, Room No. 1, Department of Oral Medicine & Radiology, Sector-4, Kharghar, Navi Mumbai, Maharashtra - 410210	Dr. Bhakti Patil Soman	bhakti04@gmail.com
77		Dr. Ulhas Patil Medical College & Hospital, Jalgaon Khurd Ta; & Dist. Jalgaon, Maharashtra - 425309	Dr. Devendra R. Chaudhari	devendra7681@gmail.com
78		Symbiosis Medical College for Women & Symbiosis University Hospital & Research Centre, Lavale, Taluka: Mulshi, Pune, Maharashtra-411215	Dr. Prasan Bhandari	hod.pharmacology@smcw.siu.edu.in
79		HCG Cancer Centre, Holy Cross Road, IC Colony, Off. Borivali-Dahisar, Link Road, Borivali (W), Mumbai, Maharashtra-400092	Dr. Japhia Saju	pharmacologist.mumbai@hcgel.com
80		MGM Medical College & Hospital Sec. 1, Kamothe, Navi Mumbai, Taluka- Panvel, Dist. Raigad, Maharashtra-410209	Dr. Santosh C. Gursale	pharmacamc@gmail.com
81		Vilasrao Deshmukh Government Institute of Medical Sciences Near Rajasthan Marawadi School, Mini Market, Latur, Maharashtra-413512	Dr Ganesh Pawar	dr_ganesh13@yahoo.com
82		HCG Manavata Cancer Centre, Near Mylan Circle, Nashik, Maharashtra-422002	Sunil Nanabhau More	msunil020@gmail.com
83		Dr. D.Y. Patil College of Pharmacy, Sector-29, Nigdi, Pradhikaran, Akurdi, Pune, Maharashtra-411044	Dr. Ashish V. Kulkarni	ashishkulkarni@dyppharmaakurdi.ac.in
84		Mahatma Gandhi Vidyamandir's Pharmacy College, Mumbai-Agra Road, Panchavati, Nashik, Maharashtra-422003	Dr. A.R. Rote	ambrote@rediffmail.com
85		Datta Meghe Medical College, Wanadongvi, Hingna Road, Nagpur-440010	Dr. Harsh Salankar	harshsalankar@gmail.com

86		K. J. Somaiya Medical College, Near Everard Nagar, Eastern Express Highway, Sion, Mumbai-400022	Dr. Usha V. Nayak	usha.nayak@somaiya.edu
87		Vedantaa Institute of Medical Sciences , Village: Saswand, Dhundalwadi, Taluka: Dahanu, District: Palghar, Maharashtra, 401606	Dr. Sachendra K. Srivastava	drsachendra5@gmail.com
88	New Delhi	Malik Radix Healthcare Pvt. Ltd., C-217, 218, Nirman Vihar, New Delhi 110092	Dr. Prince Agrawal	princegupta409@gmail.com
89		Sonia Hospital, Gulshan Park, Rohtak Road, Nangloi, Delhi-110041	Mr. Kabir Rathore	mrkabirrathore@gmail.com
90		Panchsheel Hospital (P) Ltd., C-3/63A-64A, Yamnuna Vihar, Delhi - 110053	Dr. V.K. Goyal	vkgoyal22@gmail.com
91		Northern Railway Central Hospital, Basant Lane, Panchkulan Road, New Delhi-110055	Dr. Krishan Mehra	krishanmehra@rediffmail.com
92		School of Pharmaceutical Education & Research, Jamia Hamdard New Delhi – 110062	Prof. Abul Kalam Najmi	aknajmi@jamiahamdard.ac.in
93		Rajiv Gandhi Cancer Institute & Research Centre, Sector-5, Rohini (North-West Dist.) Delhi – 110085	Rajesh Gupta	gupta.rajesh@rgcirc.org
94	Odisha	Bhima Bhoi Medical College & Hospital, At. : Balangir, PO Rajendra College, Balangir Dist., Odisha-767002	Prof. (Dr.) Supriya Pradhan	drsupriyapradhan.sp3@gmail.com
95		Shri Jagannath Medical College & Hospital, At - Samangara, PO - Baliguali, Puri, Odisha-752004	Dr. Rajlaxmi Upadhyay	dr Rajlaxmi@yahoo.co.in
96		IMT Pharmacy College, Sai Bihar, New Nabakalebara Road, Gopalpur, Puri-2, Odisha-752004	Dr. Agnimitra Dinda	agnimitrapharmaindia@gmail.com
97	Puducherry	Sri Manakula Vinayagar Medical College & Hospital, Kalitheerthalkuppam Madagadipet, Puducherry-605107	Dr. M. Shanthi	shanthibabu24@gmail.com
98	Punjab	Anil Baghi Hospital, Anil Baghi Road, Ferozepur, Punjab-152002	Dr. Neeru Chopra	neeru.handa@yahoo.com
99		Fortis Hospital, Sector-62, Phase-VIII, Mohali (Sas Nagar), Punjab-160062	Dr. Shivani Juneja Bedi	shivani.juneja@fortishealthcare.com
100		Amandeep Hospital Dalhousie Road, Pathankot, Punjab- 145001	Dr. Rakesh Bhaat	rbhat61@gmail.com

101		Akal College of Pharmacy & Technical Education, Barnala - Sangrur Highway, Mastuana Sahib, Dist. Sangrur, Punjab-148002	Dr. Sandeep K. Goyal	sangoyal2007@rediffmail.com
102		Armaan Hospital, 188-Adarsh Nagar, Near Football Jalandhar, Punjab-144003	Dr. Rachna	racha2311@gmail.com
103		Amandeep Medicity (A unit of Amandeep Healthcare (P) Ltd.), 361, Mail Road, Near Novelty Chowk, Amritsar, Punjab-143001	Rajbir Kaur	quality@amandeepmedicity.org
104		Raja Diagnostic Centre & Hospital, Mota Singh Road, Near Civil Surgeon Office, Dist. SBS Nagar, Nawanshahar, Punjab-144514	Dr. Arun Kumar Gupta	jaswinder.rajahospital@gmail.com
105		Lovely Professional University(School of Pharmaceutical Sciences), Jalandhar, Delhi-GT Road, District Kapurthala, Phagwara-144411	Dr. Bimlesh Kumar	bimlesh.12474@lpu.co.in
106	Rajasthan	Raj Jindal Hospital & Research Center Pvt. Ltd Bharatpur-321001	Mr. Rahul Agarwal	rjhospital@gmail.com
107		CKS Hospitals (A unit of cks medicare pvt. ltd.), Sikas road, Vishwakarma Fredustrial Area, Jaipur-302013	Mr. Shobraj	shobrajjat@gmail.com
108		CKRD Memorial Hospital & Research Centre, E-4, Indra Nagar, Jhunjhunu-333001	M. R. Pinak Saini	pinanksaini001@gmail.com
109		Dhanwantri Hospital & Research Center, 67 / 56- A, New Sanganer Road, Mansarovar, Jaipur-302020	Mr. Rajesh Saini	dhrjcpr@gmail.com
110		S. R. Kalla Memorial Gastro & General Hospital 78-79 Dhuleshwar Garden , Sardar Patel Marg C- Scheme , Jaipur-302001	Dr. Priyanka	tanwarpriyanka531@gmail.com
111		RVRS Medical College Bhilwara, Sindri Ke Balaji Road, Sanganer, Bhilwara, Rajasthan-311001	Dr. M.L. Aseri	aseri.madan@gmail.com
112		Government Medical College, Pali, Near Ramasiya Village, Sunerpur Road (NH-62) Pali, Rajasthan-306401	Dr. Priyanka Kumawat	kumawat.ricky@gmail.com, priyankadaksh.kumawat@gmail.com
113		Shri Kalyan Government Medical College, Sikar, Bajaj Gram, Sanwali State, Rajasthan-332001	Dr. Ateendra Singh	ateendra09@gmail.com

114		Mahatma Gandhi Medical College, RIICO Institutional Area, Sitapura, Jaipur, Rajasthan-302022	Dr. Anusha Vohra	drvohraanusha1979@gmail.com
115		Jhalawar Medical College & Associated Groups of Hospitals, N.H. 52, Kota Road, Jhalawar, Rajasthan-326001	Dr. Tarun Vijaywargia	tarunvijaywargi76@yahoo.com
116	Sikkim	Government Pharmacy College Sajong, Gangtok-737135	Dr. Gauthaman Karunakran	gauthamank@gmail.com
117	Tamil Nadu	Saveetha Medical College and Hospital, Saveetha Nagar, Thandalam, Chennai, Tamil Nadu-602105	Dr. J. Thirunavukkarasu	thiruchennai75@yahoo.co.in
118		Chettvinad Hospital & Research Institute, Chettinad Health City Campus, Rajiv Gandhi Salai, Kelambakkam, Chengalpattu Dist., Tamil Nadu-603103	Dr. S. Saradha	saradhachoks@gmail.com
119		Sree Mookambika Institute of Medical Sciences, Velayudhan Pillai Memorial Hospital Complex, Padanilam, Kulasekharam, K.K. Dist. State-Tamil Nadu-629161	Dr. Reneega Gangadhar	drreneega@gmail.com
120		Government Medical College, Virudhunagar No. 1, Collectorate Master Plan Complex, Koorakundu Village, Virudhunagar, Tamil Nadu-626001	Dr. B. Jayapriya	jayapriyabalamurugan@gmail.com
121		Government Medical College, No.1, Nallampati Road, Dindigul, Tamil Nadu-624003	Dr. T. Gowri Thilagam	drgowri97@rediffmail.com
122		Government Theni Medical College, Theni-625512, Tamil Nadu	Dr. Navajothi	nava8arul@gmail.com
123		IRT-Perundurai Medical College Hospital, Sanatorium PO, Erode Dist., Tamil Nadu-638053	Arbind Kumar Choudhary	arbindkch@gmail.com
124		Srinivasan Medical College & Hospital, Samayapuram, Trichy-621112	Dr. S. Tamilarasi	tamilsoundar@gmail.com
125		Karpaga Vinayaga Institute of Medical Science & Research Centre, GST Road, Chinnakalambakkam, Maduranthgam-TK, Chengalpattu-603308	Dr. B. Prathap	prathap.thap@gmail.com
126		Government Medical College, Mullur Village, Pudukkottai – 622001	Dr. S. Umadevi	umaboomi@gmail.com
127		Swamy Vivekanandha College of Pharmacy/Vivekanandha Medical care Hospital, Namakkal Dist., Tamil Nadu-637205	Dr. P. Sharmila Nirojini	sharmilaapractice@gmail.com

128		Shri Sathya Sai Medical College & Research Institute, Tiruporur-Guduvancherry Main Road, Ammapettai, Chengalpet Taluk, Nellikuppam, Chengalpattu District, Tamil Nadu-603108	Dr. Shree Lakshmi Devi.S	drshree20@gmail.com
129		Government Medical College, Master Plan Complex, Siluvampatty, Namakkal, Tamil Nadu-637003	Dr. M. Dhanasekaran	pharmnmch@gmail.com
130		J.K.K. Nattraja College of Pharmacy Natarajapuram, NH-544 (Salem To Coimbatore National Highway), Near Erode, Kumarapalayam - 638 183, Namakkal District, Tamil Nadu	Dr. Venkateshwara murthy.N	venkateswaramurthy.n@jkkn.ac.in
131		Vijaya Medical & Educational Trust Old no:180, New no: 434 N.S.K, Salai, Vadapalani, Chennai, Tamil Nadu-600026	Dr. Shajahan O.M	doc.shajahan.om@gmail.com
132		Melmaruvathur Adhiparasakthi Institute of Medical Sciences & Research Melmaruvathur (Village & Post), Cheyyur (Taluk), Chengalpattu (Dist.), Tamil Nadu-603319	Dr. S. Vijayalakshmi	drsviji2010@gmail.com
133		Government Medical College & Hospital, The Nilgiris, Udhagamandalam, Tamil Nadu-643001	Dr. R. Jeyalalitha	gmcnilgiris@gmail.com
134		Annai Arul Hospital, No. 270, Mudichur Road, Old Perungalathur, Chennai-600063	Ms. Pichammal. S	nabh@annaiarulhospital.com
135		Sree Renga Hospital, 12, Varada Reddy St., Vedachala Nagar, Chengalpattu, Tamil Nadu-603001	Dr. K.P. Pichumani	kppdr@yahoo.com
136		Government Medical College & Hospital, Karur, Tamil Nadu-639004	Dr. M. Mathivani	mathivani99@gmail.com
137		Meenakshi Medical College, Hospital & Research Institute Enathur, Kanchipuram, Tamil Nadu-631552	Dr. K. Parimala	parimala@mmchri.ac.in
138	Telangana	Deccan College of Medical Sciences, P.O., DMRL X Road, Santosh Nagar, Kanchan Bagh, Hyderabad, Telangana-500058	Dr. Mohammed Mohsin	mohammeddmohsin@rediffmail.com
139		Government Medical College, Yedira, Mahabubnagar, Telangana-509002	Dr. Mohd. Naseeruddin Nadeem	nad040@gmail.com
140		St. Peter's Institute of Pharmaceutical Sciences, Vidyanagar, Warangal Urban-506001, Telangana	Dr. D. Praveen	praveen.d@stpeters.in, praveendevanandan@gmail.com
141		Deccan School of Pharmacy Dar-Us-Salam, Aghapura, Nampally (PO, Hyderabad, Telangana-500001	Dr. Asif Rasheed	asifrasheed707@gmail.com

142	RBVRR Women's College of Pharmacy, 3-4-343, Barkathpura, Hyderabad, Telangana – 500027	Dr. J. Archana	archanacology@gmail.com
143	Talla Padmavathi College of Pharmacy, Orus, Kareemabad, Warangal, Telangana -506002	Dr. Varun Talla	tallavarun@gmail.com
144	Sri Venkateshwara College of Pharmacy, 86, Hitech City Road, Madhapur, Hyderabad, Telangana-500081	Dr. J. Ananthalakshmi	anu_manas0108@yahoo.com
145	All India Institute of Medical Sciences, Bibinagar, Hyderabad Metropolitan Region, Telangana-508126	Dr. Debasis Bisoi	bisoidebasis@gmail.com
146	Balaji Institute of Pharmaceutical Sciences, 15-1-237, Guardian Multispeciality Hospital, Opp. L.B. College, MULUGU 'X' Roads, Warangal, Telangana-506002	Dr. A. Shyam Sunder	shyamar9@gmail.com
147	Asian Institute of Gastroenterology (AIG) Hospitals, Mind Space Road, Gachibowli, Hyderabad, Telangana-500032	Dr. Maveen	drmaveen.ahmed@aighospital.com
148	Government Medical College, Ensanpally, Siddipet, Telangana-502103	Dr. J. Margaret Viola	margaretviola67@yahoo.com
149	Sarojini Naidu Vanitha Pharmacy Mahavidyala, Vijayapuri Colony, Tarnaka, Opp. To St. Adns High School, 12-5-31/32, S. Lala Guda, Secunderabad, Telangana-500017	Dr. T. Venu	tallavenu@gmail.com
150	Chaitanya (Deemed to be University)-Pharmacy, Ajara Hospitals, Mulugu Road, Hanumakonda, Telangana-506007	Dr. P. Shankaraiah	drspuligilla@gmail.com
151	Pulla Reddy Institute of Pharmacy, Dommadugu (V), Gummadidala (M), Sangareddy (Dist.), Hyderabad, Telangana-502313	Dr. D.K. Suresh	dksuresha@gmail.com
152	Sultan-ul-Uloom College of Pharmacy, "Mount Pleasant", 8-2-249 to 267, Road No. 3, Banjara Hills, Hyderabad, Telangana-500034	Dr. Mohammed Ashfaq Hussain	mdashfaqhussain@sucp.ac.in
153	Geethanjali College of Pharmacy, Survey No.31, Cheeryal (v), Keesara (M), Medchal District, Telangana-501301	Dr. B. Rambabu	balu019914@gmail.com;
154	MNR College of Pharmacy, MNR Nagar, Narsapur Road, Sangareddy, Gr. Hyderabad, Telangana-502294	Dr. Lankeswar Rao	lokesh.chinnuk999@gmail.com
155	Anwarul Uloom College of Pharmacy, 11-3-918, New Mallepally, Hyderabad, Telangana-500001	Dr. Kanchana, N. Dussa	dussa2512@gmail.com

156		St. Pauls College of Pharmacy, Sy No. 603, 604 & 605, Turkayamjal (Vi), Abdullapurmet (M), R.R. Dist., Telangana-501510	Dr. P. Sagar	dr.sagar@live.com
157		Sri Indu Institute of Pharmacy, Sheriguda (V), Ibrahimpatnam (M), R.R. Dist., Telangana-501510	Dr. D. Naga Latha	dnl@siip.ac.in, latha.dhulipalla9@gmail.com
158		Malla Reddy Pharmacy College, Maisammaguda, Dhulapally, Secunderabad, Telangana-500100	Dr. Kunta Naresh	kuntanaresh785@gmail.com
159		Government Medical College & Hospital, Amaravadi Nagar, Thallagaoda, Suryapet, Telangana-508213	Dr. A.R. Radhika	dradrikarayan@gmail.com
160		RVM Institute of Medical Sciences & Research Centre, Laxmakapally Village, Mulugu Mandal, Siddipet District, Telangana-502279	Dr Vedula Prasanna	prasannamuddu11@gmail.com
161	UT of Jammu & Kashmir	Government Medical College & Associated Hospital, Rajouri, UT of Jammu & Kashmir-185131	Dr. Aman Sharma	amansharma1602@gmail.com
162	Uttar Pradesh	United Institute of Medical Sciences, Prayagraj, Village-Rawatpur, Nr.-Prayagraj Airport, Uttar Pradesh-211012	Dr. Laxman Verma	drlaxman.7nov@gmail.com
163		Autonomous State Medical College, Society Siddharthnagar Park Road, Near Police Line, Tetari Bazar, Siddharthnagar, Uttar Pradesh-272207	Dr. Ravishankar Srivastava	rohit_june5@yahoo.co.in
164		Rama Medical College Hospital & Research Centre, Rama City, 38 km. Mile Stone, Near Mother Dairy, Pilkhuwa, Hapur, Uttar Pradesh-245304	Dr. Bina Shukla	bshuklabkn@rediffmail.com
165		Prasad Institute of Medical Sciences, Banthara, Kanpur Road, Lucknow, U.P.-226401	Dr. Preeti Mishra	prasadhospitalko@gmail.com
166		National Capital Region Institute of Medical Sciences, 21-KM, NH-235, Nalpur-Kharkhanda, Hapur Road, Meerut, Uttar Pradesh - 245206	Dr. Mohit Patnaik	ncrimsmeerut@gmail.com
167		Shekhar Hospital (P) Ltd., B-Block, Church Road, Indira Nagar, Lucknow, Uttar Pradesh-226016	Dr. J.S. Srivastava	mail@shekharhospital.com
168		Saraswati Medical College & Hospital, LIDA, Madhu Vihar PO, Asha Khera, Nh25, Lucknow-Kanpur Road Unnao, Uttar Pradesh-209859	Prof. Anand Verma	drvermaanand@gmail.com

169		Chandni Hospital (P) Lt., 9/60, Arya Nagar, Kanpur, Uttar Pradesh-208002	Dr. Shubhra Bajpai	shubhbajpai@gmail.com
170		Rohilkhand Medical College & Hospital, Pilibhit Bye Pass Road, Bareilly, Uttar Pradesh-243006	Dr. Chandra Mohan	info@rmcbareilly.com
171		Prayag Hospital & Research Centre (P) Ltd., 3-206/A1, Sector-41, Noida, Gautam Buddh Nagar, Uttar Pradesh-201302	Ravendra Kumar	ravendk00012@gmail.com
172		Faculty of Pharmacy, Integral University, Lucknow-226026	Dr. Badruddeen	badar@iul.ac.in
173		Mahamana Pandit Madan Mohan Malviya Cancer Centre, Sunder Bagiya, B.H.U. Campus, Varanasi-221005	Dr. Sambasivaiah kuraparthi	sambasvims@yahoo.co.in
174		Autonomous State Medical College, Marehra road Village-Siroon, Etah-207001	Dr. Meenakshi Maurya	gmceah@gmail.com
175		G. S. Medical College & Hospital, NH-9, Pilkhuwa, Hapur-245304	Dr. Bina Shukla	bshuklabkn@rediffmail.com
176		Heritage Hospitals Ltd., Madhav Market, Lanka, Varanasi-221005	Dr. S. K. Srivastava	qualitycontrol@heritagehospitals.com
177		King George's Medical University, Lucknow, Uttar Pradesh-226003	Dr. Amod Kumar Sachan	dramodkumarsachan@gmail.com
178		Shree Krishna College of Pharmacy, Gata-No.94, Ahmad Nagar, Kasraila-Naipolapur Road, Sitapur, Uttar Pradesh-261125	Dr. Anurag Mishra	anuknp80@gmail.com
179	Uttarakhand	School of Health Sciences, University of Petroleum and Energy Studies (UPES) Campus Bidholi via Prem Nagar, Dehradun, Uttarakhand-248007	Dr. Jyoti Upadhyay	jupadhyay@ddn.upes.ac.in
180	West Bengal	HCG EKO Cancer Centre, Plot No. DG-4, Premises-03-358, Near DPS, New Town, Kolkata, West Bengal – 700156	Dr. Sunny K. Gupta	sunny16498.sg@gmail.com
181		North Bengal Medical College, Sushrutnagar, Darjeeling, West Bengal – 734012	Dr. Anupam Nath Gupta	nathguptadranupam@yahoo.com
182		Rampurhat Government Medical College & Hospital, 3rd Floor, Academic Building, Rampurhat, Dist. Birbhum, West Bengal-731224	Dr. Amrita Sil	drsilamrita@gmail.com

183	Maharaja Jitendra Narayan Medical College & Hospital, Vivekananda Street, Pilkhana, Coochbehar, West Bengal-736101	Arunava Biswas	adrmc.mjnmch@gmail.com, drabiswas@gmail.com
184	Jagannath Gupta Institute of Medical Science & Hospital, K.P. Mondal Road, Buita, Budge Budge, South 24 Parganas, Kolkata, West Bengal-700137	Dr. Subhadeep Patra	dr.subhadeep.patra@gmail.com
185	Gouri Devi Institute of Medical Sciences & Hospital, Rajbandh, Durgapur, West Bengal-713212	Prof. Dr. Sudeb Mondal	sudebmondal1952@gmail.com
186	Peerless Hospitex Hospital and Research Center Ltd. 360, Panchasayar road Kolkata-700094	Dr. Subhrojoyoti Bhowmick	drsubhro@gmail.com
187	Rabindranath Tagore International Institute of Cardiac Sciences, 124, Mukundapur, E.M. Bypass, Kolkata, West Bengal-700099	Dr. Sauren Panja	sauren.panja.dr@narayanahealth.org
188	Amri Hospitals Ltd., Mukundapur, 223&230, Barakhola Lane, Purba Jadavpur, South 24 Parganas, Kolkata, West Bengal-700099	Dr. Sayantan Ghosh	clinicalpharmacist@amrimukundapur.in

Student projects and training in PvPI

S.No.	Name of Trainee	Qualification	Institution	Project	Period
1	Mr. Aryan Prakash Rawat	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Introduction to Pharmacovigilance	01-02-2021 to 01-05-2021
2	Mr. Vishal Sharma	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Introduction to Pharmacovigilance	01-02-2021 to 01-05-2021
3	Mr. Sanjay Singh	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Introduction to Pharmacovigilance	01-02-2021 to 01-05-2021
4	Dr. Sneha Pal	P.G. Diploma in Pharmacovigilance	I.G.M.P.I. New Delhi	Current Updates on Pharmacovigilance Programme of India	19-07-2021 to 31-10-2021
5	Ms. Ruchi Sengupta	B. Pharma	IIMT College of Pharmacy, Greater Noida	Current Updates on Pharmacovigilance Programme of India	01-09-2021 to 01-10-2021
6	Ms. Neha Sahay	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Current Updates on Pharmacovigilance Programme of India	06-10-2021 to 06-12-2021
7	Ms. Anshika Malik	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Current Updates on Pharmacovigilance Programme of India	06-10-2021 to 06-12-2021
8	Ms. Prachi Sharma	B. Pharma	BBDIT College of Pharmacy, Ghaziabad	Current Updates on Pharmacovigilance Programme of India	06-10-2021 to 22-11-2021
9	Mr. Abhishek	M. Pharma	MDU Rohtak	Evaluation of ADR with anxiety disorder in tertiary Health care unit: A prospective Study	03-01-2022 to 03-07-2022

MATERIOVIGILANCE PROGRAMME OF INDIA


Background

After several horrific cases of malfunctioning of medical devices, such as babies burnt to death due to short circuits in incubators or hip implants causing blood poisoning and many such incidences have been reported, the Ministry of Health & Family Welfare (MoHFW), Govt. of India (GoI) has approved the commencement of Materiovigilance Programme of India (MvPI) on 10th February 2015 in an effort to ensure safety of medical devices. Thereafter, MvPI was launched on 6th July 2015 at Indian Pharmacopoeia Commission (IPC) Ghaziabad by the then Drugs Controller General (India) with an objective to ensure the patient safety by monitoring, recording, analyzing the root cause of adverse events or risk associated with the use of medical devices and suggesting National Regulatory Authority i.e. Central Drugs Standard Control Organization (CDSCO) for appropriate action. MvPI aims to promote and facilitate adverse event reporting of medical devices and subsequently evaluating these events. The scientific and systematic evaluation of these medical device adverse events/reports will foster monitoring trends for improving and protecting the health and safety of Indian population. Initially Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST), Thiruvananthapuram served as National Coordination Center (NCC) for the programme till 2017; since 2018 IPC functions as NCC for MvPI. In addition to protection of health and safety of patients, MvPI reduces the likelihood of reoccurrence of the harmful incidents elsewhere thereby safety of medical devices. MvPI continuously work with its partnering organizations where SCTIMST, Thiruvananthapuram serves as National Collaborating Centre and National Health System Resource Centre (NHSRC), New Delhi serves as Technical Support & Resource Centre for the programme. As a dynamic process, the IPC recognizes 150 Medical Device Adverse Event Monitoring Centres (MDMCs) across India for monitoring and reporting of Medical Device Adverse Event (MDAE).

To ensure effective adverse event reporting culture among MDMCs, clinical establishments, clinicians, biomedical engineers, nurses, pharmacists and other healthcare professionals, MvPI has been imparting hand on training programmes/ awareness programmes/workshop/webinar etc. periodically.

Channels for Medical Device Adverse Event (MDAE) Reporting

A person can use the medical device adverse event reporting form which is available on the official website of IPC (www.ipc@gov.in) to report any medical device associated adverse event. Reporters from Medical Device Adverse Events Monitoring Centre (MDMC)/ Adverse Drug Reaction Monitoring Centre (AMC) after filling the above mentioned MDAE reporting form can submit it to the coordinator or associate of the respective MDMC/ AMC. A reporter who is not part of MDMC/AMC can submit the filled MDAE reporting form to the nearest MDMC/ AMC or directly to the National Coordination Center. Reporter can also mail the scanned form at shatrunjay.ipc@gov.in or mvpi-ipc@gov.in. IPC also having a facility of helpline number 1800-180-3024 available between (Monday to Friday from 09:00 AM to 5:30 PM) to report adverse events associated with medical devices and medicines. A person can also report MDAE by using PvPI mobile application, which is freely available on google play store.



MvPI Status

Year	No. of MDAE processed	Total MDMCs	MvPI Recommendations to CDSCO	MvPI safety alerts to AMCs & MDMCs
2021-2022	3868	New 100 (Total 150)	5	17

Status of MDAE reports processed at IPC

NCC-MvPI, IPC collates and analyses adverse events associated with medical devices exclusively in Indian population, analyses the benefit-risk ratio, generates evidence-based information on medical devices safety, supports regulatory bodies in the decision-making process on medical devices & communicates the safety signals on use of medical devices to various stakeholders.

- A total of 7,780 MDAE reports were received at NCC MvPI during 2015 – March 2022 from various sources i.e., MDMCs, AMCs, Marketing Authorization Holders (MAHs) and consumers.

Year wise processing of MDAE at IPC is given in figure 22.




Figure.22 Medical Device Adverse Event (MDAE) Reporting Trend – Year wise

Month wise reporting trend of MDAE

Total 3,868 MDAE reports have been received during index period.

The month wise processing of MDAE reports is given in figure 23.





Figure. 23 Month wise processing of MDAE reports

Reporter-wise MDAE Reports

The Figure 24, represents the distribution of MDAE Reports based on the sender/ reporter received during index period. 52 % reports were reported by MDMCs, 44% reports from MAHs, 1% reports from AMCs and other sources including Non-AMCs / Non-MDMCs, consumers and project trainees contributed 3% of reports.



MAHs: Marketing Authorization Holders

MDMCs: Medical Device Adverse Events Monitoring Centres

AMCs: Adverse Drug Reaction Monitoring Centres

Others: Including Non-AMCs / MDMCs, consumers and project trainees

Figure.24 Reporter wise MDAE reports

Device wise MDAE reports

The Figure 25 below, represents device wise distribution of MDAE reports received during index period. 19 % reports were from cardiac stents, 12% from IUCDs, 9% from PPEs, 3% from catheters, 3% from orthopaedic implants, 1% from heart valve and 52% from others including i.v. canula, syringes, ventilator, patient monitor, glucometers etc.




Figure.25 Device wise MDAE reports

Status of MDMCs Under MvPI

NCC-MvPI collects adverse events from licence holders and Medical Device Adverse Events Monitoring Centres (MDMCs) located pan India. Till March 2022, there are 150 MDMCs enrolled under MvPI.

Year wise and state wise enrollment of MDMCs under MvPI is given in figure 26 & 27 respectively.




Figure.26 MDMCs enrollment under MvPI- Year wise Cumulative




Figure.27 State wise 150 MDMCs pan India

MDMCs enrolled under MvPI

During the index period, NCC-MvPI has recognized 100 new MDMCs in various states of India to collect more information on safe use of medical devices in Indian population.

List of new MDMCs enrolled under MvPI in index period

S. No.	State	MDMCs Name & Address
1	Andhra Pradesh	Guntur Medical College, Guntur
2		Vignan Pharmacy College, Guntur
3		AIIMS, Mangalagiri
4		Kurnool Medical College, Kurnool
5	Bihar	National Institute of Pharmaceutical Education and Research, Hajipur, Dist. Vaishali
6		Indira Gandhi Institute of Medical Sciences Patna
7	Chhattisgarh	Ramkrishna Care Hospital, Raipur
8	Delhi	Max Super Specialty Hospital, Saket, New Delhi
9		Escorts Heart Institute and Research Centre, New Delhi
10	Gujrat	GMERS Medical College, Sola, Ahmedabad
11		Care Institute of Medical Science, Sola, Ahmedabad
12		BAPS Pramukh Swami Hospital, Surat
13		HCG Sun Hospitals, Rajkot
14	Haryana	Amritdhara Hospital Private limited, Karnal
15		Maharishi Markendeshwar Institute of Medical Sciences & Research, Ambala
16		Paras Hospital, Gurugram
17		QRG Medicare Limited, Faridabad
18		Fortis Hospital Limited Faridabad
19	Himachal Pradesh	Sri Lal Bahadur Shastri Gov. Med. College, Mandi
20		Maharishi Markandeshwar Medical College, Kumarhatti

21	Jharkhand	Kashyap Memorial Eye Hospital Pvt. Ltd, Ranchi
22		Sadar Hospital, Khasmahal, Jamshedpur
23	UT of Jammu & Kashmir	Government Medical College, Anantnag
24		Government Medical College, Jammu
25		Sri Mata Vaishno Devi Narayana Superspeciality Hospital, Katra
26	Karnataka	Kasturba Medical College, Mangalore
27		Divakar's Specialty Hospital, Bengaluru
28		Karwar Institute of Medical Sciences, Karwar
29		Dr. Chandramma Dayananda Sagar Institute of Medical Education and Research, Kanakapura
30		Kidwai Memorial Institute of Oncology, Bengaluru
31		Healthcare Global Private Limited, Bengaluru
32		A J Hospital & Research Centre, Mangalore
33		Railway Hospital Rail Wheel Factory, Bengaluru
34		Sri Adichunchanagiri College of Pharmacy, Mandya
35		SDM Narayana Heart Centre, Dharwad,
36		SS Narayana Heart Centre, Davangere
37		Manipal College of Dental Sciences, Mangalore
38		Vijayanagar Institute of Medical Sciences, Ballari
39		Alameen College of Pharmacy, Bangalore
40		Father Muller Medical College, Mangalore
41		Manipal College of Dental Sciences, Mangalore
42		Yenepoya Medical College Hospital, Mangalore
43		JSS Medical College and hospital, Mysuru
44	Kerala	Alshifa College of Pharmacy, Perinthalmanna
45		Muthoot Healthcare Private Limited, Pathanamthitta

46		Government Medical College, Pallakkad
47		Sri Narayna Inst. of Med. Science, Ernakulam
48		PRS Hospital Pvt. Ltd. Trivandram
49		Amrit Institute of Medical Sciences, Kochi
50	Madhya Pradesh	Sri Aurobindo Medical College & PGI, Indore
51		LN medical College and Research Center, Bhopal
52	Maharashtra	Breach Candy Hospital trust, Mumbai
53		Ruby Hall Clinic, Pune
54		HCG Manavata Cancer Centre, Nashik
55		Mahatma Gandhi Institute of Medical Sciences, Wardha
56		Government Medical College, Miraj
57		MGM Medical College, Aurangabad
58		Dr. D Y Patil Medical College and Hospital, Pune
59		Indra Gandhi Govt. Medical College and hospital, Nagpur
60		Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai
61	Odisha	SCB Medical College and Hospital, Cuttack
62		Hitech Medical College & Hospital, Khurda
63		Pandit Raghunath Murmu Medical College & Hospital, Mayurbhanj
64	Pondicherry	Sri Laxmi Narayana Institute of Medical Sciences, Kudapakkam
65		Sri Balaji Vidyapeeth University, Pillayarkuppam
66		Arupadai Veedu Medical College, Pillaiyarkuppam
67	Punjab	Amandeep Hospital, Pathankot
68		Amandeep Hospital, Amritsar
69		Amandeep Medicity, Amritsar
70		Armaan Hospital, Jalandhar
71		Indus international Hospital, Mohali

72	Rajasthan	JawaharLal Nehru Medical College, Ajmer
73		Sawai Man Singh Medical College, Jaipur
74	Sikkim	Government Pharmacy College, Sajong
75	Tamil Nadu	Panimalar Medical College Hospital & Research Institute, Chennai
76		ESIC Medical College & PGIMSR, Chennai
77		Saveetha Dental College and Hospital, Vellappanchavadi, Chennai
78		Coimbatore Medical College, Coimbatore
79		Government Erode Medical College and Hospital, Erode
80		Sri Ramachandra Medical College, Chennai
81		Kovai Medical Centre and Hospital, Coimbatore
82		Annai Arul Hospital, Chennai
83		Mehta Multi Speciality Hospital India Pvt. Ltd., Chennai
84	Tripura	Tripura Medical College, Agartala
85	Telangana	All India Institute of Medical Sciences (AIIMS), Bibinagar
86		ESIC Medical College and Hospital, Hyderabad
87		Kamineni Institute of Medical Sciences, Hyderabad
88		Mamta Academy of Medical Science, Hyderabad
89		Fernandez Hospital, Hyderabad
90		Appollo Institute of Medical Sciences, Hyderabad
91		Sai Sanjeevini Hospital, Hyderabad
92	Uttar Pradesh	Subharti Medical College, Meerut
93		College of Medicine & Hospital, Noida
94		Neo Hospital, Noida
95		Prayag Hospital & Research Centre Private Limited, Noida
96		Jawaharlal Nehru Medical College, Aligarh
97		Teerthankar Mahaveer Medical College, Bagadpur
98		Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi
99		Shivalik Medical Centre Pvt. Ltd., Noida
100	West Bengal	HCG EKO Cancer Centre, Kolkata

Newsletters

During the index period, 03 E-newsletters (Volume-3, Issue- 2, 3 and 4) were published and circulated to the stakeholders for promoting MvPI related activities.



Recommendations forwarded to CDSCO

NCC-MvPI has forwarded following 5 recommendations on safe use of medical devices in India to CDSCO for further necessary actions. The List of recommendations forwarded to CDSCO are as follows:

S. No.	Device	Adverse event reported	Description	Date of communication
1	Panbio COVID-19 Ag rapid test device	False negative result	Information on inadequate/incomplete details about potential adverse events in device instruction for use document	11 th October 2021
2	Antero medial distal femur locking plate	Device break	For information and necessary actions at their end	11 th October 2021
3	Ultrasound Biopsy Needle	Device break and needle deformation during use	Information on inadequate/incomplete details about potential adverse events in device instruction for use document	15 th July 2021
4	Inflatable Penile Prosthesis	Pump failure and implant related infection	Information on inadequate/incomplete details about potential adverse events in device instruction for use document	15 th July 2021
5	Amplatzer Septal Occluder	Cobra deformation during implant	Information on inadequate details about potential adverse events in device instruction for use document	12 th April 2021

Safety alerts/advisory forwarded to AMCs/ MDMCs

NCC-MvPI has forwarded 16 safety alerts on safe use of medical devices to AMCs/ MDMCs for their information and reference. List of safety alerts/advisory forwarded to AMCs/ MDMCs is as follows:

S. No.	Device	Manufacturer	Adverse event reported	Date of sending
1	AcrySof Single piece IOL	Alcon Laboratories, Inc.	Infection followed by vision loss after Implantation	5 th January 2022
2	Syringe pump	Alliance Medicaid	Short circuit	5 th January 2022
3	Internal orthopaedic fixation system	M/s Changzhou, Kanghui Medical Innovation Co., Ltd. Imported by India Medtronic Pvt. Ltd. & TRAUSON (China) Medical Instrument CO., Ltd. Imported by Stryker India Pvt. Ltd.	Implant break/Implant bent after implantation	5 th January 2022
4	MERIL-BONEWAX (Model No. BW810)	MERIL-BONEWAX (Model No. BW810)	Poor quality and suture frequently get cut off during use	5 th January 2022
5	Tendril STS (Pacing system analyser)	ST. JUDE MEDICAL, INC.	lead to Impedance, threshold-related issue, lead related issues and screw related issue during use	14 th October 2021
6	XIENCE Xpedition Drug Eluting Stent	Abbott Vascular	Balloon would not deflate during use, malfunctioning of the device	14 th October 2021
7	Antero medial distal femur locking plate	Nebula surgical Private Limited, Rajkot, Gujarat	Device break	14 th October 2021
8	ProGlide	Abbott Vascular	Oozing, hematomas, prolonged hospitalization	14 th October 2021
9	Panbio COVID-19 Ag rapid test device	Panbio COVID-19 Ag rapid test device	False negative result	14 th October 2021
10	Auto Suture Circular Stapler	Covidien (Medtronic)	Mechanical malfunction/failure - improper pin placement - device disassembly inside the patient during use - misfiring of the sutures - bleeding and suture line leakage	13 th July 2021

S. No.	Device	Manufacturer	Adverse event reported	Date of sending
11	Ultrasound Biopsy Needle	Cook Ireland Ltd	Mechanical deformation of needle during use	13 th July 2021
12	AMS 800 artificial urinary sphincter	American Medical Systems	Device erosion following the implantation Other common adverse events: - Implant placement related issues - Mechanical malfunction associated with the device - Fluid leak (de-incontinence)/ recurring incontinence	13 th July 2021
13	AMS 700 Inflatable Penile Prosthesis	American Medical Systems	Pump failure causing difficulty in achieving cylinder inflation Other common adverse events: - Severe scrotal and penile pain during full activation of the implant - Corporal perforation - Bleeding at the site of implant - Device migration out of the position	13 th July 2021
14	CPAP, BiPAP, Continuous and non-continuous ventilators	Philips Respironics (For more details, kindly refer to CDSCO recall alert attached)	- Headache, upper airway irritation, cough, chest pressure and sinus infection, nausea/vomiting - Skin, eye, and respiratory tract irritation, inflammatory response, headache, asthma - Adverse effects to other organs (e.g., kidneys and liver) - Toxic carcinogenic affects	12 th July 2021
15	Cranial perforator	Stryker Corporation	Drill bit breakage during use	13 th April 2021
16	Orthopaedic drill	Manman manufacturing company private limited, Maharashtra	Drill bit breakage during use	13 th April 2021

Advisory issued by MvPI

S. No.	Device	Adverse event reported	Date of sending
1	Perfluorocarbon Liquid	<ul style="list-style-type: none"> Acute blindness Moderate intraocular inflammatory reactions Retinal necrosis Retinal vascular occlusion Optic nerve atrophy Retinal atrophy Subretinal fibrosis Proliferative vitreoretinopathy Phthisis 	15 th April 2021
	Heavy silicone oils		
	Intraocular membrane staining dye		

This advisory was issued (based on the data of other countries) in India to report Adverse Event if any observe due to the use of above mentioned Medical Device.

Important Events

International Activities/Achievements: NCC-MvPI, IPC and University of Valladolid, Institute of Applied Ophthalmobiology (IOBA), Spain jointly organized an international webinar in collaboration with Spanish Agency of Medicines and Medical Products (AEMPS), Spain on "Ensuring safety of medical devices focused on Ocular Devices" on 09th April 2021. The webinar was attended by around 100 participants including ophthalmologists, ocular devices manufacturers/ importers/ distributors, regulators, healthcare professionals and researchers. The audience were sensitized on the safe use of ocular devices. All the eminent speakers enlightened the audience about the safe use of ocular devices and also interacted with the audience in the question-and-answer session at the end of the webinar.




Figure-28. NCC-MvPI, IPC in association with AEMPS, Spain organized an international webinar on "Ensuring safety of medical devices focused on Ocular Devices" on 09th April 2021

NCC-MvPI, IPC in association with Medical Technology Association of India (MTAI) organized a webinar on "Involvement of Medical Device Manufacturers in Materiovigilance Programme of India (MvPI)" on 03rd September 2021 via digital/virtual platform. In total, 90 participants including members from different medical device companies participated in the programme and MvPI officials delivered the concept to the participants on how, when, what and where to report adverse events associated with medical devices.



Figure-29. NCC-MvPI, IPC in association with MTAI organized a webinar on "Involvement of Medical Device Manufacturers in Materiovigilance Programme of India (MvPI)" on 03rd September 2021

MvPI Internship programme: MvPI is providing internship opportunity to the students (undergraduates, graduates, and postgraduates) to do short-term, mid-term and long-term. The Internship program enhances the knowledge of the students/ trainees on importance of Materiovigilance programme and medical device adverse event reporting.

- A brochure of MvPI Internship programme is available on IPC website
- As of now, 07 Trainees are enrolled under this internship programme and they are appointed at various MDMCs

Indian Pharmacopoeia Commission
 Ministry of Health & Family Welfare, Government of India
 New Delhi-110002

Materiovigilance Programme of India (MvPI) Internship Programme

BACKGROUND

To monitor the safety and ensuring quality of medical devices used in the country, the Ministry of Health & Family Welfare, Government of India approved and commenced the Materiovigilance Programme of India (MvPI). The objective of this programme is to improve Indian consumer safety by monitoring, recording, analyzing the root cause of adverse events or risks associated with the use of medical devices and suggesting Indian regulatory bodies for appropriate action with a sole intention of improving patient safety. Materiovigilance programme also handed hands on training for the healthcare professionals and medical device industries.

Now for the first time, MvPI is providing internship opportunity to the students (undergraduates, graduates, and postgraduates) to do short-term or long-term projects which could be advantageous learning experience for students. The internship Program enhances the knowledge of the students on importance of materiovigilance programme and medical device adverse event reporting.

ELIGIBILITY

The candidates shall be pursuing or completed any of following courses:

- Pharmaceutical sciences such as B. Pharm, M. Pharm, Pharm D, Ph. D
- Medical sciences such as MBBS, MD, DNB
- Dental Sciences such as BDS, MDS, Ph. D
- Engineering such as BE/B.Tech./M.Sc./M.Tech./M.S./Ph.D in biomedical engineering, medical electronics, clinical engineering, electronics, instrumentation & related courses
- Nursing such as AFN, GFN, DFN, RN (M.Sc. Nursing)
- Other health science courses

DURATION

The duration of internship shall be preferably:

- 3 months (Short-term)
- 6 Months (Long-term)
- 1 Year (Long-term)

BENEFITS

- Gain valuable research experience
- Develop and refine skills
- Networking with professionals
- MCC-MvPI, IPC shall provide certificate to the candidates
- No fees shall be applicable for the candidates

PROCEDURE TO APPLY

- Interested candidates can fill the following Google form: https://docs.google.com/forms/d/1u1F8qGQ3e0hA_gD8pD10G0w2A5L7-4w4N5G4X0H4/entry/guest/edit
- Interested candidates can send their updated resume to shantviji.ipc@gmail.com

APPLICATION PROCESS

- Applications will be accepted throughout the year.
- Students are required to reply directly (via google link) or mail to HCC-MvPI, IPC with an updated resume.
- Students shall submit a recommendation letter from Head of the Department/Head of the Institute from their college/university/Institute endorsing the requirement of training and declaration necessary for the fulfillment of their degree.

Contact Person
 Dr. Shantviji Shetty | E-mail: shantviji.ipc@gmail.com

Recognition of MvPI by the Government of Kerala: The Government of Kerala has issued an order on March 10, 2022 to State Mission Director, National Health Mission, Directorate of Medical Education (DME), Director of Health Services (DHS), Thiruvananthapuram respectively regarding permission to DME and DHS institutions for enrolling in to MvPI through the institutional arrangements of National Health Mission Kerala.

GOVERNMENT OF KERALA
Order
 Health & Family Welfare Department Permission to DME and DHS institutions for enrolling in to Materiovigilance Programme of India through National Health Mission (Central-Order issued)

HEALTH & FAMILY WELFARE DEPARTMENT
 G.O. (HFW) 112/2022 H&FW Dt. Thiruvananthapuram, 10-03-2022

Read 1 Letter No. DKYd/Mw/2017(141) dated 8-12-2017 from Drugs Controller General (India).

2 Letter No. NDM 1127/8-12-2018/SPMND from State Mission Director, National Health Mission dated 11-10-2021

ORDER

The Materiovigilance Programme of India (MvPI) aims to monitor input and analysis of adverse events associated with the use of Medical Device as a step forward preventing patient safety. Materiovigilance Programme of India (MvPI) also aims to collect data on Medical Device related adverse events systematically and scientifically analyse them to aid in regulatory decisions and recommendations on safe use of medical devices being made using data generated from India. The programme is meant to monitor medical device-associated adverse events (MDAAE), create evidence among healthcare professionals about the importance of MDAAE reporting in India and to monitor the benefit-risk profile of medical devices. It is also meant to generate independent, evidence-based recommendations on the safety of medical devices and to communicate the findings to all key stakeholders.

2. As per letter read in 1st paper above Drugs Controller General of India requested to expedite the process of Medical Devices Adverse Events reporting to Indian Pharmacopoeia Commission or Materiovigilance Programme of India designated centres of PAN India.

3. As per letter read in 2nd paper above SMD National Health Mission has proposed the followings regarding the same:

a. The adverse events reporting system may be internally monitored by the Biomedical Engineering wing of National Health Mission Kerala (NHEM), The

Research Study: A nationwide study on knowledge, attitude and practice (KAP Study) of healthcare professionals (HCPs) on safety surveillance practice of medical devices in India is designed by NCC-MvPI to understand the present readiness of HCPs in India and their data will be utilized for policy framing. The link to participate in this study is available on IPC website www.ipc.gov.in and as of now 1,200 HCPs have participated in the study.

Project Supervised/Guide

- A dissertation entitled "A systematic review on complications associated with hip arthroplasty surgery" was submitted by Ashish Sharma to Delhi Institute of Pharmaceutical Science and Research (DIPSAR) in the partial fulfilment for the award of degree of Master of Pharmacy in Clinical Research (Enrollment No. 10/MPH/DIPSAR/2019). The project work was supervised by Dr. V. Kalaiselvan, Sr. PSO, IPC.
- A dissertation entitled Part I "Case sheets analysis of In- Patient and Out- Patient a Tertiary Care Hospital of India for Assessing and Understanding the common adverse events associated with the use of different Copper Intrauterine Contraceptive Device" and Part II "Safety Assessment of Intrauterine Contraceptive Devices in Asian Population: A Systematic review and Meta Analysis" was submitted by G. Aishwarya to Delhi Institute of Pharmaceutical Science and Research (DIPSAR) in the partial Fulfilment for the award of degree of Master of Pharmacy in Clinical Research (Enrollment No. 06/MPH/DIPSAR/2019). The project work was supervised by Dr. V. Kalaiselvan, Sr. PSO, IPC and the data generated during study is submitted to MvPI- IPC.

Training/Awareness Programmes conducted/attended by MvPI: Till March 2022, NCC-MvPI, IPC has conducted 78 training/workshop/CME and awareness programme and trained approx. 5,280 participants including Healthcare Professionals (HCPs) such as doctors, nurses, pharmacists etc., Biomedical engineers (BMEs), Marketing Authorization Holders (MAHs) and Students from medical profession/ biomedical engineers etc.

Details of training programmes conducted during index period:

During the Index period, NCC- MvPI has conducted 30 following training/ CME/ awareness programmes & 12 stakeholder meetings in order to sensitize the healthcare providers and industry personnel to enhance the MDAE reporting and their understanding on Materiovigilance and medical device regulation in India, through these programme 2168 participants were sensitize in the index period.

- The figure 30 represents during the index period NCC-MvPI trained 2168 participants out of which 67% were HCPs including doctors, nurses, pharmacists etc., 24% students, 5% BMEs and 4% were from MAHs.




Figure.30 Trainees trained by MvPI during index period

List of training programmes organised by MvPI

1. NCC-MvPI, IPC and University of Valladolid, Institute of Applied Ophthalmobiology (IOBA), Spain jointly organized an international webinar in collaboration with Spanish Agency of Medicines and Medical Products (AEMPS), Spain on "Ensuring safety of medical devices focused on Ocular Devices" on 09th April 2021 held at IPC, Ghaziabad.
2. NCC-MvPI, IPC in association with Association of Diagnostics Manufactures of India (ADMI) organized a webinar on "Introduction to Materiovigilance Programme of India (MvPI) & Tools of Adverse Event Reporting" on 17th April 2021 held at IPC, Ghaziabad.
3. Saheed Laxman Nayak Medical College and Hospital, Koraput Odisha, MDMC under MvPI organized a sensitization programme on "Awareness on Materiovigilance Programmes of India (MvPI)" on 07th April 2021 via digital/virtual platform held at IPC, Ghaziabad (MvPI-Session was via virtual mode)
4. NCC- MvPI, IPC organized a webinar on "Medical Device Adverse Event Reporting during COVID-19 Pandemic" with coordinators of MDMCs on 11th May 2021 held at IPC, Ghaziabad.
5. NCC-MvPI, IPC in association with Indian Society of Anaesthesiology (ISA) organized a webinar on "Introduction to Materiovigilance Programme" on 24th May 2021 held at IPC, Ghaziabad.

6. NCC- MvPI, IPC in association with Indian Confederation for Healthcare Accreditations (ICHA) organized a webinar on "Medical device safety surveillance in India" on 13th June 2021 held at IPC, Ghaziabad.
7. Consortium of Chennai organized a knowledge session as a part of World Accreditation Day (WAD) 2021 on 08th to 11th June 2021 held at Chennai (MvPI- Session was via virtual mode)
8. NCC-MvPI officials presented a session on Materiovigilance Programme of India: An Overview & Medical Devices Acts & Rules in 16th Skill Development Programme on Pharmacovigilance for Medical Products on 23rd June 2021 held at IPC, Ghaziabad.
9. NCC-MvPI in association with National Institute of Mental Health and Neurosciences (NIMHANS) organized a webinar on "Overview of Materiovigilance and hands on training on MDAE reporting" on 14th July 2021 held at IPC, Ghaziabad.
10. NCC-MvPI in association with Academy of Hospital Administration (AHA) organized a webinar on "Importance of reporting adverse effects & enrolment as medical device monitoring centres" on 17th July 2021 held at IPC, Ghaziabad.
11. NCC-MvPI organized an induction-cum training programme via virtual mode for newly recruited/joined coordinators/ deputy coordinators/ Materiovigilance Associates under MvPI on 29th July 2021 held at IPC, Ghaziabad.
12. NCC-MvPI in association with Kurnool Medical College organized a webinar on "Awareness on Materiovigilance Programme and Reporting of Medical Device Adverse Events" on 31st August 2021 held at IPC, Ghaziabad.
13. NCC-MvPI organized a webinar on "Internship/Project work on MvPI & requirements of MDMC, MvPI" on 11th August 2021 held at IPC, Ghaziabad.
14. Sri Adichunchanagiri College of Pharmacy, Karnataka organized a webinar on "Medical Device safety Monitoring- Scopes and Challenges on 23rd August 2021 held at Karnataka (MvPI- Session was via virtual mode).
15. Goel Institute of Pharmacy & Sciences, Lucknow organized a webinar on "Materiovigilance programme of India: Concepts & Terminologies" on 30th August 2021 held at Lucknow (MvPI Session was via virtual mode).
16. NCC-MvPI in association with Medical Technology Association of India (MTAI) organized a webinar on "Involvement of Medical Device Manufacturers in Materiovigilance Programme of India (MvPI)" on 03rd September 2021 held at IPC, Ghaziabad.

17. NCC-MvPI in association with Private Hospitals and Nursing Homes association (PHANA) organized a webinar on "Importance of Materiovigilance Programme & Medical Device Adverse Event Reporting" on 09th September 2021 held at IPC, Ghaziabad.
18. NCC-MvPI in association with Saheed Laxman Nayak (SLN) Medical college organized a webinar on "Sensitization of Materiovigilance Programme and Reporting of Medical Device Adverse Events to health care providers" on 24th September 2021 held at IPC, Ghaziabad.
19. NCC- MvPI officials sensitized different pharmacy institutions, government/ private colleges and hospitals on the occasion of National Pharmacovigilance week on 17th to 23rd September 2021 held at various Medical Colleges, Pharmacy Institutes including AMCs, MDMCs and other institutes Sensitized by IPC officials via virtual mode.
20. NCC-MvPI, IPC in association with Andhra Pradesh MedTech Zone, Vishakhapatnam organized a training programme entitled "Role of Biomedical Engineers in assessment of Medical Device Adverse Events" from 15th to 18th November 2021 held at IPC, Ghaziabad. (Via virtual mode).
21. NCC-MvPI organized an Induction-cum-training programme for newly recognized coordinators/ deputy coordinators/ materiovigilance associates from 29th -30th November 2021 held at IPC, Ghaziabad.
22. NCC-MvPI organized a webinar on "Key role of medical technology/ medical device industries in Materiovigilance Programme of India" in association with AIMED and CDSCO on 10th December 2021 held at IPC, Ghaziabad.
23. NCC-MvPI in association with Quality & Accreditation Institute (QAI) organized a webinar on "Brain Storming session on integration of medical devices testing centres/labs with Materiovigilance Programme" 22nd December 2021 held at IPC, Ghaziabad.
24. NCC-MvPI team visited Neo Hospital, Shivalik Hospital and Prayag Hospital, Noida on 22nd February 2022 to develop the culture of adverse event reporting and capacity building of healthcare professionals.
25. NCC-MvPI physically conducted a training programme on "Overview of Materiovigilance programme and Reporting of medical device adverse events" for healthcare professionals including doctors, nurses, technicians and biomedical engineers on 22nd February 2022 held at Prayag Hospital, Noida.
26. NCC-MvPI organized an Induction-cum-training programme for newly recognized coordinators/ deputy coordinators/ Materiovigilance associates on 24th to 25th February 2022 held at IPC, Ghaziabad (via virtual mode).

27. NCC-MvPI physically conducted a training programme on "Overview of Materiovigilance programme and Reporting of medical device adverse events" on 28th February 2022 at QRG Medical Hospital, Faridabad.
28. MvPI officials have attended a physical training on "Office Procedure including Noting & Drafting for the officials of IPC" from 02nd to 04th March 2022 held at IPC, Ghaziabad.
29. To foster the culture of adverse event reporting and capacity building of healthcare professionals at the centres. NCC-MvPI, team visited Yashoda super Speciality hospital on 08th March 2022 held at Yashoda super Speciality Hospital, Kaushambi.
30. NCC-MvPI physically conducted a training programme at Paras hospital, on "Importance of Materiovigilance programme and Reporting of medical device adverse events" on 10th march 2022 held at Paras hospital, Faridabad.

List of conducted stakeholders meeting:

1. NCC-MvPI organized a Working Group Devices subcommittee meeting to discuss & review the draft monographs of medical devices: under the chairmanship of Prof. Naresh Bhatnagar on 23rd June 2021 held at IPC, Ghaziabad.
2. NCC-MvPI conducted a meeting with Technical Support Group for enrolment & excel in functioning of medical device adverse event monitoring centres (TSG-EEFM) via digital/virtual platform on 09th September 2021 held at IPC, Ghaziabad.
3. NCC-MvPI organized a meeting with Bureau of Indian Standards (BIS), Central Drugs Standard Control Organization (CDSCO) and Indian Institute of Technology, Delhi on "Harmonization in developing standards for medical devices in India" via digital/virtual platform on 16th September 2021 held at IPC, Ghaziabad.
4. NCC-MvPI organized a meeting with Eli Lilly and company on "Overview of Materiovigilance programme and Tools for reporting medical device adverse events" via digital/virtual platform on 17th September 2021 held at IPC, Ghaziabad.
5. NCC-MvPI organized a meeting for coordinators/deputy coordinators or his/her representative of non-reporting centre on "Brain storming session to encourage the MDMCs coordinators for active participation in MDAE reporting" via digital/virtual platform on 28th September 2021 held at IPC, Ghaziabad.
6. NCC-MvPI organized a meeting with Tamil Nadu Medical Services Cooperation Limited, Andhra Pradesh Medical Services & Infrastructure Development Cooperation and National Health Mission, Kerala on "Importance of enrolling & reporting to Materiovigilance Programme of India" via digital/ virtual platform on 10th October 2021 held at IPC, Ghaziabad.

7. NCC-MvPI organized a meeting with Bureau of Indian Standards (BIS), Central Drugs Standard Control Organization (CDSCO) and Indian Institute of Technology (IIT), Delhi on "Harmonization in developing standards for medical devices in India" via digital/virtual platform on 22nd October 2021 held at IPC, Ghaziabad.
8. NCC-MvPI organized a meeting with coordinators of different MDMCs to understand the role of research scholars/project trainees under Materiovigilance Programme via digital/virtual platform on 26th November 2021 held at IPC, Ghaziabad.
9. NCC-MvPI in collaboration with University Institute of Applied Ophthalmobiology (IOBA) organized a meeting on "Safety of Ocular Devices" via digital/ virtual platform on 11th February 2022 held at IPC, Ghaziabad.
10. A physical meeting with the representative of Eli Lilly and Company India Private Limited organized by NCC-MvPI to discuss the Lilly medical device adverse event reporting form on 11th February 2022 held at IPC, Ghaziabad.
11. NCC-MvPI, IPC conducted a virtual meeting on "Brain storming session (II) to encourage the MDMCs coordinators for active participation in MDAE reporting" on 02nd March 2022 held at IPC, Ghaziabad.
12. A physical meeting with the representative of Philips and the officials of IPC to discussed the medical device adverse events reporting related to voluntary recalled Philips products on 11th March 2022 held at IPC, Ghaziabad.

List of PvPI and MvPI staff at NCC and AMCs

S. No.	Name	Designation	Mail ID
1	Dr. Rajeev Singh Raghuvanshi	Secretary-cum-Scientific Director	Rajeevr.ipc@gov.in lab.ipc@gov.in
2	Dr. Jai Prakash	Sr. Principal Scientific Officer	jaiprakash.ipc@gov.in
3	Dr. V. Kalaiselvan	Sr. Principal Scientific Officer	kalaiselvan.ipc@gov.in
4	Dr. Shashi Bhushan	Senior Scientific Officer	bshashi.ipc@gov.in
5	Dr. R.S. Ray	Scientific Assistant	rayrs.ipc@gov.in
6	Mr. Rishi Kumar	Scientific Assistant	rishikumar.ipc@gov.in
7	Dr. Shatrúnajay Shukla	Scientific Assistant	shatrúnjay.ipc@gov.in
CONTRACTUAL STAFF			
8	Anindya Banerjee	Sr. Pharmacovigilance Associate (AMC)	kity.baju@gmail.com
9	Anoop Kumar	Sr. Pharmacovigilance Associate (NCC)	anoop_singh72@yahoo.com
10	B. Dharini	Sr. Pharmacovigilance Associate (AMC)	dhariniboopathi92@gmail.com
11	Bharat Kumar	Sr. Pharmacovigilance Associate (NCC)	bharatvijaykumar@gmail.com
12	Gautam Upadhyaya	Sr. Pharmacovigilance Associate (AMC)	sharmagautam973@gmail.com
13	Hari Haran	Sr. Materiovigilance Associate (MDMC)	hari.thiruvallur@gmail.com
14	Manish Soni	Sr. Materiovigilance Associate (NCC)	manishsoni.pharmacist@gmail.com
15	Rajalakshmi	Sr. Pharmacovigilance Associate (AMC)	rrajalakshmi2002@yahoo.in
16	Saurabh Kumar Jain	Sr. Pharmacovigilance Associate (AMC)	Saurabhpharma1983@gmail.com

17	Sravani Marpaka	Sr. Pharmacovigilance Associate (AMC)	sravani.marpak21@gmail.com
18	Swati Thapliyal	Sr. Pharmacovigilance Associate (NCC)	Swaticology18@gmail.com
19	Vijit Agrawal	Sr. Pharmacovigilance Associate (NCC)	dr.vijitagrawal@gmail.com
20	Vipin Kumar	Sr. Pharmacovigilance Associate (NCC)	vipin_pharma84@yahoo.com
21	Aarnika Chaure	Pharmacovigilance Associate (AMC)	aarnikachaure@gmail.com
22	Abhiramai Navi	Materiovigilance Associate (MDMC)	abiraminavin@gmail.com
23	Amar Dinkar Shinde	Pharmacovigilance Associate (AMC)	amarshinde16@gmail.com
24	Anjna Sharma	Pharmacovigilance Associate (AMC)	sharmaanjna87@gmail.com
25	Awadhesh Kumar Yadav	Pharmacovigilance Associate (AMC)	Awadeshyadav1@gmail.com
26	Balaju Deepika	Pharmacovigilance Associate (AMC)	balojudeepika@gmail.com
27	Deepa	Pharmacovigilance Associate (AMC)	chaudharydeepa22141@gmail.com
28	Doreddula Satish Kumar	Pharmacovigilance Associate (AMC)	sathishkumard11@gmail.com
29	Gufran Ali	Pharmacovigilance Associate (AMC)	ali.gufran79@gmail.com
30	Hammad Ali	Pharmacovigilance Associate (NCC)	hammadali64@gmail.com
31	Hemant Malik	Pharmacovigilance Associate (AMC)	Hemantmalik1989@gmail.com
32	Himani	Pharmacovigilance Associate (AMC)	himani34@ymail.com

33	Jayachandran Nair	Pharmacovigilance Associate (AMC)	jayanair1982@gmail.com
34	Kalpana Purohit	Pharmacovigilance Associate (AMC)	purohitkalpana128@gmail.com
35	Kamna Sharma	Materiovigilance Associate (NCC)	kamnasharma19@gmail.com
36	Mayank Shukla	Materiovigilance Associate (NCC)	mayank_rajshukla@yahoo.co.in
37	Md Faizan Khan	Materiovigilance Associate (MDMC)	pharmacistfaizan@gmail.com
38	Md. Rafi	Pharmacovigilance Associate (AMC)	rafiguddu@rediffmail.com
39	Nalini Mishra	Materiovigilance Associate (MDMC)	Nalininegi0527@gmail.com
40	Nameirakpam Surjit Singh	Pharmacovigilance Associate (AMC)	pharmacovigirims15@gmail.com
41	Nikita Mishra	Materiovigilance Associate (NCC)	Nikitamishra284.nm@gmail.com
42	Pavani Kothapalli	Pharmacovigilance Associate (AMC)	pavanireddykothapalli@gmail.com
43	Pilla.S. Surya Durga Devia	Pharmacovigilance Associate (AMC)	sreesuryadurgadevi@gmail.com
44	Piyush Nama	Pharmacovigilance Associate (AMC)	piyushnama@gmail.com
45	Preeti Singh	Pharmacovigilance Associate (AMC)	preeticology@gmail.com
46	Sabitri Pandit	Materiovigilance Associate (MDMC)	sabitri123@gmail.com
47	Sanjeev Srivastav	Pharmacovigilance Associate (AMC)	sanjivpharma@gmail.com
48	Satyagama Suvarchala	Pharmacovigilance Associate (AMC)	suvarchalasatyagama@yahoo.com

49	Sayan Bhattacharjee	Pharmacovigilance Associate (AMC)	sayanbhattacharje@gmail.com
50	Shiv Prakash Rajput	Pharmacovigilance Associate (AMC)	shivpharma122@gmail.com
51	Siddiraju Devipriya	Pharmacovigilance Associate (AMC)	amrutha.priya@gmail.com
52	Sita Ram Mane	Pharmacovigilance Associate (AMC)	rammanepharma@rediffmail.com
53	Srinivas Velupula	Pharmacovigilance Associate (AMC)	sree.velupula@gmail.com
54	Sripada Behra	Materiovigilance Associate (MDMC)	Sripadanitubehera@gmail.com
55	Swayam Sourav Sahoo	Pharmacovigilance Associate (AMC)	swayam_1984@yahoo.co.in
56	Tinu T. S	Pharmacovigilance Associate (AMC)	tinuts89@gmail.com
57	Urfan Nabi Najar	Pharmacovigilance Associate (AMC)	urfannabi8@gmail.com
58	Vinay Kumar	Pharmacovigilance Associate (AMC)	vinaykumar070786@gmail.com
59	A.S. Joseph Raju	Jr. Pharmacovigilance Associate (AMC)	josephraju145@gmail.com
60	Aakashdeep Verma	Jr. Pharmacovigilance Associate (AMC)	aakashdeep7991@gmail.com
61	Aiswarya Madhu	Jr. Pharmacovigilance Associate (AMC)	iamaishh95@gmail.com
62	Akash Deep Rawat	Jr Pharmacovigilance Associate (NCC)	aakashdeep7991@gmail.com
63	Akhil Raj	Jr. Pharmacovigilance Associate (NCC)	akhilrajmavingal@gmail.com
64	Amandeep Kaur	Jr. Pharmacovigilance Associate (AMC)	aman11091991@gmail.com

65	Anjali	Jr Pharmacovigilance Associate (NCC)	anjaligera50@gmail.com
66	Ankita Gulia	Jr. Pharmacovigilance Associate (AMC)	ankitaguliaaa@gmail.com
67	Arya Parvathy B. A	Jr. Pharmacovigilance Associate (AMC)	aryaparvathy92@gmail.com
68	Athira S R	Jr. Pharmacovigilance Associate (AMC)	srpharm94@gmail.com
69	Atul Tiwari	Jr. Pharmacovigilance Associate (NCC)	atultiwarircop@gmail.com
70	Ayushi Yadav	Jr. Pharmacovigilance Associate (NCC)	mail2ayushiyadav@gmail.com
71	Ban Ekta Mukund	Jr. Pharmacovigilance Associate (AMC)	ektaban278@gmail.com
72	Benjamin	Jr. Pharmacovigilance Associate (AMC)	suroy85@gmail.com
73	Bhagyashri Umale	Jr. Pharmacovigilance Associate (AMC)	bumale10@gmail.com
74	Bhanu Priya	Jr Pharmacovigilance Associate (NCC)	bhanupriyarai@gmail.com
75	Biswajit Patnaik	Jr. Pharmacovigilance Associate (AMC)	bpatnaik029@gmail.com
76	C. Lalramdina	Jr. Pharmacovigilance Associate (AMC)	91ramdinacr@gmail.com
77	Chaitra Shree T. J	Jr. Pharmacovigilance Associate (AMC)	chaitratj@gmail.com
78	Chintalapati Arya	Jr. Pharmacovigilance Associate (AMC)	ascharya.chintalapati@gmail.com
79	Datta prasad Kumbhakarna	Jr. Pharmacovigilance Associate (AMC)	vicky.vdk1995@gmail.com
80	Deepti Sachdeva	Jr Pharmacovigilance Associate (NCC)	deeptischdv@gmail.com
81	Dencita Merlyn Dsouza	Jr. Pharmacovigilance Associate (AMC)	dencita11dsouza@gmail.com

82	Dharmesh Ravjibhai Mevada	Jr. Pharmacovigilance Associate (AMC)	dharmeshmevada89@gmail.com
83	Fani Bhusan Mishra	Jr. Pharmacovigilance Associate (AMC)	f.fanibhusan@gmail.com
84	Girjesh Vishwakarma	Jr Pharmacovigilance Associate (AMC)	gv1448@gmail.com
85	Harishankar Sharma	Jr. Pharmacovigilance Associate (AMC)	hari.pyws@gmail.com
86	Hetvi Bachani	Jr. Pharmacovigilance Associate (AMC)	hetvibachani@gmail.com
87	John Flamitha	Jr. Pharmacovigilance Associate (AMC)	johnflamitha97@gmail.com
88	Jyothylekshmy Vijayan	Jr. Pharmacovigilance Associate (AMC)	jolekshmy@gmail.com
89	Jyoti Singh	Jr. Pharmacovigilance Associate (AMC)	jyotiteotia6@gmail.com
90	Jyotsna	Jr. Pharmacovigilance Associate (NCC)	jyotsna1712singh@gmail.com
91	K Krishna Priya	Jr. Pharmacovigilance Associate (AMC)	kanagarajkrishnapriya1997@gmail.com
92	Kapil Shivsharan	Jr. Pharmacovigilance Associate (AMC)	kapil4000@gmail.com
93	Kaushik Ranjan Deb	Jr. Pharmacovigilance Associate (AMC)	drkaushikranjandeb28@gmail.com
94	Khumanthem Deepak Singh	Jr. Pharmacovigilance Associate (AMC)	kh.deepaksg@gmail.com
95	KM. Ranjana	Jr. Pharmacovigilance Associate (AMC)	ranjana28101995@gmail.com
96	Kumari Jyoti Sinha	Jr. Pharmacovigilance Associate (AMC)	jyotiteotia6@gmail.com
97	M. Poojitha	Jr. Pharmacovigilance Associate (AMC)	mundlapatipoojitha6795@gmail.com

98	Magleen Kingsly	Jr. Pharmacovigilance Associate (AMC)	maglinjohnson1111@gmail.com
99	Mahima Maheshwari	Jr Pharmacovigilance Associate (NCC)	mahimaheshwari705@gmail.com
100	Milo	Jr. Pharmacovigilance Associate (AMC)	mooneymillo@gmail.com
101	Mortha.Bhuvana Sri	Jr. Pharmacovigilance Associate (AMC)	bhuvanasrimortha@gmail.com
102	Moutrisha M. Roy	Jr. Pharmacovigilance Associate (NCC)	moutrisha321@gmail.com
103	Mudasir Maqbool	Jr. Pharmacovigilance Associate (AMC)	bhatmudasir92@gmail.com
104	Mythili	Jr. Pharmacovigilance Associate (AMC)	mythujeevaju@gmail.com
105	Nandana Reghunath	Jr. Pharmacovigilance Associate (AMC)	nandanapharmd@gmail.com
106	Naseefudeen	Jr. Pharmacovigilance Associate (NCC)	naseefudeenk@gmail.com
107	Neha Nasim	Jr. Pharmacovigilance Associate (NCC)	neha.nasim1906@gmail.com
108	Nirakar Kar	Jr. Pharmacovigilance Associate (AMC)	nirakarkar8558@gmail.com
109	Palak Shingari	Jr. Pharmacovigilance Associate (AMC)	shingari.palak2805@gmail.com
110	Payal Mauik Patel	Jr. Pharmacovigilance Associate (AMC)	dr.pmpatel220709@gmail.com
111	Poonam Malani	Jr. Pharmacovigilance Associate (AMC)	dr.poonammalani10@gmail.com
112	Prabhjot Kaur	Jr. Pharmacovigilance Associate (AMC)	prabhjotmohar@gmail.com
113	Pratik Singh	Jr. Pharmacovigilance Associate (AMC)	drpratik060296@gmail.com

114	Praveen Kumar Uppala	Jr. Pharmacovigilance Associate (AMC)	praveen.chintu32@gmail.com
115	Preeti Acharya	Jr. Pharmacovigilance Associate (AMC)	preetiacharya94@gmail.com
116	Priyanka Sharma	Jr Pharmacovigilance Associate (NCC)	priyankash0202@gmail.com
117	Ravichandran C. V	Jr. Pharmacovigilance Associate (AMC)	ravichandravc2995@gmail.com
118	Retty Alex	Jr. Pharmacovigilance Associate (AMC)	rettyalex21@gmail.com
119	Richa Chaudhary	Jr. Pharmacovigilance Associate (AMC)	richachaudhary1410@gmail.com
120	Ritu Beniwal	Jr. Pharmacovigilance Associate (AMC)	reetubeniwal007@gmail.com
121	S. Harini	Jr. Pharmacovigilance Associate (AMC)	harinipharmd26@gmail.com
122	Saggurthi Pavani	Jr. Pharmacovigilance Associate (AMC)	pavani.saggurthi94@gmail.com
123	Saktivel	Jr. Pharmacovigilance Associate (AMC)	sakky0707@gmail.com
124	Samia Begum Barbhuiya	Jr. Pharmacovigilance Associate (AMC)	samiabarbhuiya9@gmail.com
125	Sandipta Banerjee	Jr. Pharmacovigilance Associate (AMC)	sandipta.banerjee1993@gmail.com
126	Shamna Sherif	Jr. Pharmacovigilance Associate (AMC)	shamnasheriff789@gmail.com
127	Shilpa, K	Jr. Pharmacovigilance Associate (AMC)	shilpasreedhar@ymail.com
128	Shilpi Abhirup De	Jr. Pharmacovigilance Associate (AMC)	de.shilpi1985@gmail.com
129	Shirish Awachit Chawhate	Jr. Pharmacovigilance Associate (AMC)	schawhate@gmail.com

130	Shivani Trivedi	Jr. Pharmacovigilance Associate (AMC)	shivaneetrivedee@gmail.com
131	Shruti Srivastava	Jr. Pharmacovigilance Associate (AMC)	shrutisrivastava945@gmail.com
132	Sneh Pal	Jr Pharmacovigilance Associate (NCC)	snehp94@yahoo.com
133	Sugandha Sharma	Jr. Pharmacovigilance Associate (AMC)	sug.sharma90@gmail.com
134	Sumit Bhidwaria	Jr Pharmacovigilance Associate (NCC)	sumitbhidwaria@gmail.com
135	Sushmita Sahu	Jr. Pharmacovigilance Associate (AMC)	sushmita.sahu22@gmail.com
136	Syed Zaheer Abass	Jr. Pharmacovigilance Associate (AMC)	zaheerabass002@gmail.com
137	Thatheer Zehra	Jr. Pharmacovigilance Associate (AMC)	zehratatheer.20@gmail.com
138	Tripti Purohit	Jr Pharmacovigilance Associate (NCC)	tripti8purohit@gmail.com
139	Ujwala Mahajan	Jr. Pharmacovigilance Associate (AMC)	ujwalamahajan@outlook.in
140	Vanendra Yadav	Jr. Pharmacovigilance Associate (AMC)	vanendrayadav@gmail.com
141	Vishakha Khandare	Jr. Pharmacovigilance Associate (AMC)	vishu.k501@gmail.com
142	Vratika Singh Inda	Jr. Pharmacovigilance Associate (NCC)	vratika09.indaa@gmail.com
143	Abhik Saha	Jr. Pharmacovigilance Associate (AMC)	pharma.abhik91@gmail.com
144	Abhishek Gautam	Jr. Pharmacovigilance Associate (AMC)	abhishekgautam261017@gmail.com
145	Akhayaka Guru	Jr. Pharmacovigilance Associate (AMC)	akhayaka12@gmail.com

146	Akhila Sivasdas	Jr. Pharmacovigilance Associate (AMC)	akhilasivasdas.adr@gmail.com
147	Ankur Dagar	Jr. Pharmacovigilance Associate (NCC)	ankurdagar396@gmail.com
148	Arunmozhy	Jr. Pharmacovigilance Associate (AMC)	arunmozhy1985@gmail.com
149	Banothu Vishnu Priya	Jr. Pharmacovigilance Associate (AMC)	drvishnupriya.pharmd@gmail.com
150	Bipin Prakash Tamte	Jr. Pharmacovigilance Associate (AMC)	bipinprakash035@gmail.com
151	Chinmaya Mahapatra	Jr. Pharmacovigilance Associate (AMC)	chinmaya212@gmail.com
152	Doyce Jom	Jr. Pharmacovigilance Associate (AMC)	doycejom@gmail.com
153	Harsh Deshmukh	Jr. Pharmacovigilance Associate (AMC)	harsh.freedom@gmail.com
154	Jaspinder Kaur	Jr. Pharmacovigilance Associate (AMC)	jaspindercaur@yahoo.com
155	Jayashree Sachin Pawar	Jr. Pharmacovigilance Associate (AMC)	drjayashreepawar82@gmail.com
156	Kalpana Joshi	Jr. Pharmacovigilance Associate (AMC)	jkalpana13@gmail.com
157	Lakshmi Prasanna	Jr. Pharmacovigilance Associate (AMC)	lakshmiprasanthi.nagiseti@gmail.com
158	Manjari Bhattacharya	Jr. Pharmacovigilance Associate (AMC)	manjarirocks93@gmail.com
159	Melambha Surong	Jr. Pharmacovigilance Associate (AMC)	document.melam@gmail.com
160	Moksh Tandon	Jr. Materiovigilance Associate (AMC)	moksh.tandon50@gmail.com
161	Neha Sharma	Jr. Pharmacovigilance Associate (AMC)	nehajmd8@gmail.com


162	Nensi Dhandhaya	Jr. Pharmacovigilance Associate (AMC)	dhandhalyanensi@gmail.com
163	Nivetha.C	Jr. Pharmacovigilance Associate (AMC)	nivethajss27@gmail.com
164	Pawan Kushwah	Jr. Pharmacovigilance Associate (AMC)	pawankushwah060@gmail.com
165	Polla Govindraj	Jr. Pharmacovigilance Associate (AMC)	p.g.raj1123@gmail.com
166	Praveen Kumar	Jr. Pharmacovigilance Associate (AMC)	praveen.chintu32@gmail.com
167	Priyanka Birhare	Jr. Pharmacovigilance Associate (AMC)	priyankabirhare19@gmail.com
168	Ramani Gade	Jr. Pharmacovigilance Associate (AMC)	ramanigade169@gmail.com
169	Rasita	Jr. Pharmacovigilance Associate (AMC)	rasitaohlan@gmail.com
170	Raunak Srivastav	Jr. Pharmacovigilance Associate (AMC)	raunaksri18@gmail.com
171	Renuka Bhoi	Jr. Pharmacovigilance Associate (AMC)	bhoiren0207@gmail.com
172	Rohit Sharma	Jr. Materiovigilance Associate (NCC)	rohit.rs2528@gmail.com
173	Shaik Sabiya Begum	Jr. Pharmacovigilance Associate (AMC)	sabiyasabi121@gmail.com
174	Shatavisa Mukherjee	Jr. Pharmacovigilance Associate (AMC)	shatavisa100@gmail.com
175	Shilpa	Jr. Pharmacovigilance Associate (NCC)	shilpa.bhardwaj25@gmail.com
176	Shilpa Choudhary	Jr. Pharmacovigilance Associate (AMC)	shilpa0090@gmail.com
177	Surya Pratap	Jr. Materiovigilance Associate (NCC)	suryapratapyadav158@gmail.com

178	Uppu Jhansi Rani	Jr. Pharmacovigilance Associate (AMC)	uppuj562@gmail.com
179	Vardhiparthy Sravana Swati	Jr. Pharmacovigilance Associate (AMC)	swathiparmacoo@gmail.com
180	Ms. Anusha.R	HR Associate	anusha693@gmail.com
181	Ms. Madhu Smita	HR Associate	madhusmita1287@gmail.com
182	Ms. Priyanka Sharma	Graphic Designer	sharma79priyanka@gmail.com
183	Ms. Ayushi Upadhyay	Data Entry Operator	netshreya@gmail.com
184	Mr. Deepak Malik	IT Associate	deepakmalikd74@gmail.com
185	Mr. Tarun Kumar	IT Associate	t4runt3watia@gmail.com
186	Mr. Girish Pal Singh	MTS	chauhansundar2789@gmail.com
187	Mr. Murari	Attendant	

PHOTO GALLERY



NCC-PvPI organized a webinar on "How to develop a positive culture of Adverse Event Reporting by Pharmaceutical Industries/Marketing Authorization Holders?" on 29th April 2021.



Virtual National AEFI committee meetings was attended by PvPI representatives



AIIMS - Mangalagiri, Andhra Pradesh conducted the first CME on "Awareness and Sensitization on Pharmacovigilance and ADR Reporting" on 10th April 2021.



Virtual 17th Skill Development Programme on "Pharmacovigilance for Medical Products" from 21st to 25th June, 2021



NCC-PvPI organised a virtual interactive meeting with PV officials of Emcure Pharmaceuticals Ltd. India for improving the quality of ICSRs on 24th June 2021.



The 7th CTP-cum-6th RTC Coordinators Meeting of PvPI was held on 15th July, 2021 through Video Conferencing.



Induction-cum-Training Programme was organized from 26th to 27th August 2021 to enhance Pharmacovigilance skill of Coordinators & Pharmacovigilance Associates of newly recognized AMCs to promote patient safety.




The NCC-PvPI initiated the celebration of National Pharmacovigilance Week (NPW 2021) from 17th to 23rd September 2021 on the theme "Pharmacovigilance: A step towards patient safety."



PvPI in News and Media during National Pharmacovigilance Week 2021.

18th Skill Development Programme on Pharmacovigilance of Medical Products was organized from 13th to 17th September 2021.



Launch of Sixth edition of National Formulary of India 2021 by the Hon'ble Union Minister of Health & Family Welfare, Dr. Mansukh Mandaviya on 28th October 2021 at Nirman Bhavan, New Delhi.



BJMC, Ahmedabad organized an advanced level training programme in Pharmacovigilance through virtual mode on 13th October 2021.



Glimpses of #MedsafetyWeek 2021 at social medial, celebrated from 1st-7th November 2021.



Medsafety Week Celebration & Inauguration of RTC, Amrita Institute of Medical Sciences on 8th November 2021.



Meeting of Pharmacovigilance Programme of India and Indian Medical Association held on 10th November 2021 via virtual mode.



SMS Medical College, Jaipur organized a sensitization programme on Pharmacovigilance & Materiovigilance as a part of "World Antimicrobial Week" on 18th-24th November 2021.



National AEFI Committee Meeting, held on 16th November, 22nd November and 20th December, 2021 via virtual mode.



A Healthcare Leadership Conclave, organized by Healthcopeia Foundation in collaboration with NCC-PvPI held on 25th November, 2021 at FICCI Federation House, New Delhi.



19th Skill Development Programme conducted by NCC-PvPI from 8th November to 12th November 2021.



Induction-cum-Training Programme on Pharmacovigilance for Coordinators, Deputy Coordinators & Pharmacovigilance Associates of newly recognized AMCs conducted from 16th to 18th November 2021.



NCC-PvPI had a virtual interactive meeting with Amgen Technology Private Limited representatives on 17th November 2021.



Online advanced level training on Pharmacovigilance with the theme 'Redefining Pharmacovigilance Research' organised virtually by IPGMER Kolkata on 13th December 2021.



Workshop on "Essentials of Pharmacovigilance: Basics to advanced" conducted by RTC & AMC at Amrita Institute of Medical Sciences, Kochi, in collaboration with RTC & AMC at JSS Medical College & Hospital, Mysore under the aegis of NCC-PvPI on 18th December 2021.



Webinar on "Basics of Good Pharmacovigilance Practices with reference to Module VI" organized by NCC-PvPI on 29th December 2021.



Meeting of NCC-PvPI and NABH officials held on 8th December 2021, with the objective to extend PvPI and to report ADR to PvPI



Meeting on the review of ocular adverse events associated with the use of Miltefosine held on 8th December , 2021



FDA-INO meeting with USFDA Delegation, held at IPC on 14th December 2021.




Technical Advisory Committee meeting on reporting of ocular complications due to the use of Miltefosine in Post Kala-azar Dermal Leishmaniasis (PKDL) cases, held on 22nd December 2021.



Pharmacovigilance Conference organized by IMT Pharmacy College, Puri, Odisha with the theme "Pharmacovigilance from the student's perspective" on 24th December, 2021.



Joint meeting between NCC-PvPI & National AIDS Control Programme organized virtually on 14th January, 2022.



Virtual sensitization programme for case management of Post Kala-Azar Dermal Leishmaniasis attended by PvPI representatives held on 18th January, 2022.



NCC-PvPI, IPC has organized virtual workshop-cum-training programme on 21st January, 2022 to train the NABH accredited hospitals staffs on Pharmacovigilance.



Advanced Level Training Programme on "The Art and Science of Benefit-Risk analysis" organized by KEM - Mumbai on 19th February, 2022.



NCC-PvPI organized virtually 20th Skill Development Programme on Pharmacovigilance for Medical Products from 07th to 11th March, 2022 through virtual mode.



Field Visit to monitor the Visceral Leishmaniasis & PKDL status in Jharkhand by PvPI representatives from 07th – 11th March, 2022.




20th Signal Review Panel Meeting organised by NCC-PvPI on 11th March, 2022 .



NCC-PvPI, IPC has organized a virtual 15th regional workshop on "Pharmacovigilance and Establishment of Pharmacovigilance System in Pharmaceutical Industries -A Way Forward" for the MAHs/Pharmaceutical industries on 29th March, 2022.



NCC-PvP conducted virtual interactive session with Intas Pharmaceutical Limited on 30th March, 2022.



NCC-MvPI, IPC in association with Agency of Medicines and Medical Products, Spain organized an international webinar on "Ensuring safety of medical devices focused on Ocular Devices" on 09th April 2021



NCC-MvPI, IPC in association with Mtal organized a webinar on "Involvement of Medical Device Manufacturers in Materiovigilance Programme of India (MvPI)" on 03rd September 2021

Acknowledgements

I sincerely acknowledge the efforts and contribution of the following members of my team for compiling and meticulously preparing this Performance Report 2021-22:

Dr Jai Prakash, Senior Principal Scientific Officer & Officer-in-Charge, PvPI

Dr V Kalaiselvan, Senior Principal Scientific Officer & Officer-in-Charge, MvPI

Dr Shashi Bhushan, Senior Scientific Officer

Dr R S Ray, Scientific Assistant

Dr Shatrunjay Shukla, Scientific Assistant

Mr Rishi Kumar, Scientific Assistant

Mr Vipin Kumar, Senior Pharmacovigilance Associate

Ms Neha Nasim, Junior Pharmacovigilance Associate

Ms Priyanka Sharma, Graphic Designer

All PvPI teams at National Coordination Centre & ADR Monitoring Centres.

All other Technical, Administrative and Financial staff of IPC.

Dr Rajeev Singh Raghuvanshi

Secretary-cum-Scientific Director

Indian Pharmacopoeia Commission

Ghaziabad-201002

ANNEXURES

Annexure - I

Version 1A



SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

For VOLUNTARY reporting of ADRs by Healthcare Professionals

INDIAN PHARMACOPOEIA COMMISSION (National Coordination Centre-Pharmacovigilance Programme of India)

Ministry of Health & Family Welfare, Government of India, Sector-23, Raj Nagar, Ghaziabad-201002

PvPI Helpline (Toll Free): 1800-180-3024 (9:00 AM to 5:30 PM, Monday-Friday)

Initial Case <input type="checkbox"/>		Follow-up Case <input type="checkbox"/>		FOR AMC / NCC USE ONLY						
A. PATIENT INFORMATION *				Reg. No. / IPD No. / OPD No. / CR No. :						
1. Patient Initials:		2. Age or date of birth:		AMC Report No. :						
3. Gender: M <input type="checkbox"/> F <input type="checkbox"/> Other <input type="checkbox"/>		4. Weight (in Kg.)		Worldwide Unique No. :						
B. SUSPECTED ADVERSE REACTION *				12. Relevant investigations with dates :						
5. Event / Reaction start date (dd/mm/yyyy)										
6. Event / Reaction stop date (dd/mm/yyyy)										
7. Describe Event/Reaction management with details, if any				13. Relevant medical / medication history (e.g. allergies, pregnancy, addiction, hepatic, renal dysfunction etc.)						
				14. Seriousness of the reaction: No <input type="checkbox"/> If Yes <input type="checkbox"/> (please tick anyone) <input type="checkbox"/> Death (dd/mm/yyyy) <input type="checkbox"/> Congenital anomaly <input type="checkbox"/> Life threatening <input type="checkbox"/> Disability <input type="checkbox"/> Hospitalization-Initial/Prolonged <input type="checkbox"/> Other Medically important						
				15. Outcome: <input type="checkbox"/> Recovered <input type="checkbox"/> Recovering <input type="checkbox"/> Not Recovered <input type="checkbox"/> Fatal <input type="checkbox"/> Recovered with sequelae <input type="checkbox"/> Unknown						
C. SUSPECTED MEDICATION(S) *										
S. No.	S. Name (Brand / Generic)	Manufacturer (if known)	Batch No. / Lot No.	Expiry Date (if known)	Dose	Route	Frequency	Therapy Dates Date Started Date Stopped	Indication	Causality Assessment
i										
ii										
iii										
iv*										
9. Action taken after reaction (please tick):								10. Reaction reappeared after reintroduction of suspected medication (please tick)		
S. No. as per C	Drug withdrawn	Dose increased	Dose reduced	Dose not changed	Not applicable	Unknown	Yes	No	Effect unknown	Dose (if re-introduced)
i										
ii										
iii										
iv										
11. Concomitant medical product including self-medication and herbal remedies with therapy dates (Exclude those used to treat reaction)										
S. No.	Name (Brand / Generic)	Dose	Route	Frequency (OD, BD, etc.)	Therapy Dates Date Started Date Stopped	Indication				
i										
ii										
iii*										
Additional Information :							D. REPORTER DETAILS *			
							16. Name & Address : _____			
							Pin : _____ Email : _____			
							Contact No. : _____			
							Occupation : _____ Signature : _____			
							17. Date of this report (dd/mm/yyyy) :			
Signature and Name of Receiving Personnel :										
Confidentiality : The patient's identity is held in strict confidence and protected to the fullest extent. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction. Submission of an ADR report does not have any legal implication on the reporter.										

* Use separate page for more information

* Mandatory fields for suspected ADR Reporting form

ADVICE ABOUT REPORTING

A. What to report?

All adverse events should be reported

Report non-serious, known or unknown, frequent or rare adverse drug reactions due to Medicines, Vaccines & Herbal Products.

Report every serious adverse drug reactions. A reaction is serious when the patient outcome is :

- Death
- Life-threatening
- Hospitalization (initial or prolonged)
- Disability (significant, persistent or permanent)
- Congenital anomaly
- Report intervention to prevent permanent impairment or damage

NOTE : Serious/Adverse Event following immunization can also be reported in Serious AEFI case Notification Form available on <http://www.ipc.gov.in>

B. Who can report?

All healthcare professionals (Clinicians, Dentists, Pharmacists and Nurse etc.) can report adverse drug reactions

C. Where to report?

Duly filled in Suspected Adverse Drug Reaction Reporting Form can be sent to the nearest Adverse Drug Reaction Monitoring Centre (AMC) or directly to the National Coordination Centre (NCC) for PvPI.

Call on Helpline (Toll Free) 1800 180 3024 to report ADRs or directly mail this filled form to pvpi.ipc@gov.in

A list of nationwide AMCs is available at : <http://www.ipc.gov.in>, http://www.ipc.gov.in/PvPI/pv_home.html

D. What happens to the submitted information?

- Information provided in this form is handled in strict confidence. The causality assessment is carried out at AMCs by using WHO-UMC scale. The analyzed forms are forwarded to the NCC-PvPI through ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Centre in Sweden.
- The reports are periodically reviewed by the NCC-PvPI. The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.
- The Signal Review Panel of PvPI reviews the data and suggests any interventions that may be required.

E. Mandatory fields for suspected ADR Reporting Form (*)

Patient initials, age at onset of reaction, reaction term(s), date of onset of reaction, suspected medication(s) & reporter information.

For Adverse Drug Reaction Reporting Tools

- E-mail : pvpi.ipc@gov.in
- PvPI Helpline (Toll Free) : 1800 180 3024 (9:00 AM to 5:30 PM, Monday-Friday)
- ADR Mobile App : "ADRPvPI"

Annexure - II

Version 1.0

संस्करण 1.0



MEDICINES SIDE EFFECT REPORTING FORM (FOR CONSUMERS)

औषधि दुष्प्रभाव सूचना फॉर्म (उपभोक्ताओं के लिए)

Indian Pharmacopoeia Commission, National Coordination Centre- Pharmacovigilance Programme of India, Ministry of Health & Family Welfare, Government of India.

भारतीय वैद्यक संहिता आयोग, राष्ट्रीय समन्वय केंद्र - भारतीय फार्माकोविजिलेस कार्यक्रम, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार।

1. Patient Details/ रोगी का विवरण				
Patient initials/ रोगी के आधाक्षर: <input type="text"/>		Gender/ लिंग (M): Male/ पुरुष <input type="checkbox"/> Female/ स्त्री <input type="checkbox"/>		Age (Year or Month)/ आयु (वर्ष या माह): <input type="text"/>
2. Health information/ स्वास्थ्य संबंधी जानकारी				
a. Reason(s) for taking medicine(s)/ रोग/लक्षणों/ लेने का कारण (रोग/ लक्षण): <input type="text"/>				
b. Medicines Advised by/ दवाई की सलाह देने वाला (M): Doctor/ डॉक्टर <input type="checkbox"/> Pharmacist/ फार्मासिस्ट <input type="checkbox"/> Friends/Relatives/ मित्र/ रिश्तेदार <input type="checkbox"/>				
Self (Past disease experienced/No past disease experienced)/ स्वयं (पूर्व बीमारी का अनुभव/पूर्व बीमारी का कोई अनुभव नहीं) <input type="checkbox"/>				
3. Details of Person Reporting the Side Effect/ दुष्प्रभाव की सूचना देने वाले व्यक्ति का विवरण				
Name (Optional)/ नाम (वैकल्पिक): <input type="text"/>				
Address/ पता: <input type="text"/>				
Telephone No./ टेलीफोन नं.: <input type="text"/>			Email/ ईमेल: <input type="text"/>	
4. Details of Medicine Taking/Taken/ ली जा रही है / ली जा चुकी दवाई का विवरण				
Name of Medicines/ दवाइयों के नाम	Quantity of Medicines taken (e.g. 250 mg, Two times a day / ली गई दवाई की मात्रा (उदाहरण के लिए 250 मिग्रा, एक दिन में दो बार)	Expiry Date of Medicines/ दवा के शिफ्टिव डेटे की तिथि	Date of Start of Medicines/ दवाइया आरंभ करने की तिथि	Date of Stop of Medicines/ दवाइया रोकने की तिथि
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
Dosage form/खुराक का स्वरूप (M): Tablet/ गोलियाँ (टेबलेट) <input type="checkbox"/> Capsule/ कैप्सूल <input type="checkbox"/> Injection/ इंजेक्शन <input type="checkbox"/> Oral Liquids/ मौखिक तरल <input type="checkbox"/> If Others (Please Specify) यदि अन्य (कृपया निर्दिष्ट करें) <input type="text"/>				
5. About the Side Effect/ दुष्प्रभाव के बारे में				
When did the side effect start?/ दुष्प्रभाव की शुरुआत कब हुई थी? <input type="text"/>		Side Effect is still Continuing (Yes/No)/ दुष्प्रभाव अभी भी जारी है (हां/नहीं) <input type="text"/>		
When did the side effect stop?/ दुष्प्रभाव कब समाप्त हुआ था? <input type="text"/>		क्या दुष्प्रभाव जारी है (हां/नहीं) <input type="text"/>		
6. How bad was the Side Effect? (Please ✓ the boxes that Apply)/ दुष्प्रभाव कितने हानिकारक थे? (कृपया जो लागू हो, उस पर ✓ का चिह्न लगाएं)				
<input type="checkbox"/> Did not affect daily activities/ दैनिक गतिविधियां प्रभावित नहीं हुई थी		<input type="checkbox"/> Affect daily activities/ दैनिक गतिविधियां प्रभावित हुई		
<input type="checkbox"/> Admitted to hospital/ अस्पताल ले जाना पड़ा		<input type="checkbox"/> Death/ मृत्यु		
<input type="checkbox"/> Others/ अन्य <input type="text"/>				
7. Describe the Side Effect (What did you do to manage the side effect?)/ दुष्प्रभाव की व्याख्या करें (आपने दुष्प्रभाव से निपटारा करने के लिए क्या किया)?				
<input type="text"/>				

This reporting is voluntary, has no legal implication and aims to improve patient safety. Your active participation is valuable. The information provided in this form will be forwarded to ADR Monitoring Centre for follow-up. You are requested to cooperate with the programme officials when they contact you for more details. Please do report even if you do not have all the information.

यह रिपोर्टिंग अनिवार्य है, कोई संपत्ति मिलित नहीं है और इसका उद्देश्य रोगी की सुरक्षा में सुधार करना है। आपकी सक्रिय भागीदारी मूल्यवान है। इस फॉर्म में दी गई जानकारी को अनुसंधान के लिए एडीआर मॉनिटरिंग केंद्र को भेजा जाएगा। आपको अनुरोध है कि जब भी अधिक जानकारी प्राप्त करने के लिए आपको संपर्क करें। कृपया पूर्ण जानकारी न होने पर भी रिपोर्ट करें।

Please turn the page to read the instructions
मिशन को पढ़ने के लिए दूसरा पृष्ठ पढ़ें

Send your report by mail or Fax to/ भेजें या फॉक्स के द्वारा अपनी रिपोर्ट निम्न पते पर करें

Pharmacovigilance Programme of India
National Coordination Centre,
Indian Pharmacopoeia Commission,
Ministry of Health & Family Welfare, Govt. of India
Sector-23, Rajnagar, Ghaziabad-201002, Uttar Pradesh
Tel.: 0120-2783400, 2783401, 2783392
FAX: 0120-2783311
Email: pvpi.compat@gmail.com
For more information visit us at www.ipc.gov.in



Call us on Helpline/ हेल्पलाइन पर हमें फोन करें
1800-180-3024 (Toll Free/
(टोल फ्री))
(9:00 AM to 5:30 PM, weekdays/ प्रातः 9:00 बजे
5:30 बजे तक, प्रत्येक कार्यदिवस पर)

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public.

गोपनीयता: रोगी की पहचान को पूर्णतः गुप्त और सुरक्षित रखा जाएगा है। कार्यक्रम के स्टाफ से उम्मीद की जाती है कि स्टार का कोई भी व्यक्ति सार्वजनिक अनुष्ठान पर रिपोर्ट देने वाले की पहचान का खुलासा नहीं करेगा।

Instructions to Complete the Reporting Form सूचना फॉर्म को पूरा करने के लिए निर्देश

<p>Section 1 - Patient Details</p> <ul style="list-style-type: none"> ✓ In patient initial, write first letter of the name and first letter of the surname (e.g. Pradeep Sharma-PS). ✓ Provide personal information (Gender, Age). <p>Section -2 Health Information</p> <ul style="list-style-type: none"> ✓ Provide reason(s) for taking medicines and medicines advised by (Doctor, Pharmacists, Friends/ Relatives and Self). <p>Section 3 - Details of Person Reporting the Side Effect</p> <ul style="list-style-type: none"> ✓ Provide the name (optional), address, telephone no. and email are necessary to assess the report. <p>Section 4 - Details of the Medicines Taking/Taken</p> <ul style="list-style-type: none"> ✓ Give all details about the Medicines (Name of Medicines, Quantity of Medicines taken, Expiry Date, start and stop date of Medicines) that have caused side effect. ✓ Please provide Dosage form (Tablets, Capsule, injections, Oral liquid) and if others please specify. <p>Section 5 - About the Side Effect</p> <ul style="list-style-type: none"> ✓ Provide side effect start and stop dates and also specify whether the side effect is still continuing. <p>Section 6 - How bad was the Side Effect</p> <ul style="list-style-type: none"> ✓ Please tick marks the appropriate boxes that apply. <p>Section 7 - Describe the Side Effect</p> <ul style="list-style-type: none"> ✓ Please describe the details of side effect and what treatment was taken to manage the side effect. 	<p>निर्देश 1 - रोगी का विवरण</p> <ul style="list-style-type: none"> ✓ रोगी को जानकार में, नाम का पहला अक्षर लिखें और उपनाम का प्रथम अक्षर लिखें (जैसे प्रदीप शर्मा-प्रश)। ✓ व्यक्तिगत जानकारी (लिंग, आयु) प्रदान करें। <p>निर्देश -2 स्वास्थ्य संबंधी जानकारी</p> <ul style="list-style-type: none"> ✓ दवा लेने के कारण और परामर्शदाता का नाम दें (डॉक्टर, फार्मासिस्ट, मित्र / रिश्तेदार और स्वयं)। <p>निर्देश 3 - दुष्प्रभाव की रिपोर्ट करने वाले व्यक्ति का विवरण दें</p> <ul style="list-style-type: none"> ✓ रिपोर्ट के मूल्यांकन हेतु नाम (वैकल्पिक), पता, टेलीफोन नं. और ई-मेल उपलब्ध कराएं। <p>निर्देश 4 - जो या रही है / जो या चुकी दवाइयों का विवरण</p> <ul style="list-style-type: none"> ✓ उन दवाइयों (दवाइयों का नाम, जो गई दवाइया, निर्माण होने की तिथि, दवाइया शुरू करने एवं रोकने की तिथि) का विवरण दें जिनके कारण आपको दुष्प्रभाव हुआ है। ✓ दवाओं का वस्तुत्व (गोली (टेबलेट), कैप्सूल, इंजेक्शन, मौखिक तरल (पिने वाली दवा) और यदि कोई अन्य हो तो निर्दिष्ट करें। <p>निर्देश 5 - दुष्प्रभाव के प्रभाव के बारे में</p> <ul style="list-style-type: none"> ✓ दुष्प्रभाव जल्द और लगातार होने की तिथि बताएं और यह भी निर्दिष्ट करें कि क्या दुष्प्रभाव अभी भी जारी है। <p>निर्देश 6 - दुष्प्रभाव कितने घातक/कम है?</p> <ul style="list-style-type: none"> ✓ कृपया उचित डिब्बे पर निशान लगाएं। <p>निर्देश 7- दुष्प्रभाव की व्याख्या करें</p> <ul style="list-style-type: none"> ✓ कृपया दुष्प्रभाव का विवरण और उस दुष्प्रभाव से छुटकारा पाने के लिए क्या उपचार किया गया, विवरण दें।
---	--

इस फॉर्म को पूरा करने के लिए अपना समय देने हेतु आपका धन्यवाद।

Annexure - III


**SUSPECTED ADVERSE DRUG REACTION REPORTING FORM
(FOR DRUGS USED IN PROPHYLAXIS/TREATMENT OF COVID-19)**

For **VOLUNTARY** reporting of ADRs by Healthcare Professionals
INDIAN PHARMACOPOEIA COMMISSION (National Coordination Centre-Pharmacovigilance Programme of India)
 Ministry of Health & Family Welfare, Government of India, Sector-23, Raj Nagar, Ghaziabad-201002
PvPI Helpline (Toll Free) : 1800-180-3024 (9:00 AM to 5:30 PM, Monday-Friday)

A. PATIENT/SUBJECT INFORMATION				
Patient/Subject Category : a. Lab confirmed COVID-19 case <input type="checkbox"/> b. Asymptomatic Healthcare Worker involved in the care of suspected or confirmed COVID-19 cases <input type="checkbox"/> c. Asymptomatic household contacts of laboratory confirmed cases <input type="checkbox"/> d. Others (Please specify) _____			Reg. No./IPD No./OPD No./CR No. : _____ AMC Report No. : _____ Worldwide Unique No. : To be generated by PvPI	
1. Patient/Subject Initials _____			9. Relevant tests/laboratory data with dates Test for COVID-19 : RT PCR Test <input type="checkbox"/> Rapid Antibody Test <input type="checkbox"/> Positive <input type="checkbox"/> Negative <input type="checkbox"/> Not done <input type="checkbox"/>	
2. Age/Date of Birth _____		3. Weight (in Kg) _____		
4. Gender : Male <input type="checkbox"/> Female <input type="checkbox"/> Transgender <input type="checkbox"/>		5. If female pregnant Yes <input type="checkbox"/> No <input type="checkbox"/>		6. Lactating Yes <input type="checkbox"/> No <input type="checkbox"/>
B. SUSPECTED ADVERSE REACTION				
S.No.	Reaction	Start Date	End Date	Outcome*
* Outcome may be indicated as (✓) one of the following (a) Recovered (b) Not Recovered (c) Recovered with sequelae (d) Recovering (e) Fatal (f) Unknown				
7. Describe Event(s)/Reaction(s) with treatment details, if any in chronological order				
8. Seriousness of the reaction : No <input type="checkbox"/> if Yes <input type="checkbox"/> (please tick appropriate box) Death (dd/mm/yyyy) <input type="checkbox"/> Life threatening <input type="checkbox"/> Hospitalization/Prolongation of hospitalization <input type="checkbox"/> Other Medically important events <input type="checkbox"/>				
12. Relevant medical/medication history : Allergy/Hypersensitivity Reaction <input type="checkbox"/> Chronic Alcoholism <input type="checkbox"/> Smoking <input type="checkbox"/> Obesity <input type="checkbox"/> Renal Dysfunction <input type="checkbox"/> Hepatic Dysfunction <input type="checkbox"/> Diabetes <input type="checkbox"/> Epilepsy/Seizures <input type="checkbox"/> Bronchial Asthma <input type="checkbox"/> Cardiovascular Disease <input type="checkbox"/> Chronic Lung Disease <input type="checkbox"/> Immunodeficiency Disorder <input type="checkbox"/> Immunosuppressant Drug <input type="checkbox"/> Anaemia <input type="checkbox"/> Neurological disorder <input type="checkbox"/> G-6-PD Deficiency <input type="checkbox"/> Dermatological findings, if any <input type="checkbox"/> Others <input type="checkbox"/>				
13. Drug Interaction : Mention name of any interacting (with Suspected Drug) drug taken : _____				

C. SUSPECTED MEDICINE(S)

S. No.	Drug Name (Brand/Generic)	Manufacturer/ MAH (if known)	Batch No./Lot No.	Exp. Date (if known)	Dosage Form	Dose used	Route of Admn.	Frequency (Once a day, twice a day etc.)	Therapy Dates Date started Date stopped	Indication	Causality Assessment (Prefer WHO-UMC Scale)
i.											
ii.											
iii.											
iv.											

S.No.	Drug Name	Reaction abated on (please tick)				Reaction if reappeared after drug reintroduction			
		Drug withdrawal	Dose reduction	Without modification of dose	Any other	Yes	No	Effect unknown	Dose (if reintroduced)
i.									
ii.									
iii.									

14. Concomitant medication including drug used for co-morbidities, and complementary medicines with therapy dates (Exclude those used to treat reaction)

S.No.	Name (Brand/Generic)	Dose used	Route used	Frequency (Once a day, twice a day etc.)	Therapy Dates Date started Date stopped	Indication
i.						
ii.						
iii.						
iv.						

D. REPORTER DETAILS

15. Name of the Healthcare Professional with Address : _____

Pin : _____ E-mail : _____ Tel. No. (with STD code) : _____

Occupation : _____ Signature : _____

16. Date of this report (dd/mm/yyyy) : _____

Sign. and Name of Receiver -

Confidentiality : The patient's identity is held in strict confidence and protected to the fullest extent. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction. Submission of an ADR report does not have any legal implication on the reporter.

* Use separate page for more information, #MAH-Marketing Authorization Holder

ADVICE ABOUT REPORTING**A. What to report?****All adverse events should be reported**

Report every serious adverse drug reactions. A reaction is serious when the patient outcome is :

- Death
- Life-threatening
- Hospitalization (initial or prolonged)

Report all non-serious, known or unknown, frequent or rare adverse drug reactions.

B. Who can report?

All healthcare professionals (Clinicians, Dentists, Pharmacists and Nurse etc.) can report adverse drug reactions

C. Where to report?

Duty filled in Suspected Adverse Drug Reaction Reporting Form can be sent to the nearest Adverse Drug Reaction Monitoring Centre (AMC) or directly to the National Coordination Centre (NCC) for PvPI.

Call on Helpline (Toll Free) 1800 180 3024 to report ADRs or directly mail this filled form to pvpi.ipc@gov.inA list of nationwide AMCs is available at : <http://www.ipc.gov.in>, http://www.ipc.gov.in/PvPI/pv_home.html**D. What happens to the submitted information?**

Information provided in this form is handled in strict confidence. The causality assessment is carried out at AMCs by using WHO-UMC scale. The analyzed forms are forwarded to the NCC-PvPI through ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Centre in Sweden.

The reports are periodically reviewed by the NCC-PvPI. The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.

The Signal Review Panel of PvPI reviews the data and suggests any interventions that may be required.

E. Mandatory fields for suspected ADR Reporting Form

Patient initials, age at onset of reaction, reaction term(s), date of onset of reaction, suspected medication(s) & reporter information.

For Adverse Drug Reaction Reporting Tools

- E-mail : pvpi.ipc@gov.in
- PvPI Helpline (Toll Free) : 1800 180 3024 (9:00 AM to 5:30 PM, Monday-Friday)
- ADR Mobile App : "ADRPvPI"

Annexure - IV



PERSONAL PROTECTIVE EQUIPMENT ADVERSE EVENT REPORTING FORM

Version no. 1.1

Materiovigilance Programme of India (MvPI)

Where to report: Duly filled form can be sent to Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23, Rajinder, Ghaziabad-201002, Tel-0120-2783406, 2783401 and 2783392, FAX-0120-2783311 or email to shatrunjay-ipc@gov.in Or Call on Helpline no. 1800 180 3924 to report Adverse event.

1. General Information:		2. Type of report:	
Date of report: _____		<input type="checkbox"/> Initial <input type="checkbox"/> Follow-up (Ref. no. _____)	
Date of event: _____			
3. Reporter details:			
Name: _____			
Address: _____			
Contact No.: _____			
E-mail address: _____			
4. PPE Type:			
<input type="checkbox"/> Gloves <input type="checkbox"/> Coverall <input type="checkbox"/> Goggles <input type="checkbox"/> N-95 Masks <input type="checkbox"/> Shoe Covers <input type="checkbox"/> Face Shield <input type="checkbox"/> Body Bags <input type="checkbox"/> Triple Layer Medical Mask <input type="checkbox"/> Sanitizer <input type="checkbox"/> Other (Specify): _____			
5. PPE Details:			
Brand name: _____			
Manufacturer name and address: _____			
Importer name and address: _____			
Distributor name and address: _____			
Marketed by: _____			
License No. / Registration No.: _____			
Model No.: _____		Batch No.: _____	
Unique Certification Code: _____		Test Standard: _____	
Manufacturing Date: _____		Expiry Date: _____	
PPE Current Location: <input type="checkbox"/> Device destroyed <input type="checkbox"/> Still in use <input type="checkbox"/> Return to manufacturer			
6. Location of event:		7. Type of event:	
<input type="checkbox"/> Point of Entry (Immigration counters, customs and airport security) <input type="checkbox"/> Hospital Setting <input type="checkbox"/> In-patient Services <input type="checkbox"/> Emergency Department <input type="checkbox"/> Pre-hospital (Ambulance) Services <input type="checkbox"/> Other Supportive/ Ancillary Services (Laboratory, Mortuary, Sanitation) <input type="checkbox"/> Health Workers in Community Setting <input type="checkbox"/> Quarantine facility <input type="checkbox"/> Home Quarantine <input type="checkbox"/> Other (Specify): _____		Serious: <input type="checkbox"/> <input checked="" type="checkbox"/> Non-Serious <input type="checkbox"/> Death <input type="checkbox"/> Life Threatening <input type="checkbox"/> Disability or permanent damage <input type="checkbox"/> Hospitalization / Prolonged Hospitalization <input type="checkbox"/> Congenital anomaly / birth defect <input type="checkbox"/> Any other serious _____	
		8. User details:	
		Initials: _____	
		Age: _____	
		Gender (M/F/O): _____	
		Outcome: <input type="checkbox"/> Recovered <input checked="" type="checkbox"/> Not yet recovered	
		<input type="checkbox"/> Death <input type="checkbox"/> Other: _____	
9. Detailed Description of Event:			
10. Hospital/Quarantine facility details:			
Facility Name: _____			
Address: _____			
Contact Person: _____			

Annexure - V



ADVERSE DRUG REACTION REPORTING FORM FOR KALA-AZAR TREATMENT

I. PATIENT DETAILS

Patient Initials:	Patient Code No:	Patient Contact No:	AMC report number:
Patient Age: (Yr)		Weight: (Kg)	
Gender: M <input type="checkbox"/> F <input type="checkbox"/> Others <input type="checkbox"/>	Breastfeeding an infant: Yes <input type="checkbox"/> No <input type="checkbox"/>		Worldwide unique number:
Pregnant: Yes <input type="checkbox"/> No <input type="checkbox"/> Uncertain <input type="checkbox"/>	If Pregnant, estimated current gestation (weeks):		

II. TREATMENT

A) CONDITION TREATED								
Kala Azar (VL) <input type="checkbox"/>	Post Kala Azar Dermal Leishmaniasis (PKDL) <input type="checkbox"/>	HIV-VL Co-infection <input type="checkbox"/>	Others <input type="checkbox"/> (Specify)					
B) TREATMENT RECEIVED								
Mono Therapy <input type="checkbox"/>				Combination Therapy <input type="checkbox"/>				
Drug Received	Batch No./ Expiry Date	Drug Dose & Unit	Frequency	Route	Start Date (dd/mm/yyyy)	Start Time (Hr:Min)	Stop Date (dd/mm/yyyy)	Stop Time (Hr:Min)
Liposomal Amphotericin B								
Miltefosine								
Paromomycin								
Amphotericin B deoxycholate								
SSG/ SAG								

III. CONCOMITANT DRUGS

S. No.	Name	Indication	Batch Number/ Expiry Date	Drug Dose Unit (if I.V) Infusion rate in ml/hour	Dose & Unit	Frequency	Route	Start Date	Stop date

IV. ADVERSE EVENTS INFORMATION

Reporter's Narrative (Describe the course of events, timing and suspected causes):			
Adverse Event/ Reaction Term	Event I	Event II	Event III
Date of Onset	DD/MM/YY	DD/MM/YY	DD/MM/YY
Date Resolved	DD/MM/YY	DD/MM/YY	DD/MM/YY
Severity	<input type="checkbox"/> Mild <input type="checkbox"/> Moderate <input type="checkbox"/> Severe	<input type="checkbox"/> Mild <input type="checkbox"/> Moderate <input type="checkbox"/> Severe	<input type="checkbox"/> Mild <input type="checkbox"/> Moderate <input type="checkbox"/> Severe
Seriousness	<input type="checkbox"/> Non-Serious ADR <input type="checkbox"/> Serious AE/ADR please specify category : <input type="checkbox"/> Death <input type="checkbox"/> Hospitalization/ Prolonged <input type="checkbox"/> Life threatening <input type="checkbox"/> Permanent disability/disabling <input type="checkbox"/> Congenital anomaly/ birth defect <input type="checkbox"/> Other medically important condition	<input type="checkbox"/> Non-Serious ADR <input type="checkbox"/> Serious AE/ADR please specify category : <input type="checkbox"/> Death <input type="checkbox"/> Hospitalization/ Prolonged <input type="checkbox"/> Life threatening <input type="checkbox"/> Permanent disability <input type="checkbox"/> Congenital anomaly <input type="checkbox"/> Other medically important condition	<input type="checkbox"/> Non-Serious ADR <input type="checkbox"/> Serious AE/ADR please specify category : <input type="checkbox"/> Death <input type="checkbox"/> Hospitalization/ Prolonged <input type="checkbox"/> Life threatening <input type="checkbox"/> Permanent disability <input type="checkbox"/> Congenital anomaly <input type="checkbox"/> Other medically important condition

Outcome	<input type="checkbox"/> Recovered/ resolved <input type="checkbox"/> Recovering/resolving <input type="checkbox"/> Fatal <input type="checkbox"/> Not Recovered/not resolved <input type="checkbox"/> Recovered with Sequelae <input type="checkbox"/> Unknown	<input type="checkbox"/> Recovered/ resolved <input type="checkbox"/> Recovering/resolving <input type="checkbox"/> Fatal <input type="checkbox"/> Not Recovered/not resolved <input type="checkbox"/> Recovered with Sequelae <input type="checkbox"/> Unknown	<input type="checkbox"/> Recovered/ resolved <input type="checkbox"/> Recovering/resolving <input type="checkbox"/> Fatal <input type="checkbox"/> Not Recovered/not resolved <input type="checkbox"/> Recovered with Sequelae <input type="checkbox"/> Unknown
Dechallenge/ Action Taken	<input type="checkbox"/> Drug Withdrawn <input type="checkbox"/> Dose Reduced <input type="checkbox"/> Dose <input type="checkbox"/> Dose not changed <input type="checkbox"/> Unknown <input type="checkbox"/> Not Applicable	<input type="checkbox"/> Drug Withdrawn <input type="checkbox"/> Dose Reduced <input type="checkbox"/> Dose <input type="checkbox"/> Dose not changed <input type="checkbox"/> Unknown <input type="checkbox"/> Not Applicable	<input type="checkbox"/> Drug Withdrawn <input type="checkbox"/> Dose Reduced <input type="checkbox"/> Dose <input type="checkbox"/> Dose not changed <input type="checkbox"/> Unknown <input type="checkbox"/> Not Applicable
Rechallenge	<input type="checkbox"/> No <input type="checkbox"/> Yes Dose (if reintroduced) <input type="checkbox"/> Unknown	<input type="checkbox"/> No <input type="checkbox"/> Yes Dose (if reintroduced) <input type="checkbox"/> Unknown	<input type="checkbox"/> No <input type="checkbox"/> Yes Dose (if reintroduced) <input type="checkbox"/> Unknown
Expectedness	<input type="checkbox"/> Expected (yes) <input type="checkbox"/> Unexpected (no)	<input type="checkbox"/> Expected (yes) <input type="checkbox"/> Unexpected (no)	<input type="checkbox"/> Expected (yes) <input type="checkbox"/> Unexpected (no)
For Death	Date of Death Primary cause of death (if known): Was autopsy performed? <input type="checkbox"/> No <input type="checkbox"/> Yes Hospital Admission Date Hospital Discharge Date	Date of Death Primary cause of death (if known): Was autopsy performed? <input type="checkbox"/> No <input type="checkbox"/> Yes Hospital Admission Date Hospital Discharge Date	Date of Death Primary cause of death (if known): Was autopsy performed? <input type="checkbox"/> No <input type="checkbox"/> Yes Hospital Admission Date Hospital Discharge Date
Causality [-Certain -Probable -Possible -Unlikely -Conditional -Unassessable]	<input type="checkbox"/> Ambisome <input type="checkbox"/> Miltefosine <input type="checkbox"/> Paromomycin <input type="checkbox"/> Amphotericin deoxycholate <input type="checkbox"/> SSG/ SAG <input type="checkbox"/> Others (.....)	<input type="checkbox"/> Ambisome <input type="checkbox"/> Miltefosine <input type="checkbox"/> Paromomycin <input type="checkbox"/> Amphotericin deoxycholate <input type="checkbox"/> SSG/ SAG <input type="checkbox"/> Others (.....)	<input type="checkbox"/> Ambisome <input type="checkbox"/> Miltefosine <input type="checkbox"/> Paromomycin <input type="checkbox"/> Amphotericin deoxycholate <input type="checkbox"/> SSG/ SAG <input type="checkbox"/> Others (.....)

V. MEDICAL HISTORY

Briefly describe diseases and concurrent illness:

VI. RELEVANT LABORATORY TESTS

LABORATORY TESTS					
Test	Date	Result (units)	Test	Date	Result (units)
Haemoglobin			Creatinine		
ALT (SGPT)			Na ⁺		
AST (SGOT)			K ⁺		

VII. OTHER CLINICALLY RELEVANT INFORMATION

Treatment For Managing ADR:

Counseling with Toll Free Number (18001803024): ☐ Yes ☐ No**VIII. REPORTERS INFORMATION**

Name:	Designation:	Signature:
Email:	Contact No.:	
Professional Address:	PIN Code:	Date:
Name of Paramedical:	Designation:	Signature:

Annexure - VI

Serious AEFI Case Notification Form – ADR Monitoring Center*	
ICSR No. _____	Reporting Format No. _____
Name & address of ADR Monitoring center (AMC): _____	
Patient Name _____	
Age: _____	Sex: Male/Female _____
Father/Husband's Name _____	
Complete Address of the Case with landmarks (Street name, house number, village, block, Tehsil, PIN No., Telephone No. etc.) _____	
P I N - _____ P H O N E - _____ Date of Vaccination: ____/____/_____ Address of health facility where vaccinated (include name of village/urban area, block, DISTRICT and STATE)#: _____	
Name of vaccines with dose received (if known) _____	
Date of first symptom _____	Time of first symptom _____ (AM/PM)
Hospitalization: (No/ Yes) Date- _____	Time of hospitalization _____ (AM/PM)
Name and address of hospital (if hospitalized): _____	
CR No./MRD No _____	
Current status (encircle)	Death / Still Hospitalized / Recovered & Discharged with sequelae / Recovered completely and discharged / Left Against Medical Advice (LAMA) / Not hospitalized
If died, Date of Death _____	Time of Death _____ (AM/PM)
Describe AEFI (signs and symptoms): _____	
Name & signature of AMC Coordinator/ Medical officer: _____	
Email: _____	
Contact No. _____	
*Date form sent to District Immunization Officer# (where patient was vaccinated)- ____/____/____	
*Date form sent to State Immunization Officer# (where patient was vaccinated)- ____/____/____	
*Date form sent to PVPI, Ghaziabad- ____/____/____	
*Date form sent to Immunization Division / AEFI Secretariat (aeifiindia@gmail.com)- ____/____/____	
Name & signature of Pharmacovigilance Associate: _____	
E mail: _____	
Contact number: _____	

#The case is to be notified to the DIO of the district where the vaccine was administered.

*This form should be scanned and emailed simultaneously to DIO, SEPIO, PVPI and AEFI Secretariat.

Annexure - VII



Version-1.1

MEDICAL DEVICE ADVERSE EVENT REPORTING FORM

Materiovigilance Programme of India (MvPI)

This form is intended to collect information on Medical Devices Adverse Event in India. The form is designed to be used voluntarily by Manufacturer/Importer/Distributor of Medical Devices, Healthcare Professionals and anyone with direct/indirect knowledge of Medical Devices Adverse Event.

General Information		
1. Date of Report :		
2. Type of Report : Initial <input type="checkbox"/> Follow up <input type="checkbox"/> Final <input type="checkbox"/> Trend <input type="checkbox"/>		
3. Reporter Reference for MDMC only: • Centre • Location • Month-Year • Case No.		
Reporter Details		
1. Type of Reporter : (a) Manufacturer <input type="checkbox"/> (b) Importer <input type="checkbox"/> (c) Distributor <input type="checkbox"/> (d) Healthcare Professional <input type="checkbox"/> (e) Patient <input type="checkbox"/> (f) Others <input type="checkbox"/> specify		
2. In case, where the reporter is not manufacturer, fill the following details:-		
(a) Has the reporter informed the incident to the manufacturer?		
Yes <input type="checkbox"/> No <input type="checkbox"/>		
(b) Is the reporter also submitting the report on behalf of the manufacturer?		
Yes <input type="checkbox"/> No <input type="checkbox"/>		
3. Reporter contact information:		
a) Name :		
b) Address :		
c) Tel. /Mobile :		
d) Email :		
Device Category		
Medical Device	In Vitro Diagnostics (IVD)	Medical Equipments / Machines
I. Therapeutic <input type="checkbox"/> Diagnostic <input type="checkbox"/> Both <input type="checkbox"/> Preventive <input type="checkbox"/> Assistive <input type="checkbox"/>	I. Kits <input type="checkbox"/> II. Reagents <input type="checkbox"/> III. Calibrator <input type="checkbox"/> IV. Control Material <input type="checkbox"/> V. Others <input type="checkbox"/> VI. IVD electronic reader/ Analyzer <input type="checkbox"/>	I. Therapeutic <input type="checkbox"/> Diagnostic <input type="checkbox"/> II. Therapeutic & Diagnostic <input type="checkbox"/> III. Preventive <input type="checkbox"/> IV. Assistive <input type="checkbox"/> V. Imaging <input type="checkbox"/> VI. Invasive <input type="checkbox"/> Non-Invasive <input type="checkbox"/> VII. Others <input type="checkbox"/>
II. Implantable device <input type="checkbox"/> Non-Implantable device <input type="checkbox"/>		
III. Invasive <input type="checkbox"/> Non-Invasive <input type="checkbox"/>		
IV. Single use device <input type="checkbox"/> Reusable device <input type="checkbox"/> Reuse of manufacture marked Single use device <input type="checkbox"/>		
V. Sterile <input type="checkbox"/> Non Sterile <input type="checkbox"/>		
VI. Personal use / Homecare use <input type="checkbox"/>		
Instruction for use Section A-F • If Medical Devices/Equipments/Machines : Please fill all the sections i.e. A, B, C, D, E & F • If In Vitro Diagnostics (IVD) : Please fill sections i.e. A (except 6, 7, 8, 13, 14 & 15), B (except 1, 2, 6 & 8), D, E, & F		

Page 1 of 5

(A) Device Details**Device Name / Trade Name / Brand Name:**

Details	Name	Address
Manufacturer		
Importer		
Distributor		

1. a) Is the device notified/regulated in India : Yes ☐ No ☐
- b) Device Risk Classification as per India MDR 2017 : A ☐ B ☐ C ☐ D ☐
2. License No. (Manufacture/Import) :
3. Catalogue No. :
4. Model No. :
5. Lot / Batch No. :
6. Serial No. :
7. Software Version :
8. Associated Devices / Accessories :
9. Nomenclature Code if applicable; GMDN/UMDNS :
10. UDI No. (If applicable) :
11. Installation Date :
12. Expiration Date :
13. Last preventive maintenance date (dd/mm/yyyy) :
14. Last calibration date (dd/mm/yyyy) :
15. Year of manufacturing :
16. How long was device/Equipment/Machine in use :
17. Availability of device for evaluation : Yes ☐ No ☐
If no, was the device destroyed ☐ Still in use ☐ return to manufacturer or importer/distributor ☐
18. Is the usage of device as per manufacturer claim /Instruction for use/user manual: Yes ☐ No ☐
If no specify usage
19. For devices not regulated / notified in India : Regulator / Regulatory status in country of origin

(B) Event Description

1. Date of Event / Near miss incident: 2. Date of Implant/Explant (If applicable): 3. Location of Event: Hospital Premise <input type="checkbox"/> Manufacture/Distributor premise <input type="checkbox"/> Home <input type="checkbox"/> Others <input type="checkbox"/> 4. Device Operator:- Healthcare Professional <input type="checkbox"/> Patient <input type="checkbox"/> Others <input type="checkbox"/> Problem noted prior to use/near miss event <input type="checkbox"/> 5. Device disposition / Current location: a) Returned to company <input type="checkbox"/> If yes, date/...../..... b) Remains implanted in patient <input type="checkbox"/> c) Within the healthcare facility <input type="checkbox"/> d) At patient home <input type="checkbox"/> e) Destroyed <input type="checkbox"/> f) Others (specify) <input type="checkbox"/> 6. Is device in use after incidence : Yes <input type="checkbox"/> No <input type="checkbox"/>	7. Serious event: <input type="checkbox"/> If serious, Tick the appropriate reason a) Death (DD/MM/YY) <input type="checkbox"/>/...../..... b) Life Threatening <input type="checkbox"/> c) Disability or permanent damage <input type="checkbox"/> d) Hospitalization <input type="checkbox"/> e) Congenital anomaly /birth defect <input type="checkbox"/> f) Any other serious (Imp. medical event) <input type="checkbox"/> g) Required intervention to prevent / permanent Impairment / damage device <input type="checkbox"/> 8. Non serious event <input type="checkbox"/> 9. Whether other medical devices were used at same time with above device if yes, please specify name(s)/use(s)
--	---

10. Detail description of Event:-*For manufacturer/authorized representative use only**Continue on Page 5*

11. Frequency of occurrence of similar Adverse Event in India in past 3 years	Year	No. of Similar Adverse Events	Total No. Supplied	Frequency of Occurrence (%)
12. Frequency of occurrence of similar Adverse Event in globally in past 3 years	Year	No. of Similar Adverse Events	Total No. Supplied	Frequency of Occurrence (%)

(C) Patient Information, History & Outcome

1. Patient Hospital ID : 2. Patient Initial : 3. Age : 4. Gender : Male <input type="checkbox"/> Female <input type="checkbox"/> Others <input type="checkbox"/> 5. Weight : 6. Other relevant history, including pre-existing medical conditions	7. Patient Outcomes: a) Recovered Date (DD/MM/YY) <input type="checkbox"/>/...../..... b) Not yet recovered <input type="checkbox"/> c) Death (DD/MM/YY) <input type="checkbox"/>/...../..... d) Others <input type="checkbox"/> Please specify
--	--

(D) Healthcare Facility Information (if available)

1. Name :
2. Address :
3. Contact Person Name at the site of event :
4. Tel. No. :

(E) Causality Assessment

1. Investigation action taken:

Continue on Page 5

2. Root cause of problem (Applicable for follow up / final reports):

Continue on Page 5

(F) Manufacturer/Authorized Representative Investigation & Action taken

1. Manufacturer/Authorized Representative device risk analysis report:

2. Corrective / preventive action taken:

Continue on Page 5

3. Device history review:

Continue on Page 5

Continue on Page 5

(B) Event Description (Continued)

10. Detail description of Event:-

(E) Causality Assessment (Continued)

1. Investigation action taken:

2. Root cause of problem (Applicable for follow up / final reports):

(F) Manufacturer/Authorized Representative Investigation & Action taken (Continued)

1. Manufacturer/Authorized Representative device risk analysis report:

2. Corrective / preventive action taken:

3. Device history review:

Where to report?

Duly filled Medical Device Adverse Event Reporting Form can be sent to Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23, Rajnagar, Ghaziabad-20002, Tel-0120-2783400, 2783401 and 2783392, FAX:0120-2783311 or email to shatrughjay.ipc@gov.in Or Call on Helpline no. 1800 180 3024 to report Adverse event.

Partnering
Organizations

**Disclaimer:**

Confidentiality: The patient's identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter's identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the adverse event.

Let us join hands with PvPI to ensure patient safety



www.ipc.gov.in

Toll Free No.
1800 180 3024



ipcgzb

@ IPC_Ghaziabad



ADR PvPI Mobile-app

pvpi.ipc@gov.in





Indian Pharmacopoeia Commission
 National Coordination Centre
 Pharmacovigilance Programme of India
 Ministry of Health & Family Welfare, Govt. of India
 Sector-23, Raj Nagar, Ghaziabad-201002
 Tel. : 0120-2783400, Extn.-155



**World Health
 Organization**

A WHO Collaborating Centre
 for Pharmacovigilance in Public
 Health Programmes and
 Regulatory Services

For any other Information/Suggestions/Query

Please Contact: Officer-in-Charge, Pharmacovigilance Programme of India
 Email: pvpi.ipc@gov.in, lab.ipc@gov.in website: www.ipc.gov.in